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Eukaryotic cells rely on quality control mechanisms to sustain protein homeostasis by regulating 
protein folding, targeting and degradation. These mechanisms involve the recognition of exposed 
hydrophobic regions of membrane proteins that have mislocalized to the cytosol to prevent them 
from misfolding and aggregation. In mammals, the heterotrimeric BAG6 complex, composed of 
three proteins, BAG6, UBL4A and TRC35, work closely with the co-chaperone SGTA to triage 
hydrophobic protein clients ensuring their delivery to the ER or to the proteasomal degradation 
pathway. Recently, RNF126 has been identified as the BAG6-dependent E3 ligase, which 
ubiquitinates lysine residues on BAG6 associated substrates. However, the decision-making 
process in classifying hydrophobic protein clients for degradation or rescue are unclear. 
Therefore, the characterisation of proteins involved in triage system is critical to understanding 
the mechanisms of protein sorting. The work presented here provides insights into functions of 
the co-chaperone SGTA and the E3 ubiquitin ligase, RNF126, within the BAG6 quality control 
module. It also focuses on the additional role of the co-chaperone SGTA and its yeast homologue 
Sgt2, which is the interaction with molecular chaperones such as Hsp70 (Ssa1 in yeast) and Hsp90 
(Hsc82 in yeast) through the central tetratricopeptide repeat (TPR) domain. The solution 
structures of the N-terminal dimerisation domain of SGTA and N-terminal zinc finger motif of 
RNF126 E3 ligase are presented in Chapter 3 and 4 respectively. The interactions of both RNF126 
and SGTA with the UBL domains of BAG6 and UBL4A are also characterised. This includes the 
structural models of complexes of RNF126_NZF and SGTA_NT with UBLs using NMR 
spectroscopy and HADDOCK (Chapters 3 and 4). Chapter 5 contains the x-ray structures of 
Sgt2_TPR and its complex with the extreme C-terminal of Ssa1. In addition, it shows that 
Sgt2_TPR interacts with C-terminal fragments of Ssa1, Hsc82 and Ybr137wp (a protein whose 
function is yet to be elucidated) in the similar binding mode and with comparable binding 
affinities. The binding studies were performed using biophysical methods, such as isothermal 
titration calorimetry and microscale thermophoresis. Together, this work aims to extend our 
understanding of the quality control mechanism in yeast and mammals, by providing molecular 
details of the components of the SGTA/BAG6 complex quality control module. 
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Chapter 1.   Introduction 
1.1   Protein quality control in the cytosol and the endoplasmic reticulum 
There are several billion protein molecules in human cells which differ in size, assembly, shape, 
and stability (1, 2). To ensure the correct functioning of these versatile proteins, eukaryotic cells 
have developed an intricate network of protein quality control pathways. Sustaining protein 
homeostasis (also known as proteostasis) requires monitoring of protein biosynthesis, by 
reviewing their folding and localisation in the cell, and degradation of aberrant proteins (3-5). 
Quality control systems operate in different compartments of the eukaryotic cell, including 
ribosomes and the endoplasmic reticulum (ER) and at multiple steps of protein biosynthesis. 
Protein quality checkpoints act during protein translation at the ribosome, and post-
translationally, to monitor the nascent polypeptides and avoid the emergence and accumulation 
of aberrant proteins at this early stage of protein maturation (6-8). Some proteins require a 
cotranslational folding of their long polypeptides to prevent the formation of intermediate 
assemblies, which could impede the protein’s folding to its native state (9). In eukaryotes, a subset 
of highly conserved heat shock proteins (Hsp40 and Hsp70 families) can bind to the newly 
synthesised protein chains and assist their cotranslational folding (10). In human cells, the fully 
synthesized proteins which do not contain signal sequences for entering the secretory pathway, 
peroxisomes or mitochondria are released from the ribosomes and their folding can also be 
supported by the same sets of heat shock proteins in the cytosol (which in yeast are called Ssa1-
4) (11, 12). The heat shock chaperones are ubiquitous and can interact with a range of substrate 
conformers, varying from entirely unfolded to natively folded and even aggregated protein states 
(13). It has been shown that Hsp70 binding can also induce conformational changes in proteins 
(14) and support protein disaggregation through one or several ATP-regulated cycles of binding 
and hydrolysis (15, 16). 
 
Maintaining protein homeostasis is particularly challenging for membrane and secretory proteins 
because they are imported to the ER for maturation in an unfolded state (17). The long 
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hydrophobic stretches which characterise integral membrane proteins require protection from the 
cytosol to avoid the exposure of their hydrophobic residues and subsequent misfolding (6). 
Furthermore, failure in targeting and mislocalisation of membrane proteins to the cytosol can lead 
to the formation of aggregates which are toxic to the cell (8, 18, 19). Most secretory membrane 
proteins are delivered and inserted to the ER membrane cotranslationally and depend on their 
recognition by the Signal Recognition Particle (SRP) and subsequent targeting to the protein 
transport Sec61 translocon channel localised at the ER (20-23). The first hydrophobic residues to 
emerge from a ribosome exit tunnel, either a transmembrane domain (TMD) or a cleavable N-
terminal sequence, act as an ER-targeting signal and are recognised and shielded by the 54 kDa 
subunit of SRP (SRP54) (24-26). This then targets these membrane clients, via the SRP receptor, 
to the Sec61 translocon for insertion (27-29) The same large multiprotein complex Sec61 is also 
responsible for the translocation of soluble proteins across the ER membrane (30-32). 
Nevertheless, inaccessibility or mutations of residues within the central hydrophobic core in the 
targeting signals severely affect SRP binding (33). Moreover other internal cellular stresses like 
transcriptional and translational failures, aberrant protein conformational changes, or faulty 
translocated secretory and mitochondrial precursors (34, 35) can affect the efficiency of SRP-
dependent targeting and increase the production of misfolded proteins which can mislocalise to 
the cytosol. Furthermore, a number of external factors like oxidation, heat, aging, and cancer (36) 
can result in misfolding of some proteins and increase the danger of protein aggregation (4, 37) 
which can subsequently lead to development of disease states including neurodegenerative 
disorders such as Parkinson’s disease, Alzheimer’s disease and diabetes. Moreover, although the 
majority of membrane and secretory proteins are targeted and inserted to the ER cotranslationally, 
a subpopulation inserts posttranslationally via an SRP-independent route and these proteins can 
also accidently mislocalise to the cytosol (8, 38). 
 
To minimize protein homeostasis perturbations, misfolded polypeptides must be either refolded 
and re-delivered in the case of mislocalised proteins (MLPs) (39) or, failing correction, they must 
be targeted for degradation. Central to these quality control mechanisms are networks of 
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specialised chaperones (40). At the endoplasmic reticulum, terminally misfolded proteins are 
recognised by ER-resident chaperones and retro-translocated in the ER-associated degradation 
(ERAD) pathway to the cytosol for degradation. The clearing process of misfolded peptides is 
constantly performed by a highly conserved set of ERAD components that promote their 
ubiquitination by specialized E3 ubiquitin ligases, and subsequent digestion by the proteasome 
(41). The folding status at the ER is also constantly monitored by the Unfolded Protein Response 
(UPR) to control the accumulation of unfolded and misfolded proteins (42). Degradation of 
substrates that are misfolded, unfolded, or no longer required by the cell can also be removed by 
macroautophagy driven lysosomal-mediated hydrolysis (43).  
 
Triage decisions between numerous coexisting quality control pathways, need to be adaptable so 
they can meet the changing requirements of the cell and allow for correct decisions between 
chaperone-mediated refolding, stabilisation of misfolded and aggregated proteins, and 
elimination of damaged polypeptides. The sorting mechanism highly depends on dedicated co-
chaperones, E3 ubiquitin ligases and their direct interactions with Hsp70 and Hsp90 chaperones. 
 
1.1.1   TA-proteins 
Tail-anchored proteins (TA) belong to the family of membrane proteins whose transmembrane 
domains (TMD) emerge from the ribosome only after translation terminates and thus their ER-
signal sequences are obscured by the ribosome and they cannot be delivered to the ER by the 
cotranslational mechanism (21, 44-46). Instead, these proteins are inserted into ER membranes 
posttranslationally in a pathway, called Transmembrane Recognition Complex (TRC) in 
mammals and Guided Entry of TA proteins (GET) in yeast (46) [described in more detail in 




TA proteins constitute approximately 5% of all human membrane proteins, including SNAREs 
(N-ethylmaleimide–sensitive factor attachment protein receptors), ER translocon components, 
Bcl-2 family members, and signalling proteins involved in fundamental cellular processes, e.g. 
vesicular traffic, stress-response, electron transfer and apoptosis (47-51). TAs contain their single 
transmembrane domain within the final ~40 residues of the C terminal, which tethers them to the 
lipid bilayer such that the majority of the protein is located in the cytoplasm (52). The soluble part 
of the protein is typically most important for biological function, as in the case of the SNARE 
proteins, in which the cytoplasmic domain plays a vital role during vesicular transport (53). 
 
In eukaryotes, functionally diverse tail-anchored proteins exist in different organelles including 
the mitochondria, the peroxisome, and chloroplast (in plants) with the ER containing the largest 
number of proteins (54). To reach compartments of the secretory pathway, TA proteins are 
thought to be first delivered to the ER and then forwarded to their final destination by vesicular 
trafficking (20, 55-57). In contrast, TA proteins destined for the mitochondrial outer membrane 
and the chloroplast envelope can be targeted directly from the cytosol (46).  
 
Diverse TA proteins are equipped with their own characteristic tail and TMDs also contains the 
membrane targeting signal (58). Furthermore, the amino acid sequence of the tail can affect both 
the efficiency with which the protein is inserted into the membrane (47, 59) and its cellular 
location, e.g. moderate hydrophobicity of these elements shows a predisposition for ER residence 
(54, 60). Interestingly, in mammals, both TMD hydrophobicity and a tail charge define delivery 
to individual organelles. For example, positive charge of the tail region seems to be a common 
property of peroxisomal TA proteins, which differentiates them from mitochondrial and ER tail-
anchored proteins. In contrast, the presence of significantly higher TMD hydrophobicity of TAs 
in endoplasmic reticulum as compared to those destined for mitochondria, indicates that a 




The detailed mechanisms of sorting and delivery to peroxisomes and mitochondria are less 
understood. No components of the mitochondrial TA targeting machinery have yet been identified 
and it has been proposed that the process can occur via unassisted insertion, with the composition 
of the mitochondrial outer membrane mediating targeting specificity e.g. for cytochrome b5 (62-
64). However, at the ER, the biogenesis of tail-anchored proteins involves one or more cytosolic 
factors including HSP70 (65-68). 
 
Despite the importance of TA proteins in numerous cellular processes, their targeting mechanisms 
and signals are not fully understood. Furthermore it is essential to study TA insertion mechanisms 
and underlying regulation because mutations in genes encoding tail-anchored proteins have been 
detected in several inherited disorders (69, 70). 
 
1.2   The BAG6 complex and SGTA in TA targeting 
In mammals, TA proteins are targeted and inserted to the ER membrane by a conserved TMD 
recognition complex (TRC), a pathway in which SGTA (small glutamine-rich tetratricopeptide 
repeat containing protein alpha) together with the heterotrimeric BAG6 complex, composed of 
BAG6 (BCL2-associated athanogene 6), TRC35 (transmembrane recognition complex 35) and 
UBL4A (ubiquitin-like protein 4A) play crucial roles (71-73). TA protein delivery is subject to 
rigorous quality control to degrade proteins that fail targeting (Figure 1) (74, 75). 
 
It is established that loading of nascent TA proteins onto to the downstream targeting factor 
TRC40 requires SGTA and the BAG6 complex (72, 76). TRC40 can recognise hydrophobic TA 
regions (77-79) and promotes their membrane insertion at the ER through components of the 
transmembrane domain recognition complex, a cognate receptor composed of tryptophan-rich 
basic protein (WRB) and calcium-modulating cyclophilin ligand (CAML) (80, 81). Absence of 
any component in the BAG6 complex impairs SGTA-TRC40 bridging and TA protein capture by 
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TRC40 (73). However, free, newly-synthesised TA proteins are preferentially captured by SGTA 
which shields their TMD regions from the aqueous cytosol as they are released by the ribosome. 
SGTA can bind to BAG6 and UBL4A of the Bag6 complex via their UBL (ubiquitin like) 
domains (71, 82). However, SGTA’s interaction with the UBL domain of BAG6 (the N-terminal 
of BAG6 complex) seem to be dispensable for TRC40 capture because only the C-terminal of 
BAG6 can form a complex with UBL4A and TRC35 (19, 73). The BAG6 complex acts as a 
scaffolding binding platform which connects SGTA and TRC40 via the UBL4A and TRC35 
subunits (Figure 1) and allows for the transfer of TAs from SGTA to TRC40 (76). The small 
portion of TA proteins which spontaneously dissociate from SGTA before loading onto TRC40, 
or those that fail to be delivered to TRC40, can be re-captured by either SGTA or BAG6 and 
further triaged (73). The conserved ATPase, TRC40 (also called ASNA1) is at the centre of TA 
targeting in mammals in a process regulated by ATP binding and hydrolysis (66, 79). TRC40 was 
shown to promote the membrane insertion of several model TA proteins with similarly 
hydrophobic tail-anchor regions, including RAMP4 and Sec61β (66, 79). Although the 
mammalian structure of TRC40 has not yet been solved, the structures of yeast (83) and bacterial 
Methanothermobacter thermautotrophicus homologues have been characterised by 
crystallography (84). Overall the structural and functional analysis of tail-anchored delivery to 
the ER has been completed in greater detail in yeast as compared to mammals. Although studies 
of processing the TA proteins by the components of the TRC pathway in mammals have provided 
considerable mechanistic insights, there are still issues which remain unclear e.g., understanding 
the function of SGTA in TA protein targeting or details pertaining to degradation. To date there 
is no structure solved of SGTA with bound TA substrate. Likewise, it is not known if sequences 




Figure 1: Current models of targeting and quality control of hydrophobic substrates in mammals 
and yeast. SGTA (Sgt2 in yeast) captures free newly synthesised TA proteins and other hydrophobic 
substrates (MLPs, ERAD substrates), a process facilitated by its C-terminal domain (58, 85, 86) and hands 
over the substrates downstream onto components of the TRC pathway (Get pathway in yeast, downstream 
Get5-Get4-Get3) for delivery to the ER or mammalian quality control pathway for degradation. The BAG6 
complex is composed of BAG6, UBL4A and TRC35 proteins, and interacts with SGTA through its UBLs 
(82). The BAG6 complex connects SGTA and TRC40 via the UBL4A and TRC35 subunits, and allows for 
a rapid transfer of TA protein from SGTA to TRC40 (73, 79). TA proteins that fail to load onto TRC40, 
and other hydrophobic substrates which dissociate from SGTA, are re-captured by either SGTA or BAG6 
(73). The BAG6 complex associated substrates can be ubiquitinated by the E3 ligase RNF126 and targeted 
to the proteasome for degradation (75). 
 
 
1.3   Sgt2 in the GET pathway 
TA protein targeting via Guided Entry of Tail- anchored (GET) pathway has been characterised 
in more detail in Saccharomyces cerevisiae than in the mammalian system (Figure 3). The 


















































reconstituted from purified recombinant components (58, 78, 87, 88). The tail-anchored targeting 
mechanism begins with, a TA chaperone, Small, glutamine-rich, tetratricopeptide repeat protein 
2 (Sgt2) forming a complex with TA substrates released to the cytosol. BAG6 is found widely 
across metazoans, but not in fungi and instead the analogous complex contains just two proteins 
forming a tetramer made of dimers of Get4 and Get5 corresponding to TRC35 and UBL4A, 
respectively (Table 1). Sgt2 escorts TA substrates onto GET components by binding to the UBL 
domain of Get5 (87, 89, 90). The structure of Sgt2-Get5 complex has been solved by 
crystallography (87, 89, 90). Get4 and Get5 form a heterodimeric pretargeting complex, with Get4 
recruiting the central targeting factor Get3. The role and structures of Get3 at various stages of 
TA targeting has been well characterised. A ‘closed’ state formed upon binding of adenosine 5’-
triphosphate (ATP) is competent to bind substrates in a process mediated by the Get4-Get5 
heterodimeric scaffolding complex (78, 87, 88, 90). Following the release of TA substrates from 
Sgt2, Get3 binds them within the hydrophobic groove formed by the two helices from the two 
Get3 subunits in a dimer (78). Several complexes of Get3 with TMDs bound (e.g. Sec22, Pep12) 
have been crystallised and the solved structures showed that one of the helices can function as a 
‘dynamic lid’ protecting the TMD during transit to ER membrane (78). Conversely, the Get3 
‘open’ state, triggered by the ATP hydrolysis, is followed by TA handover to the heterodimeric 
Get1-Get2 membrane receptor complex which finally facilitates their insertion into the ER 
membrane (50, 72, 80, 88). Get3 is recruited to the membrane via its initial interaction with Get2 
followed by binding to Get1. This drives TA protein release in an ATPase-dependent reaction. 
Free Get3 recycles back to the cytosol, prepared for another insertion cycle (91). All Get pathway 
components are important and there is evidence that deletion of any of the Get genes can result 
in ER-bound TA proteins misguidedly inserting into mitochondria or aggregating in the cytosol 
(88). 
 Thus far, Get3 has been the main focus of high-resolution structural studies, with crystal 
structures solved in both open and closed nucleotide-bound states (78, 91-94). These structures 
have provided some molecular insights into the mechanisms that promote Get3 substrate binding 
and release, and helped to propose models describing how ATP binding and hydrolysis might 
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affect these steps (83, 95, 96). The 3D structures of Get3 in complex with the cytoplasmic domains 
of Get1 and Get2 have also been determined and unravelled more details in the next step of TA  
protein insertion (91). The crystal structures of S. cerevisiae Get4 in a complex with an N-terminal 
fragment of Get5 (87, 89, 97) and a crystal structure of a Get3-Get4-Get5 intermediate complex 
from S.cerevisiae (98) provided insights into the mechanistic details of pretargeting complexes in 
the Get pathway. However, the earliest steps involving TA substrate capture by Sgt2 and SGTA 
are not clear. Sgt2/SGTA facilitates the biogenesis of TA proteins by their high-affinity (with 
rapid kinetics) interaction with Get5 in the Get4-Get5 complex, ensuring the effective capture of 
hydrophobic substrates (87, 89, 90). It has also been proposed that SGTA-dependent 
deubiquitination of TA substrates presents a mechanism for rescue and subsequent handover to 
downstream targeting factors (86, 99). Although the existence of a pretargeting factor may suggest 
how substrates are sorted and loaded onto Get3, it is not known how TA proteins are initially 
captured by Sgt2. The structurally characterized domains of proteins studied in this project and 
their homologues are shown in Figure 2. 
Table 1: Analogous protein components of GET pathway in fungi and TRC pathway in mammals. 
 





Get2 CAML receptor (functional homologues) 





Figure 2: Structures of domains of the proteins studied in this project and their homologues. Sc 




Figure 3: Details of tail-anchored protein targeting to the ER in the GET pathway. In Saccharomyces 
cerevisiae, the chaperone Sgt2, captures and shields ER-destined TA proteins released from the ribosome 
into the cytosol and hands them over to components of the Get pathway via its interaction with Get5   (88). 
The pathway is centered around the cytosolic targeting factor Get3, an ATPase that interacts with the 
heterodimer of Get1-Get2 ER membrane receptor complex to mediate TA protein insertion (88, 91, 93). 
Loading Get3 with a TA protein requires the heterodimeric Get4-Get5 pretargeting complex (72, 78, 88, 
91, 98, 100), which mediates transfer onto dimeric Get3. Get4-Get5 complex recruits Sgt2 in a complex 
with a TA protein, while Get4 recruits ATP-bound ‘open’ Get3 (101). Following the ATP hydrolysis, TA 
substrates are transferred onto ‘closed’ Get3, which dissociates from Get4 (102-104). No BAG6 homologue 
exists in the Get pathway and there is no known analogous quality control and degradation pathway in 
yeast. However, Sgt2's interactions with Hsp70/Hsp90 chaperones (105) via its TPR domain likely provide 
substrate access to additional quality control networks. 
 
1.4   Degradation of MLPs by the ubiquitin-proteasome system 
Failure in targeting of membrane and secretory proteins can result in their mislocalization to the 
cytosol and accumulation of misfolded proteins that are prone to aggregation poses the danger of 
developing aggregation related diseases (8, 106). Such aberrant proteins, including MLPs, after 



































The degradation mechanism should be able not only to recognise a broad range of substrates but 
also to allow for a proficient selection to ensure the correct protein disposal (107, 108). A 
substantial proportion of intracellular proteins are degraded by the Ubiquitin-Proteasome System 
(UPS) (109-111). However, extracellular proteins and some cell surface proteins (e.g. cell 
receptors) are eliminated in a process of endocytosis and degraded within lysosomes (112). In the 
UPS, damaged or no longer needed, cytosolic proteins are tagged for degradation at the 
proteasome with a small, 8.5 kDa protein called ubiquitin. The 26S proteasome, a very large 
multicatalytic protease complex can then recognise ubiquitin, covalently attached to protein 
clients and degrade these into small peptides. Proteases hydrolyze amino acid chains and break 
peptide bonds, yielding peptides of about seven to eight amino acids long, which can then be 
further degraded into shorter amino acid sequences and used in synthesizing new proteins (113). 
The 26S proteasome in eukaryotes is made of a 20S proteolytic core and a 19S ATP-dependent 
regulatory cap (114) and is localised in the nucleus and in the cytoplasm (115). The ubiquitin 
tagging reaction called ubiquitination involves the collaborative action of three proteins: an E1 
(ubiquitin-activating enzyme), an E2 (ubiquitin-conjugating enzyme) and an E3 (ubiquitin protein 
ligase) (116, 117). The client protein is tagged with one or more ubiquitin molecules which can 
bind to one another, forming polyubiquitin chains. The pattern and distribution of ubiquitination 
determines the final fate of a protein (118). Notably, ubiquitin molecules can connect mostly via 
Lys48 or Lys63, with potential to form chains with a variety of linkage types, attached to the 
protein client which can promote different outcomes for the substrate: Monoubiquitination may 
facilitate protein recognition, complex formation, or allosteric regulation, whereas 
polyubiquitination via Lys48 is a signal for proteasomal degradation. In contrast, 
polyubiquitination of Lys63-linked chains have non degradative roles in cellular signaling, 
intracellular trafficking and DNA repair (119, 120). Typically, a polyubiquitin chain made of four 





In the sequential action of the E1/E2/E3 ubiquitination cascade, a free ubiquitin is activated by an 
E1 ubiquitin-activating enzyme which hydrolyses ATP and adenylylates a ubiquitin molecule. 
Typically a cysteine at the active site of the E1 enzyme then forms an energy-rich thioester bond 
with the C-terminal glycine residue of ubiquitin in concert with adenylylation of a second 
ubiquitin (107, 123). Subsequently the adenylylated ubiquitin is conjugated to the cysteine residue 
at the active site of an E2 ubiquitin-conjugating enzyme, from where the ubiquitin is transferred 
onto the lysine side chain of a protein client generating an isopeptide bond, in a process catalysed 
by E3 ubiquitin ligase, that directly binds to the E2 enzyme (124-127), (Figure 4). In multi 
monoubiquitinated substrates, several Lys residues on the same protein are modified with one 
ubiquitin and in polyubiquitinated substrates, a lysine residue on a preceding ubiquitin molecule 
becomes covalently attached to a glycine residue of the next ubiquitin. The formation of 
polyubiquitin chains, commonly through internal Lys48 residues of ubiquitin, leads to recognition 
by the proteasome and degradation (108, 121, 122). 
 
Degradation may require additional factors, such as the AAA ATPase p97-Ufd1 (ubiquitin fusion 
degradation 1)-Npl4 (nuclear protein localization 4) complex, a ubiquitin-selective segregase 
which functions in the detection of a number of polyubiquitin-tagged proteins and mediates their 
presentation to the 26S proteasome for degradation (128-131). 
 
Although the whole enzymatic E1/E2/E3 ubiquitination cascade is needed to link ubiquitin 
molecules to client proteins, the key regulatory enzymes in the process are the E3 ubiquitin–
protein ligases, which maintain the specificity of this process by selecting the suitable substrate 
for ubiquitination via collaboration with several molecular chaperones involved in the recognition 
and binding of MLPs (4, 132, 133). To determine substrate selectivity, E3 ligases bring together 
the appropriate E2 with the specific substrate. There are >600 mammalian E3s thought to facilitate 
recognition of a broad range of substrates, although no biological function, mechanism of action 
and substrate specificity has been characterised for many of them (127). Nevertheless, E3s are 
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classified into three main families of E3 ubiquitin ligase classes, each characterised by conserved 
structural domains and different mechanism by which ubiquitin is transferred from the E2 enzyme 
to the substrate and the way in which E3 ubiquitin ligases contact the E2 (Figure 4). The first 
type is E3 RING (really interesting new gene) ligases, which typically catalyze direct transfer of 
ubiquitin from the E2 enzyme to the protein client, simultaneously binding both the E2~Ub cargo 
and the substrate (134, 135). In some of the E2-E3 pairs, E3 attachment can induce a 
conformational change in the E2 leading to an increased rate of ubiquitin release (136, 137). The 
families of HECT (homologous to E6-AP COOH terminus) and the RING-between-RING (RBR) 
E3 ligases ubiquitinate substrates in a two-step mechanism in which ubiquitin is first transferred 
from the E2 to a catalytic cysteine of the E3 and then from the E3 to the protein client (138). The 
HECT domain’s active site cysteine can form a thiol-ester bond with ubiquitin (139). There is 
evidence that some E3 ligases may play a role in regulating chain topology e.g. some of the HECT 
E3 ligases preferentially form K63-linked chains irrespective of the identity of the E2 (140). 
Furthermore, a number of E3 ligases have been shown to ubiquitinate misfolded proteins in an 
Hsp70-dependent manner. Likewise, the mammalian E3 ligase CHIP (carboxy-terminal Hsp70 
interacting protein) directly binds to Hsp70 and Hsp90 and can direct some of the Hsp70-bound 
proteins for degradation (141, 142). However, despite many studies of substrate ubiquitination by 
the E2-E3 pairing, the catalytic mechanisms by which E3 ligases recognise substrates and regulate 
ubiquitin transfer remain elusive.  
 
In yeast, some of the ubiquitin ligases can directly interact with misfolded proteins in chaperone-
mediated quality control pathways. E3 ligase Ubr1 (ubiquitin protein ligase E3 component N-
recognin 1) and Ubr2 can mediate degradation of misfolded proteins in the cytosol while another 
E3 ligase, San1 (Sir antagonist 1), operates in the nucleus and binds misfolded proteins via its 





1.4.1   Ubiquitin binding domains 
The mechanism of proteasomal targeting of polyubiquitinated proteins is not entirely clear. 
Nevertheless, the ubiquitin modification of target proteins can be specifically recognised by 
various ubiquitin-binding domains (UBDs) or ubiquitin receptors that contain one or more UBD 
within their structure (144, 145). UBDs can noncovalently interact with monoubiquitin or 
polyubiquitin chains and the majority of identified UBDs bind to a hydrophobic area surrounding 
Ile 44, Leu 8, Ile 44, and Val 70 residues of ubiquitin. The residues flanking the binding surfaces 
on ubiquitin have also been shown to contribute to the binding specificity of different UBDs (96, 
146, 147). Ubiquitin chains attached to proteins destined for proteolysis can be bound directly by 
a proteasome subunit or by a shuttle factor which links ubiquitinated proteins with the proteasome. 
The 26S proteasome regulatory subunit Rpn13 and Rpn10 are two intrinsic ubiquitin receptors, 
present at the 19S regulatory particle of the proteasome that bind mono- and poly-ubiquitin chains 
as well as UBL domains (148-151). The shuttle factors Rad23 (UV excision repair protein) and 
Dsk2 (Ubiquitin domain-containing protein), contain both UBDs and Ubiquitin-like (UBL) 
domains and, through binding both ubiquitin and the proteasome, deliver the polyubiquitinated 
cargo to the 26S proteasome for degradation (152-155). 
 
The UBL proteins which can bind substrates in a similar manner to ubiquitin are often referred to 
as type I UBLs (156). Other UBLs, present as functional domains in larger proteins are termed 
type II UBL domains (157). Many type II UBLs interact with a broad range of UBDs whereas 
type I UBLs seem to have more specific binding partners. Some of the type II UBLs can interact 
with ubiquitin binding domains (UBDs) such as UBA (Ubiquitin Associated), UIM 
(Ubiquitin Interacting Motif), and CUE (Coupling of Ubiquitin to ER degradation) or PAZ 
(polyubiquitin-associated ZINC FINGER), (144, 158). Ubiquitin, UBLs and UBDs, all have role 
in the ubiquitin proteasome system and ERAD pathway in fundamental protein-protein 
interactions (154, 159). The BAG6 complex includes two type II UBLs, one in the UBL4A 
subunit which does not seem to bind canonical UBDs but does interact with SGTA. The second, 
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at the N-terminal of BAG6 itself, can bind canonical UBDs but also has the ability to interact with 
the unusual UBD of SGTA  (82, 160). 
 
Work focusing on UBD–ubiquitin interactions, has shown that the majority of them and especially 
those with monoubiquitin are typically on the low to medium affinity scale. The range of UBD–
ubiquitin affinities, varies between Kd values of 10–500 µM (144, 161). 
 
1.4.2   Deubiquitinases 
Coupled to the UPS cycle are deubiquitinases (DUBs), proteases, which exist in cells in large 
numbers and can reverse protein ubiquitination (119). The E3 ligases associate with the client 
protein for a period of time necessary for the attachment of one or more ubiquitin. Following the 
ligase dissociation, there is a competition between Ub cleavage by DUBs and ligase reassociation 
(162). DUBs can hydrolyze the isopeptide or peptide bond between the ubiquitin C terminus and 
a substrate (e.g., another ubiquitin molecule). The linkage specificity of DUBs and the recognition 
mechanisms of the highly complex, so-called, ubiquitin codes has been the subject of extensive 
study (Figure 4) (119, 163, 164). The extent of linkage specificity varies between DUB families. 
Some DUBs can bind directly to a protein client and remove ubiquitin from it while another can 
recognise the ubiquitin chain itself. The orientation of Ub-binding sites in DUBs determine 
whether polyubiquitin is removed from the external distal or proximal end, from within a chain 
or from the branch points in polyubiquitin (164). The role of DUBs in ubiquitin chain cleavage is 
wide-ranging and involves recycling of ubiquitin from cargo destined for the proteasome or 
lysosome (165), or freeing up the proteasome from proteins that are difficult to degrade to avoid 
the accumulation of ubiquitinated proteins (166). Furthermore, a great number of DUBs work as 
parts of larger macromolecular machinery (e.g., the proteasome), which recruit substrates for 
deubiquitination. In these cases, DUB–substrate interaction is indirect and may not be governed 




Figure 4: Substrate ubiquitination by the E1/E2/E3 enzymatic cascade. A) The coordination between 
E1, E2 and E3 enzymes transfers the ubiquitin onto the substrate. Two different modes of action are shown 
for HECT and RING E3 ligases. Deubiquitinases (DUBs) cleave the ubiquitin from modified proteins. B) 
The types of ubiquitin linkages. Monoubiquitin, can be extended on one of its eight lysine residues or its 
N-terminal methionine (Met 1) residue, forming different patterns of homotypic or heterotypic 
polyubiquitin chains. The heterologous modifications may involve the incorporation of modifiers like 
ubiquitin-like domains (UBLs) or various adaptors and also post-translational modification like 
phosphorylation or acetylation (Ac) (adapted from (158) (top) and (164) (bottom). 
 
1.5   SGTA, the BAG6 complex and RNF126 in protein quality control 
It has gradually been established that the BAG6 complex (BAG6, UBL4A, TRC35) together with 
SGTA play a crucial role in the quality control of misfolded and mislocalised proteins (Figure 1). 
They receive and triage various substrates, each characterised by an exposed hydrophobic region, 
and maintain them in a soluble state until they can be transferred to the following partner in the 
relevant pathway (74, 86). The quality control mechanisms, in which SGTA and the BAG6 
complex are involved, include transient binding to components of the ribosome (72) and the 
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proteasome (74, 167, 168). They participate in the DNA damage response when localised to the 
cell nucleus via the nuclear localization signal on BAG6 (169) and in ERAD, where misfolded 
proteins are ubiquitinated and retrotranslocated from the ER to the cytoplasm to enable their 
proteasomal degradation (160, 170, 171). SGTA recognises and binds exposed hydrophobic 
regions of different targets (TMDs of TA proteins and hydrophobic regions of mislocalised 
membrane and secretory proteins) and transfers them onto the BAG6 complex to facilitate either 
the polyubiquitination of hydrophobic substrates and degradation at the proteasome or their 
appropriate onward delivery to the ER (19, 74, 172). Previous experiments showed that SGTA’s 
depletion from a cell-free translation lysate impeded nascent TA protein capture by TRC40 and 
BAG6 with subsequent reductions in both ER insertion and ubiquitination (73). Conversely, 
depletion of the BAG6 complex or TRC40 caused TA proteins to be retained on SGTA (73). This 
suggests that SGTA facilitates both targeting and degradation, indicating that TA proteins bound 
to SGTA at this stage are not necessarily committed to either fate (73). A few years ago, RNF126 
(ring finger protein 126) was identified as a soluble E3 ligase which is recruited to BAG6 for 
ubiquitination of BAG6 associated hydrophobic clients that are destined for degradation (75). 
RNF126 contains two individual domains: an N-terminal zinc-finger domain and a C- terminal 
RING domain (173)  with the former region considered to play an key role in the interaction with 
the UBL domain of BAG6 (75). Furthermore, SGTA and RNF126, both bind to the same region 
of the BAG6 complex (174). The precise details of the sorting mechanisms are unclear. Hence it 
seems that the triage decision between degradation at the proteasome or the dedicated onward 
delivery to the ER after the recognition of the exposed hydrophobic regions of TAs and MLPs 
depends on accurate time and kinetics (19, 73). After hydrophobic substrates dissociate from 
SGTA, they are transferred onto the components of the ER targeting module (C-terminal BAG6/ 
UBL4A/TRC35/TRC40) and the quality control module (N-terminal BAG6/RNF126). The triage 
depends on how fast they can bind the hydrophobic substrate and how long they can maintain it 
bound. The abilities of SGTA, BAG6 and TRC40 to compete for free TA protein are inversely 
associated to their ability to retain the bound client (73). Hence, TAs transfer from SGTA to 
TRC40 through the C-terminal of BAG6 is faster than the rate of spontaneous TA protein 
dissociation from SGTA. Conversely, TAs handover from SGTA to BAG6 is slower and involves 
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a free TA intermediates (73). SGTA collaborates with the BAG6 complex and links the targeting 
and ubiquitination pathways. However, the precise function of SGTA in each of these processes 
is less well established. 
 
The role of SGTA in the specific recognition of hydrophobic substrates has been studied using 
short hydrophobic fragments and showed that SGTA interacts directly with MLPs, both in 
vitro and in vivo. They highlight the importance of an uninterrupted hydrophobic sequence for 
this binding to occur (86). It has also been suggested that SGTA can actively promote the 
deubiquitination of mislocalised proteins by binding their exposed hydrophobic sequences in the 
cytoplasm and rescuing them from degradation (86, 99). In the case of TAs, it has even been 
proposed that SGTA may be able to rescue substrates that are prematurely ubiquitinated (19, 74). 
Furthermore SGTA and the BAG6 complex are also involved in the elimination of aberrantly 
folded proteins from the ER in the endoplasmic reticulum-associated degradation pathway 
(ERAD) (160, 171, 175, 176). In this quality control mechanism, SGTA and the BAG6 complex 
maintain retrotranslocated polypeptides in a soluble state, promoting their turnover (171). 
Importantly, SGTA deficiency impairs ERAD and induces unfolded protein response, a stress 
response induced by the accumulation of misfolded proteins at the ER (171). 
 
The importance of the collaborative work of SGTA and the BAG6 complex in the quality control 
of hydrophobic substrates has been established. However, much structural information on the 
complete BAG6 complex remains to be obtained. For example, the structure and oligomerization 
architecture of the 119 KDa BAG6 (also known as Bat3 and Scythe) protein itself has not yet 
been defined. The non-canonical ‘BAG domain’ close to the C-terminal part of BAG6 is known 
to bind directly to a C-terminal region of UBL4A with crystal structures of the minimal complex 
solved (76, 177). TRC35 also binds to the C-terminal region of BAG6, called the ‘nuclear 
localization sequence’ which is close to the ‘BAG domain’, through its own C-terminal domain. 
Hence, BAG6 connects TRC35 and UBL4A (76) and allows substrate transfer between SGTA, 
38 
 
BAG6 and TRC40 (73). The BAG domain from BAG6 is called a ‘mock BAG’ domain because 
it does not share the function of other BAG domains like the one of BAG1 which can bind 
Hsp/Hsc70 and inhibit its actions involved in vitro refolding of an unfolded protein substrates 
(178, 179). Additionally, the BAG domain is structurally different, compared to canonical BAG 
domains (76, 180). Interestingly, before BAG6 was established as BAG6 family member, the 
protein was initially associated with apoptosis based on its interaction with an apoptosis-inducing 
protein, in Drosophila melanogaster (called Reaper) (181). The poorly defined middle region of 
BAG6 is capable of binding hydrophobic substrates (19).  
 
Notably, the activity of the BAG6 complex itself is also subjected to the quality control. The 
ERAD E3 ligase, GP78, in addition to ubiquitination of ERAD substrates, can also tag UBL4A, 
a key component of the BAG6 complex. Interestingly, instead of directing UBL4A for 
proteasomal degradation, polyubiquitination is linked to the irreversible proteolytic processing 
and inactivation of BAG6. However, ubiquitin molecules can be removed from UBL4A by 
USP13, a GP78-associated DUB which maintains the functionality of the BAG6 complex (182). 
 
In yeasts, which do not have the BAG6 quality control subunit, cytosolic chaperones like Hsp70 
chaperones (Ssa 1-4 in yeast), the Hsp40 chaperone (Ydj1 in yeast) and Hsp104 disagregase, have 
the ability to extract and refold proteins from aggregates (183-186). The main E3 ligase 
responsible for ubiquitination of misfolded proteins in the cytosol is the E3 ubiquitin-protein 
ligase Ubr1 (187), which involves Hsp70 and Hsp110 chaperones in substrate ubiquitination (143, 
188). While, at the endoplasmic reticulum, the ER membrane brings E3 ligases together with the 
components of ERAD such as the Cdc48 (Cell division control protein 48) machinery which 
typically act in ubiquitination of ERAD substrates but are also capable to target some substrates 
localised in the cytoplasm for degradation by the proteasome. Other cytoplasmic substrates are 
transported into the nucleus in a process mediated by chaperones where ubiquitination is 
facilitated by the E3 ubiquitin-protein ligase San1, which tags misfolded nuclear proteins for 
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degradation (143, 189). Furthermore, some aberrant proteins at the cytoplasm and nucleus can 
also be targeted by autophagy and degraded by the vacuole/lysosome in mammalian and yeast 
cells (4, 190, 191).  
 
1.6   Structural and functional overview of RNF126  
RNF126 belongs to the family of RING (really interesting new gene) E3 ligases and comprises 
two individual zinc finger domains: an N-terminal zinc-finger domain (residues 1-100), and a C-
terminal RING domain (residues 229-270) (75, 173). The N-terminal zinc-finger domain is 
considered to play an important role in the interaction with the UBL domain of BAG6 (75) while 
the RING domain is required for the E3 ubiquitin ligase activity (173). In addition, RNF126 
contains an unusual stretch of ∼12 serines at the C-terminal that is evolutionarily conserved 
between zebrafish and human and is similar to stretches found in transcriptional activators present 
at RNAPII-dependent promoters (192, 193). 
 
Zinc fingers are small motifs which usually contain multiple finger-like overhangs that interact 
with their target molecules including RNA, DNA and proteins. They vary in function and 
topology and require coordination of one or more zinc ions to stabilise their structures. The 
binding properties of zinc fingers rely on the amino acid sequence of the domain and the linkers 
between fingers, as well as the three dimensional architecture and the number of fingers (194). 
They are classified into several different families based on their structure and the residues 
coordinating the zinc ion, usually a combination of four amino acids, either cysteine or histidine. 
The most abundant in eukaryotic genomes are proteins containing the Cys2His2 motif many of 
which function as zinc finger transcription factors that recognise specific DNA sequences (195). 
Other examples of zinc finger families include Cys4-, Cys6- or Cys3His	  -­‐types. RNF126 belongs 
to a family of proteins containing a RING finger domain comprising a Cys3HisCys4 amino 
acid motif which binds two zinc ions (seven cysteines and one histidine). Most RING domains 
are small and contain from 40 to 60 residues (196). The solution structure of the mouse RNF126 
40 
 
RING domain has been solved (PDB Accession Number: 2ECT; with no associated publication) 
and the structure of the N-terminal zinc finger domain is described in chapter 4. However, to date, 
full-length RNF126 has not yet been structurally characterised. Like RNF126, other proteins 
containing a RING finger are also involved in the ubiquitination pathway (197). Examples include 
several functionally diverse RING finger proteins, like BRCA1 (breast cancer type 1 
susceptibility protein) and TRC8 (Translocation in renal carcinoma on chromosome 8 protein), 
which can facilitate E2-dependent ubiquitination (198). 
 
Typically, RING domains of E3 ligases transiently interact with the N-terminal helix of E2 
conjugating enzymes (199) and may compete with binding of the E1 enzyme to E2 (200). In 
addition to the E2-binding domain, RING E3 ligases possess domains like regions that can bind 
substrates destined for ubiquitination. For example, the RING E3 gp78 ligase contains an 
additional domain, that binds to the E2 β-sheet on the side opposite to the active site (to which 
free ubiquitin can bind in solution) and can cause allosteric changes in the E2, opening the active 
site for substrate binding and promoting ubiquitination (136, 201). Although a number of 
structures of RING domain–E2 complexes have been characterised (199, 202-205), the 
mechanism by which RING domains facilitate ubiquitin transfer remains elusive. 
 
1.6.1   RNF126 as an E3 ligase 
The E3 ligase activity of RNF126 relies on its recruitment to the UBL domain of BAG6 where it 
can ubiquitinate BAG6-associated hydrophobic clients through its C-terminal RING domain (75). 
Although the substrates specificity of RNF126 is unclear, it has been reported that it preferentially 
ubiquitinates lysine residues which are close to the BAG6 binding site, which may suggest that 
RNF126 recruits the E2-ubiquitin conjugate in close proximity to the BAG6 substrate binding 
region (75). RNF126 can mediate the formation of K63-linked ubiquitin chains with ubiquitin-
conjugating E2 enzymes Ubc13/Uev1a and also K48-linked chains with E2 conjugating enzyme 
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UbcH5b in vitro (206). The N-terminal zinc finger domain is not required for formation of a poly-
ubiquitin chains in vitro (206). 
 
While BAG6-RNF126 ubiquitination is considered to be a primary substrate degradation 
pathway, there is also evidence that there must be alternative ubiquitination systems operating in 
the absence of RNF126 (75). It is unclear whether another E3 ligase, RNF115 (also called 
Rabring7 or BCA2 - breast cancer-associated gene 2), which is similar to RNF126, can function 
in a rescue degradation pathway and ubiquitinate the same range of substrates (75). RNF126 
shares similar structural features with RNF115, which also contains N-terminal and C-terminal 
zinc fingers. RNF115 has previously been shown to have RING finger dependent auto-
ubiquitination activity (207-209). The malfunction of RNF115 is linked to invasive breast cancer 
related to the regulation of the estrogen receptor (210, 211). Furthermore, RNF115 promotes the 
lysosomal degradation of trapped human immunodeficiency virus (HIV-1) virions and also 
functions as anti-HIV factor by targeting Gag (HIV-1 precursor of the structural proteins) for 
lysosomal degradation impairing virus assembly and release (212, 213). 
 
1.6.2   The role of RNF126 in cancer 
The past few years have seen efforts in identification of E3 ligases as anti-cancer targets (214-
216). The activity of RNF126 has been linked to cancers, including breast cancer, prostate cancer 
and tongue cancer (173, 193). It has been reported that RNF126 can regulate the cell cycle by 
promoting cancer cell proliferation and targeting the tumor suppressor p21 cyclin-dependent 
kinase inhibitor for ubiquitin-mediated degradation (173). Furthermore, RNF126 knockdowns 
inhibit the cell viability of tongue cancer cells and prostate cancer (173, 193). RNF126 also 
exhibits ubiquitin ligase activity against pyruvate dehydrogenase kinase (PDK) where it is 
necessary for the tumorigenicity of cancer cells in mice (217) and also targets activation-induced 
cytidine deaminase (AID), an enzyme that deaminates deoxycytidines in single-stranded DNA 
(192). Conversely, the function of RNF126 was linked to the regulation of homologous 
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recombination (HR)-mediated DNA double-strand break repair by promoting the expression of 
BRCA1 tumor suppressor, in a manner independent of its E3 ligase activity but by direct 
interaction with the E2F1 transcription factor (218).  
 
1.6.3   RNF126 in the regulation of cell signalling 
Both, RNF126 and RNF115 regulate the ubiquitin-­‐dependent endosomal sorting of cell surface 
receptors, like epidermal growth factor receptor (EGFR) and chemokine receptor type 4 (CXCR4) 
(206). They associate with EGFR and CXCR4 via their ubiquitin binding N-terminal zinc finger 
domains and promote ubiquitination leading to lysosomal degradation (206). Furthermore, 
RNF126 and RNF115 alter the sorting machinery found at the late endosome and inhibit the 
formation of multivesicular bodies (206). Moreover, RNF126 regulates the retrograde sorting of 
the cation-independent mannose 6-phosphate receptor (CI-MPR) in the pathway where a protein 
cargo undergoes retrograde transport from the endosome to the trans-Golgi network within the 
endocytic system (219). 
 
1.6.4   RNF126 and Frataxin 
Friedreich’s ataxia is a neurodegenerative disease caused by decreased expression of the 
mitochondrial protein frataxin of which levels are controlled by the ubiquitin-proteasome system. 
To date, there is no effective therapy to treat the disease (220-222). Patients live with 5%–30% 
residual frataxin and the severity of the disease progresses with the reduction of frataxin (223). 
Frataxin is synthesized in the cytosol in a precursor form and contains an N-terminal 
mitochondrial localisation signal, which allows the precursor to be targeted to mitochondria (224), 
where it plays a crucial role in the biosynthesis of iron-sulfur clusters (225, 226) and in iron 
metabolism (227, 228). RNF126 was shown to preferentially bind to the precursor form of 
frataxin as compared to the intermediate and mature forms and to promote frataxin ubiquitination 
and degradation (229). Binding experiments using catalytically inactive RNF126 with mutations 
of the two critical cysteines in the RING domain show that the mutant maintains the ability to 
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interact with frataxin, although can no longer ubiquitinate frataxin (229). Further study is 
necessary to clarify which domain of RNF126 directly interacts with frataxin.  
 
1.7   Structural and functional overview of the co-chaperones SGTA and Sgt2 
Small glutamine-rich tetratricopeptide repeat-containing protein α (SGTA) was discovered almost 
twenty years ago as a novel interaction partner of viral proteins (230, 231). SGTA is conserved 
amongst species with a common ancestor in animals and fungi (Figure 5). The S. cerevisiae 
orthologue to human SGTA (called Sgt2) shares 32% sequence identity (82). Other homologues 
include C. elegans, D. rerio, M. musculus, X. laevis, P. pastoris and A. fumigatus (Figure 5). 
SGTA is expressed in almost all tissues with the protein levels varying between species (232) and 
the alternative isoform b-SGT is predominantly brain-specific and shares 60 % amino acid 
sequence identity with SGTA (232, 233). SGTA has been found to localise primarily to the 
cytoplasm. However, its presence in the nucleus has also been detected (232).  
 
Since their discovery, the roles of SGTA and Sgt2 have been established in several biological 
processes. These include the post-translational transport of TA membrane proteins (87, 88, 90, 
97, 105), regulation of protein quality control (19, 86, 99, 234), cell cycle and apoptosis (235), 
intracellular compartmentalization (236, 237), neuronal synaptic transmission (238), viral 
infection (230, 231, 239-241) and hormone signalling (232, 235, 237, 242-244). 
 
Since SGTA is engaged in such a variety of biological processes, it is not surprising that it has 
been implicated in many diseases including cancer of the prostate (237, 245-247), ovary (248), 
liver (249)  and oesophagus (250); polycystic ovary syndrome (251); Alzheimer’s disease 
(238) and prion disease (252). Furthermore, a functional in vitro study showed that knockdown 
of SGTA in some cells can reduce cell viability and proliferation (237) and promote cell death 
(235, 253) while SGTA’s ablation in mice models limits the viability and growth of offspring 
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(254). Given the importance of SGTA in so many diverse cellular processes it is important to 
understand its mechanism of action in health and disease.  
 
1.7.1   Structural overview of SGTA/Sgt2 
SGTA and Sgt2 are both approximately 34kDa dimers and thus far, a number of biophysical 
techniques have been used to characterise their structure in some detail (Figure 5), and to study 
their interactions with binding partners in diverse biological systems. SGTs consists of three 
structural domains (Figure 5) with individual functions: an N-terminal dimerisation domain, 
followed by the conserved, central TPR domain and a glutamine rich region towards the C-
terminus (82, 87, 90, 101, 234, 255). SGTs of C. elegans, D. rerio, and A. fumigatus seem to have 
longer N-terminal linkers compared to both mammalian and yeast homologues. TPR domains are 
the most conserved, but the TPR capping helix (helix 7) shows lower conservation in fungi than 
in mammals (Figure 5). The N-terminal domain of SGTA (Sgt2) can directly bind the ubiquitin-
like (UBL) domain of BAG6 and UBL4A (Get5 in yeast) and facilitate the handover of TA 
substrates downstream onto components of the TRC pathway (Get pathway in yeast) for 
membrane delivery (73, 82, 87, 99). The C-terminal domain includes a glutamine-rich region, 
which comprises a stretch of 39 amino acids including 12 glutamine residues (231, 234) and is 
structurally uncharacterised. These domains of both Sgt2 and SGTA bind hydrophobic proteins 
including the TMDs of TA substrates (171, 234, 240, 256). Tetratricopeptide-repeat (TPR) 
domains typically consist of three or more tandem repeats of a loosely conserved 34 residue motif 
(257). Each tandem motif is formed of two anti-parallel α-helices, organised in a helix-turn-helix 
system, and forming arrays of 3–16 motifs (258). The TPR sequence varies with large and small 
hydrophobic amino acid residues highly conserved at positions that are important for structure 
and function. Other positions are less conserved and allow the replacement by amino acids with 
similar properties (258, 259). TPR domains are well-known for mediating protein-protein 
interactions (136). The structure of the human SGTA TPR domain was determined previously by 
X-ray crystallography (240) and has been reported to interact directly with Hsp70/Hsp90 
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chaperones, the proteasomal subunit Rpn13 and a variety of disease-related proteins (168, 236, 
240, 260). 
 
The TPR domain of SGTA exhibits sequence similarity to the TPR domains of Hop (Co-
chaperone Hsp70/Hsp90 organizing protein), CHIP (C-terminus of Hsc/p70-Interacting Protein), 
and TOM70 (Mitochondrial import receptor subunit) (236). These TPR domains are known to 
interact with Hsp70/Hsp90 proteins. The high-resolution structures of such complexes were 
reported for HOP TPR1 with an Hsp70–derived peptide, HOP TPR2A with an Hsp90-derived 
peptide (261), CHIP TPR with an Hsp70 C-terminal (171, 262) and AfSgt2_TPR (from 
Aspergillus fumigatus) modeled with its C-terminal linker (263). The common mode of 
interaction involves the formation of a carboxylate clamp where both the side-chain and main-
chain terminal carboxylate groups of the C-terminal aspartic acids of these peptides form salt 
bridges with residues within the groove of the co-chaperone’s TPR domains (264). To date the 
structure of the Sgt2 TPR domain from Saccharomyces cerevisiae has not been solved.  
 
Notably, the simple architecture of tandem-repeat proteins allows investigation of protein folding 
kinetics, thermodynamic characteristics (stability, energetics, and equilibrium two/multistate 
folding) (265-268). Such investigations allow controlled protein design to engineer the folding of 
repeat proteins, which then can be used in biomaterials (269) antibody substitutes (270) and 
disease therapeutics (265). Furthermore, specifically designed TPR proteins can serve as scaffolds 
for protein-ligand interactions and can help in understanding novel binding specificities (265). 
The structures of full-length SGTs presents a challenge because of their flexible linkers and 
dynamic C-terminal region. The full-length protein architecture of the dimer has been suggested 
to be elongated, with the three domains adjacent to each other (82, 234, 271). Evidence for this 
comes from the reported hydrodynamic radius of Sgt2’s C. elegans  homologue which has been 
observed to be larger than that of a globular protein (271). This is also supported by small angle 
X-ray scattering (SAXS) studies of the yeast Sgt2 devoid of its C-terminal domain which also 
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exhibits an elongated arrangement (263). Overall, the structural information on domain 
organization in the context of the full-length protein is yet to be discovered. In addition, the lack 
of conservation of the region between the N-terminal domain and the TPR, together with its length 
(10-15 amino acids) suggests the presence of a flexible linker between these two regions (260).  
 
1.7.2   The interaction of SGTA and Sgt2 with molecular chaperones 
SGTA/Sgt2 are co-chaperones, known to interact with general chaperones. SGTs associate with 
several heat-shock proteins such as Hsp104, Hsc82 (yeast homologue of Hsp90) and Ssa1/Ssa2 
(yeast homologues of Hsp70), which can bind directly to its central TPR domain (105, 253). The 
Hsp70 and Hsp90 chaperones are important parts of the cellular machinery for protein folding, 
maturation and structural stability (272, 273). They often associate with co-chaperones containing 
multiple copies of TPR domains (273, 274) which help them to facilitate correct folding of client 
proteins (88, 275). The activity of chaperones, Hsp70 and Hsp90 is tightly coupled to ATP 
binding and hydrolysis, and is subject to complex regulation by a large number of co-chaperones 
(276, 277).  It has been proposed that SGTA can also regulate the ATPase activity and folding 
rates of Hsp70 (242). General chaperones of the eukaryotic cytosol bind a wide range of 
substrates, among them proteins involved in signal transduction such as protein kinases and 
transcription factors. However, the detailed mechanism of the substrate recognition is poorly 
characterised and may partially reside within specific co-chaperones. While Hsp90 is thought to 
bind and stabilise partially folded polypeptides of some of its substrates, other proteins may be 
recognised in elongated conformations (6, 277). 
A brain-specific isoform of SGTA, βSGT, shares 60% amino acid sequence identity and can also 
interact with Hsc70 (233). βSGT has also been discovered to bind the cysteine string protein 
(CSP), a small protein with string of 14 cysteine residues  (244, 272). Modification of the 
cysteines mediates the attachment of CSP to secretory and synaptic vesicles and binding of the 
CSP to Hsc70 may recruit the chaperone to these vesicles (278). Trimeric complexes of CSP-
Hsc70-SGT were also detected on synaptic vesicles (272). However, the functional implication 
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of this interaction remains to be elucidated, but the presence of the trimeric complex on synaptic 
vesicles suggests a specialised role in neuronal function (233). 
 
Yeasts, which do not have the BAG6 quality control subunit, deal with damaged proteins in 
alternative ways and, for example, employing disaggregases and using general cytosolic 
chaperones like Hsp70 to refold proteins from aggregates. However it is not yet known whether 
the interaction between Sgt2 and chaperones is important in this context (183-186). 
 
1.7.3   Role of SGTA in viral cycles 
SGTA was first identified in the context of its ability to form a complex with a viral protein, a 
nonstructural protein of parvovirus H-1 (NS1) which is crucial for viral DNA replication and 
transcriptional gene expression. Evidence for this derives from data suggesting that SGTA is 
localised in both the cytoplasm and nucleus of rat fibroblasts, potentially linking SGTA’s role to 
parvoviral replication and/or gene expression (231). Later it was discovered that SGTA has a 
wider role in viral infections and interacts with other viral proteins too. For example, SGTA also 
interacts with an accessory severe acute respiratory syndrome coronavirus protein 7a (SARS-CoV 
7a), via its TPR domain (241). However, details relevant to mechanisms of this interaction and 
how SGTA is involved in the life cycle of this virus is poorly characterised. 
 
In contrast, the role of SGTA in human immunodeficiency virus type 1 (HIV-1) particle release 
has been elucidated in some detail (230, 279, 280). HIV-1 encodes three key structural 
polyproteins (Gag, Pol and Env), two regulatory proteins (Tat and Rev), and four accessory 
proteins (Vif, Vpr, Vpu and Nef) (281). The two main roles of Vpu include degradation of CD4, 
the primary receptor for HIV-1 (282, 283) and enhancement of the viral particles release from the 
cell surface by inhibiting the activity of the host restriction factor tetherin (213, 280, 284). There 
is evidence that SGTA is involved in Vpu () mediated enhancement of newly formed viral particle 
48 
 
release. Overexpressed SGTA interacts with HIV-1 Gag (a viral core protein precursor) in a way 
that can be reversed by competition with Vpu. Interestingly, SGTA can interact with both Vpu 
and Gag. It has been suggested that in the absence of Vpu, SGTA binds to HIV-1 Gag and forms 
a complex that inhibits HIV-1 release. However, in the presence of Vpu, the SGTA-Gag 
interaction is abrogated, possibly caused by SGTA forming a more stable complex with Vpu. An 
independent study reported that SGTA’s overexpression in mammalian cell lines transfected with 
HIV-1 proviral constructs reduced the efficiency of virus particle release (230). Furthermore, it 
has been suggested that SGTA may promote shuffling of the viral protein Gag to the plasma 
membrane where it assemblies into HIV-1 virus capsids (279). However, the interaction between 
SGTA and Gag is terminated when Vpu is overexpressed in the cell. It has also been shown that 
Vpu can influence cellular localisation of SGTA and Gag proteins (230, 279). Nonetheless, the 
TPR domain has been shown to be sufficient for SGTA's binding to Vpu and Gag albeit with 
lower efficiency than full length SGTA (240). In addition, SGTA can stabilise expression of a 
non-glycosylated form of the host restriction factor, tetherin, and it is the C-terminal of SGTA 
which appears to be necessary and sufficient for this action (280). Notably, the non-glycosylated 
tetherin form appears to partially mislocalise to the cytosol in the presence of Vpu and SGTA, 
and the relocalisation depends on the presence of the C-terminal domain of SGTA (280). 
 
Interestingly, the role of SGTA in ERAD may be extended into extraction of a hydrophobic 
protein complex Simian virus 40 (SV40) from the ER into the cytosol during SV40 infection. This 
way it may be promoting viral infections by assisting in membrane penetration (239, 285). During 
ER-to-cytosol membrane transport of the nonenveloped polyomavirus SV40, a decisive infection 
step, a cytosolic complex composed of Hsc70-SGTA-Hsp105 was previously shown to associate 
with the ER membrane. SGTA-Hsp105 extract SV40 from the ER and transport the virus into the 
cytosol. However how SGTA assists Hsc70 and Hsp105 in ejecting SV40 into the cytosol, remain 




1.7.4   Role of SGTA in the regulation of hormone receptor signalling 
Steroid hormone receptors are ligand-dependent transcription factors (typically either 
cytoplasmic or nuclear) that require the multi-chaperone complexes for their correct folding and 
transcriptional activity  (286-288). There has been growing evidence that the co-chaperone 
SGTA, through its interactions with chaperones and steroid receptors, may be important in the 
pathogenesis of androgen-associated disorders like prostate cancer, breast cancer and polycystic 
ovary syndrome (248-251). Research investigating the role of SGTA has been conducted in 
several model organisms and cell types, showing that SGTA interacts with several steroid receptor 
complexes and signaling pathways. SGTA specifically regulates the activity of the androgen 
receptor (AR), a nuclear transcription factor (289). This occurs through the interaction between 
the TPR domain of SGTA and the part of the AR localised between the DNA-binding domain 
and the ligand-binding domain, called a hinge region (236). The role of SGTA in the AR signaling 
pathway is not clear but it appears to be upregulated in most cancer cell lines (289). SGTA’s 
knockdown/deletion enhances receptor activity, while SGTA overexpression suppresses receptor 
activity (289). It is also speculated that SGTA dimerization is linked to the suppression of the 
androgen receptor signalling by negative regulation of AR transport to the nucleus and by 
inhibiting the connection between the cytoplasmic AR complex and the dynein motor complex 
(236, 237, 254, 290). The tumor suppressor, REIC/DKK-3 (Reduced Expression 
in Immortalized Cells/Dickkopf-3) seemingly interferes with SGTA dimerization and rescues AR 
signaling (247). REIC/DKK-3 is expressed ubiquitously in normal cells, whereas its expression 
is downregulated significantly in various types of cancer cells, including prostate cancer (291, 
292). Furthermore, another protein which is a member of the endogenous retroviruses of the 
HERV-K (HML-2) family, Rec, has been proposed to regulate AR activity through its interaction 
with SGTA (290). It has also been shown that SGTA modulates the activity of glucocorticoid and 
progesterone receptors (289). In addition, SGTA has been linked to mechanisms that involve 
endocytosis of the growth hormone receptor which is regulated by the ubiquitin-conjugating 
system. SGTA was shown to interact with growth hormone receptor through its first TPR motif 
in a study involving using yeast two hybrid and pull-down assays (243). However, in the absence 
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of molecular details describing the direct interactions of SGTA with hormone receptors, the role 
of SGTA in pathogenesis of hormone signaling related diseases remain largely elusive. 
 
1.7.5   The interaction of SGTA with the proteasomal ubiquitin receptor Rpn13 
Rpn13 and Rpn10 are two intrinsic ubiquitin receptors of the 26S proteasome regulatory subunit 
19S that facilitates substrate capture prior to degradation (148, 149). Two years ago it was shown 
that SGTA associates with the proteasome through a direct interaction between its TPR domain 
and the C-terminal domain of Rpn13 (167). Furthermore, the BAG6 subunit of the BAG6 
complex can bind Rpn10 (293, 294). On that basis, it has been proposed that the BAG6/SGTA 
quality control cycle may be operating at the 19S regulatory particle of the proteasome, capable 
of moderating the access of MLPs targeted for degradation to the proteolytic machinery (167). 
This would allow the substrates several rescue attempts before being terminally committed to 
degradation. Furthermore Rpn13 also interacts with the deubiquitinating enzyme UCH37 (UCH-
L5) in a mechanism that faciliates UCH37 access to its ubiquitinated substrates (295).  Hence in 
the context of the BAG6/SGTA actions, it has been proposed that the binding of SGTA to Rpn13 
provides SGTA-associated substrates with access to the UCH37 deubiquitinase and could 






Figure 5: Domain architecture and a sequence alignment of SGTA. A) Full length SGTA contains an 
N-terminal dimerization domain followed by a 14-residue linker, three TPR repeats with a capping helix 
and a C-terminal domain comprising a Q-rich region. Numbers indicate the number of amino acids in the 
proteins. B) Sequences of SGTA and its homologs are aligned, and domains annotated according to the 
human SGTA sequence. Secondary structure as predicted by Jpred is depicted as red cylinder for helices. 
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1.8   The SND alternative membrane protein targeting pathway 
A new pathway in Saccharomyces cerevisiae has recently been discovered which has been 
proposed to be the back-up mechanism for delivery of substrate proteins to the endoplasmic 
reticulum and can also operate in the event of GET system failure (296). The three proteins which 
are part of this pathway, named Snd1, Snd2 and Snd3 (named for SRP-independent targeting), 
were reported to work together with a possible role in targeting substrates to the translocation 
machinery Sec61 (296). Snd1 (SRP-independent targeting protein1) is predicted to be soluble, 
localizes to the cytosol (296, 297) and has been proposed to associate with eukaryotic ribosomal 
complexes (298). Snd2 (SRP-independent targeting protein2) is predicted to have four 
transmembrane domains, has been shown to localize to the ER membrane (296) and was 
previously shown to affect the maturation of the  carboxypeptidase Y (299). Snd3 (SRP-
independent targeting protein 3), is predicted to have one transmembrane domain (296) and also 
localizes to the ER (297). All three Snd proteins appear to collaborate and operate in one pathway, 
in which Snd1 interacts with Snd2 and Snd2 can bind Snd3 (296). Furthermore, Snd2 and Snd3 
were found in a complex with the Sec61 translocon and a model substrate (296). Although the 
relationship between the SND proteins and the SRP and GET pathways has been investigated, the 
mechanistic details have yet to be elucidated. Nevertheless, discovery of the new pathway and the 
role of the Snd proteins demonstrates the complexity of the cellular networks involved in efficient 
targeting. 
 
1.9   Sgt2 and Ybr137wp in the GET pathway  
Recently, Sgt2 was reported to interact with Ybr137wp, a protein that is specific to fungi and no 
homologous sequence has been found in mammals to date. The Sgt2 TPR domain binds to the C-
terminal end of Ybr137. Ybr137wp forms a decamer in its crystal form and also in solution as 
observed by size exclusion chromatography and analytical ultracentrifugation (300). In the crystal 
structure five Ybr137wp molecules form a homodecamer and each Ybr137wp monomer contains 
seven α-helices and four β-strands (β1 to β4). The four β-strands form an antiparallel β-sheet 
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creating the core of Ybr137wp surrounded by α-helices (300). An immunoprecipitation study 
indicates that Arg171 and Arg175 of the Sgt2 TPR domain interact with Ybr137wp and the two 
point mutations of these two arginine residues abolish the interaction of Sgt2 with Ybr137wp 
(88). In addition, isothermal titration calorimetry (ITC) experiments using a Ybr137wp construct 
lacking the C-terminal SLEEDLNLD motif abolished its binding to the TPR domain of Sgt2, 
indicating that the C-terminal acidic motif of Ybr137wp is necessary for the interaction (300). 
The function of Ybr137 has been investigated in the context of the Get pathway and yeast cell 
viability assays demonstrate that Ybr137wp is not essential for a regular TA protein targeting 
under normal conditions. However, it is able to rescue the TA protein delivery defect caused by 
a GET system that is impaired under starvation conditions (300). Furthermore, a deletion 
of ybr137w from the yeast strain promotes the association of heat-shock chaperones Hsp104 or 
Hsp70 with Sgt2 (88). This suggests that Ybr137wp and the chaperones compete for the same 
binding site on the Sgt2 TPR domain. Interestingly, Ybr137wp can also form a complex with 
Kap142p in the cytosol (301). Kap142p is a karyopherin that mediates nuclear export and import 
(301). However, the role of Ybr137wp in this interaction with a karyopherin is unclear. While it 
has been shown that Ybr137wp may contribute regulate TA protein targeting under certain 
condition, its detailed function in this pathway also remains to be uncovered. 
 
1.10   Aims 
The overall objective of this PhD project was to contribute to understanding the mechanisms 
governing the quality control pathways and the decision-making process in classifying 
hydrophobic protein clients either for degradation or biosynthesis. To achieve this, I aimed to 
biophysically characterise crucial proteins involved in the triage system, including the co-
chaperone SGTA and E3 ligase RNF126, in relation to the BAG6 complex. To study the full 
length proteins of the SGTA/RNF126/BAG6 complex module in vitro is challenging, because of 
hydrophobicity/flexibility leading to aggregation or excessive size. Therefore, this study explores 
the structures and interactions of excised domains. To provide a better understanding of 
mechanistic details underlying the interactions between these proteins, the structures of the N-
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terminal dimerisation domain of SGTA and the zinc finger motif of RNF126 E3 ligase, and their 
complexes with the UBL domains of BAG6 and UBL4A were determined. Project also focused 
on an additional role of the co-chaperone SGTA and its yeast homologue Sgt2, which is their 
interaction with general chaperones Hsp70 and Hsp90. Thus, the structure of the TPR domain of 
S.cerevisiae Sgt2 in complex with the C-terminal peptide of Ybr137wp was determined. In 
addition, the interactions of the TPR domain of Sgt2 with C-terminal fragments of Hsp70 and 
Hsp90 were also characterised. The methodology chosen to use in structural experiments included 
crystallography and nuclear magnetic resonance spectroscopy while the biophysical 
characterisations mainly involved isothermal titration calorimetry and microscale 
thermophoresis. Characterisation at the atomic level aimed to expand our understanding of the 
quality control mechanism in yeast and mammals, by providing molecular details of the 
components of the SGTA/BAG6 complex quality control module. They also have implications 














Chapter 2.   Methods 
The majority of the research in this thesis uses nuclear magnetic resonance (NMR) spectroscopy, 
X-ray crystallography, and isothermal calorimetry (ITC). Throughout these studies NMR is used 
extensively to assess the folding of protein constructs, assign protein resonances to facilitate 
protein structure solution, map chemically perturbed residues onto structure and determine 
protein-protein interactions. 1D NMR experiments have also been used to access the stability and 
folding of mutants (e.g., RNF126 mutants). ITC together with NMR was used to establish the 
binding affinities and molar ratios of interacting partners. Crystallography was used to solve the 
structures of a protein in its free state and in complex with a peptide. This chapter gives a brief 
overview of the theoretical and practical aspects of protein NMR spectroscopy, crystallography 
and ITC in the context of the experiments I have performed throughout these studies.  
 
2.1   Principles and practice of solution NMR spectroscopy 
2.1.1   Overview of basic concepts in NMR spectroscopy 
NMR utilizes a physical property of atomic nuclei which means they can absorb and re-
emit electromagnetic radiation, when placed in a magnetic field. Magnetic nuclei, composed of 
neutrons and protons, possess an intrinsic angular momentum known as spin. The spin has a 
magnitude and a direction and has an associated nuclear spin magnetic moment and a spin 
quantum number. Elementary quantum mechanics defines the spin quantum number, I, to have a 
integer or half integer value (e.g., 0, ½, 1,1½, 2, …). Any nucleus containing an odd number of 
protons or neutrons or both will possess a non-zero spin that can be detected as an electrical signal 
on NMR spectra. Typical NMR experiments employ nuclei with I = ½ such as 1H, 15N and 13C, 
19F, 31P, while 14N and 2H have an I value of 1. A nucleus with spin quantum number I in a 
magnetic field can occupy 2I+1 non-degenerate energy levels. Therefore, spins with I of ½ can 
occupy only two orientations, often labelled a and b. In a static magnetic field B0, the two allowed 
orientations of the nuclear magnetic spin moment have slightly different energies; a lower energy 
orientation aligned parallel to the field B0 and a higher energy orientation antiparallel to the field. 
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The energy levels of these orientations are described by the quantum number, m, which has values 
in integer steps from -I to I. For example, for I of ½, m has a value of -½ and ½ and the number 
of energy levels equals 2. In a static magnetic field, such as is generated by an NMR spectrometer, 
in a sample at thermal equilibrium, the states are populated according to the Boltzmann 
distribution. The energy difference between the a and b states is minor and the difference in 
population is also small. However, there is some excess of spins in the slightly preferred lower 
energy level, which leads to a bulk magnetization M, aligned parallel to the magnetic field B0 
along the z axis. The direction of the magnetic field B0 is described by the z axis of an x,y,z 
Cartesian coordinate axis system, known as the laboratory frame. A pulse is a linearly oscillating 
magnetic field applied along e.g., the x axis at a frequency (known as the transmitter frequency) 
typically around several hundred MHz. The pulse leads to the magnetization vector M tilting away 
from the z axis and a precession of the bulk magnetization in the xy-­‐plane and around the z-­‐axis 
which can be called the B0 axis (Figure 6). The frequency of this rotation is known as the Larmor 
frequency and therefore the NMR frequency of the nucleus in the molecule is determined by its 
gyromagnetic ratio and the strength of the field. The rate of the Larmor frequency or angular 
frequency of precession can be defined as w0= -gB0, where g is the gyromagnetic ratio of the nuclei 
under the pulse. The angle of the pulse depends on the angular frequency and the pulse length and 
can, for example, be equal to p/2 (a 90° pulse) or p (a 180° pulse) as shown in Figure 7. The 
flipping of the direction of the pulse axis can be achieved by modifying the phase of the 
radiofrequency field relative to the phase of the reference frequency of the detector. This 
magnetization produced by the pulse does not precess in the xy plane indefinitely and gradually 





Figure 6: Classical representation of the magnetic moment of a nucleus with a ½  spin. A) Orientation 
of the B0 and the bulk magnetisation before the pulse, magnetic moment M is aligned along the z axis of 
the laboratory frame. B) and C) The effect of the radiofrequency pulse. During the pulse, M precesses 
around the B0 field along the x axis. 
 
 
Figure 7: The effect of the radiofrequency pulse on the bulk magnetisation, M. A) after 90° pulse and 
B) after 180° pulse around the x axis. The flip of the bulk magnetisation is followed by a free precession. 
 
2.1.2   The basic NMR experiment and detection of signals in the spectrometer 
A common magnetic field used in NMR experiments is 2.35-23.5 T (tesla), which gives hydrogen 
nuclei resonance frequency of between 100 – 1000 MHz that is within the radiofrequency region 
of the electromagnetic spectrum (Figure 8). Proteins studied by NMR are commonly produced 
using isotopically-labeled media to generate proteins that contain 13C and 15N so that the 
specific quantum mechanical magnetic properties of these atoms can be measured. To date in 





Figure 8: The electromagnetic spectrum and relative frequencies of NMR experiments. The 
electromagnetic spectrum with NMR operating frequencies compared to other spectroscopic methods (left). 
In the middle is the enlarged region of NMR frequency close to 400MHz for some nuclei. On the right is 
an expanded region of 400MHz showing some of the 1H chemical shifts in parts per million, ppm, of a few 
functional groups of a peptide adapted from (302).  
 
In a typical experiment the sample is placed in a receiver/transmitter coil of wire which is used to 
produce a short radiofrequency pulse (RF) that excites spins within a molecule and generates a 
phase coherence of magnetic moments. The coherent precession of spins induces an alternating 
current in the receiver coil, which is amplified and then detected to give the free induction signal. 
The signal decays over time which is called a free induction decay (FID) and this is recorded for 
a time called an acquisition time. Finally, a Fourier transformation of the FID mathematically 
transforms the NMR	  signal from its time domain into a frequency domain to obtain the peaks we 
can observe in the NMR spectrum. The way the NMR spectrum is recorded using a pulsed 
experiment is shown in Figure 9. The initial delays allow the system to return to equilibrium after 
a period of time typically from microseconds to seconds (called tr for relaxation time). The NMR 
signal is usually weak and the spectrum obtained from a single FID is not sufficient for a good 
quality spectrum and signal-to-noise ratio. To improve the spectral quality, we repeat the 
experiment several times and add together the resulting FIDs. The FID is the sum of many 
oscillating waves of different frequencies, amplitudes and phases and, to filter this information, 
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the spectrometer employs detection channels known as quadrature detection during the Fourier 
transformation. 
 
Figure 9: Schematic view of the recording of basic NMR experiments. A) and B) During time tr the 
spins achieve equilibrium. A short RF pulse is applied for time tp and the subsequent FID is recorded for 
time tacqu. To collect sufficient information, the processes is repeated several times and FIDs added together. 
The location of RF pulses is marked as tx (for a RF transmitter) and the NMR signal is detected by a receiver 
(rx). C) The Fourier transformation is a process which turns a time domain signal, the FID, into a frequency 
domain, the spectrum (adapted from (303). 
 
There are two distinct types of relaxation, the spin-lattice or longitudinal relaxation (T1) and spin-
spin or transverse relaxation (T2). A T1 is a process in which bulk magnetisation returns to 
alignment along the z axis. It is caused by the local magnetic fields fluctuating at the Larmor 
frequency of the spins and allow spins to flip between the energy levels until the magnetization 





Along with the external magnetic field, nuclei also experience different local electromagnetic 
environments. Hence, nuclei of the same residue but in different chemical environments within 
the molecule will have different Larmor frequencies. This effect is called the chemical shift. NMR 
experiments rely on the concept that the spins between different nuclei interact, either through 
covalent bonds or by existing at close distances to each other. These interactions reveal 
information that can be used to extrapolate structural features. Hence, the chemical shift of nuclei 
is influenced by electron shielding, the magnetic anisotropy of neighboring groups and ring 
current effects. Electron shielding occurs when, in an applied magnetic field (B0), electrons 
circulate and produce an electric current which opposes B0. As a consequence, the effective field 
at the nucleus is reduced by the shielding effect. Electron density shields nuclei from the external 
field and the distribution of electrons is influenced by the electronegativities of covalently bound 
atoms. A nucleus in the vicinity of an electronegative atom experiences reduced electron density 
and the nucleus is therefore deshielded. Protons attached to more electronegative nuclei which 
are less shielded have higher Larmor frequencies and will appear at higher ppm values on the 
chemical shift scale. Furthermore, the distribution of environment around a nucleus is generally 
anisotropic, i.e. it is not spherical around a nucleus but varies on different sides of the nucleus. 
This means that the shielding and the chemical shift experienced by a nucleus is also anisotropic 
and depends on the orientation of a molecule with respect to the magnetic field. This is called 
chemical shift anisotropy (CSA). Nevertheless, in solution NMR, the anisotropy of the chemical 
shift is averaged out by rapid tumbling of a molecule through Brownian motion and a single 
isotropic chemical shift value is observed. In addition to these effects, chemical shift is also 
influenced by the ring current effects caused by aromatic rings in proteins. Under the influence 
of external magnetic field B0, aromatic rings can create their own local magnetic fields which 
have strong effects on neighboring molecules. A ring current is generated by the delocalised π 
electrons of the aromatic ring which cause the magnetic field inside the ring to counteract the 
externally applied field. In contrast, the field generated outside the ring matches the direction of 
B0 and reinforces it. As a result, protons within the plane of the aromatic ring and outside the ring 
resonate at higher frequencies while protons above and below the ring resonate at lower 
frequencies. This effect is used in molecular structure determination and in assessing protein 
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folding. The ring protons of aromatic residues in proteins are known to resonate around 7 ppm. 
In a folded protein aromatic residues are often buried within the hydrophobic core and packed 
against the aliphatic residues of which the methyl groups which are above or below the aromatic 
ring will resonate at characteristic lower frequencies (between 0 to -1 ppm). 
 
In systems with two or more nuclear spins, which evidently include proteins, it is necessary to 
consider the energy state effects that neighboring nuclei have on each other. The a and b energy 
transition state of one nucleus influences the neighboring spin, causing an effect called a spin 
coupling, scalar coupling or J-coupling (Figure 10 A). The coupling is mediated through a 
chemical bond and it is useful in determining which nuclei are close to one another. The presence 
of these couplings generates multiplets in the spectrum. For example, if two ½ spins are coupled, 
the resonance from each spin splits symmetrically about the chemical shift into two lines called a 
doublet. Each doublet is split by an equal amount and the distance is called a coupling constant, 
J. If another coupling forms between one spin couple and the next spin, a multiplet is formed 
(Figure 10 B). 
 
J-coupling and dipolar mechanisms are utilised in correlation spectroscopy to allow generation of 
the multiple dimensions in NMR spectra. This is beneficial in particular in protein characterisation 




Figure 10: Scalar coupling between spins. A) Singlet peaks, at frequencies n1 and n2 from two different 
spins (top). Two doublets formed by the scalar coupling between peaks. The frequency splits symmetrically 
into two and gives a coupling constant of J12 (bottom). The green arrows indicate a (up) and b (down) 
energy states of the coupling. B) and C) Schematic representation of multiplet formation using tree 
diagrams. B) A doublet formed by the coupling of the first spin to a second spin with the coupling constant 
J12. r coupling between peaks. The frequency splits symmetrically into two and gives a coupling constant 
of J12 (bottom). The green arrows indicate a (up) and b (down) energy states of the coupling. C) The 
coupling of the first spin to the third spin, with coupling constant of J13 causes each line of the doublet to 
split again. Subsequent formation of the multiplet is called a doublet of doublets. The green arrows indicate 
a (up) and b (down) energy states of the coupling and the spin states of the second spin are presented as 
red arrows, a (up) and b (down). The illustration was adapted from (303). 
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2.1.3   NMR in protein characterisation 
NMR is an important tool for the structural biologist. It is a common experimental method used 
to characterise proteins, nucleic acids, and protein complexes. Since protein structure relates to 
function, such information can shed light on biological processes in health and disease states. 
NMR offers a broad range of routinely used 1D, 2D, 3D and even 4D experiments to carry out 
protein research. These experiments are used for the assignment of atomic chemical shifts, 
measurements of coupling constants, relaxation experiments, interaction studies and 
measurements of short proton-proton distances. Rapidly developing NMR research allows for 
determination of structures, dynamics, and interactions of larger and larger molecules including 
membrane proteins which are key drug targets.  
 
2.1.3.1   1D NMR 
A one dimensional proton NMR experiment (1D) provides a quick method which helps to judge 
whether a protein is folded and therefore likely to be functional. The basic 1D NMR experiment 
has been described in the previous section (Figure 9). The simplest experiment uses a single 90° 
pulse (for example applied along the x axis) and it also includes water suppression because the 
signal of the solvent is significantly stronger than the protein signals (Figure 11).  
 
A typical 1D 1H NMR protein spectrum contains many overlapping peaks because each peak 
corresponds to a particular proton in the protein. This means a spectrum of a protein of 100 
residues could feature up to 1000 NMR peaks. The general concept is that if a small protein is 
properly folded, the peaks in the 1D NMR spectrum are sharp, narrow and well resolved on the 
chemical shift scale. However, if the protein is partially folded or self-associating, the NMR 
signals are broader and less dispersed. The main indicator of folded globular proteins is a good 
dispersion of the NMR signals in the regions of the methyl protons (–0.5 to 1.5 ppm), α-protons 





Figure 11: 1D and 2D NMR experiments. A) In a 1D 1H NMR experiment, during the tr time the spins 
recover to equilibrium. The 90° pulse generates transverse magnetisation and the subsequent FID signal is 
sampled. B) The general scheme of 2D NMR experiment. The preparation period is followed by the 
evolution of the signal (t1), a mixing period and a detection period (t2). C) Pulse sequences for the HSQC 
experiment. The frequencies of 1H and 15N are correlated. The sequence starts with the equilibrium 
magnetization on the 1H spin, which is transferred onto the 15N spin in the Insensitive Nuclei Enhancement 
by Polarisation Transfer (INEPT) sequence.  The 15N magnetization evolves during t1 with the centrally 
placed 180°  pulse that refocuses chemical shift evolution and the magnetization is transferred back onto 
spin 1H, where it is observed. Dark blocks correspond to 90° pulses and white blocks to 180° pulses. The 





2.1.3.2   2D NMR 
Modern NMR spectroscopy routinely uses multidimensional experiments which involve 
generation of 1H, 13C, and 15N nuclei in isotopically labeled proteins. 2D spectroscopy provides 
better resolution of NMR signals by preferentially selecting them and reducing the signal overlap. 
The typical 1D NMR experiment produces a spectrum that correlates an intensity of absorption 
with frequency, while in 2D experiments the intensity is linked to two frequency co-ordinates. It 
is common to use 2D experiments that correlate the shifts of different types of nuclei such as 15N 
and proton or 13C and proton. The heteronuclear single quantum coherence (HSQC) experiment 
is used to correlate 1H nuclei with either 15N nuclei or 13C nuclei, with the proton being the 
observed nucleus. In this experiment, magnetisation is transferred from the first spin (1H) to the 
second (15N) through scalar coupling (also called J-coupling) using an INEPT sequence which is 
the building block of pulse sequences for 2D and 3D experiments. The chemical shift evolves on 
15N and then the magnetisation is transferred back onto 1H, where it detected (Figure 11). The 
resulting 1H- 15N-HSQC spectrum has peaks corresponding to all H-N groups, which are mostly 
the backbone amide groups in the protein and so it is called the protein fingerprint. Hence, this 
experiment is very useful for protein backbone assignments and to monitor chemical shift 
changes. 
 
Another type of important experiment in structural studies is the 2D Nuclear Overhauser 
Enhancement Spectroscopy (NOESY). The Nuclear Overhauser Effect (NOE) used in these 
experiments relies on the magnetic dipole interaction in which magnetisation transfers in an effect 
of relaxation. This effect occurs throughout radiofrequency saturation of one spin, which then 
influences the intensity of other spins. The NOESY spectrum presents cross peaks which are 
generated by cross-relaxation between nuclear spins instead of coherence through couplings. 
Hence, NOESY correlates protons which are close in space (up to approximately 5 Å) rather than 
coupled through-bond. The cross-peak intensities of the correlated signals are equal to a nuclear 
distance of 1/r6. This NMR experiment provides useful information about the distances between 
atoms which can be used as restraints in protein structure calculations.  
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2.1.4   Chemical shift assignment 
The assignments of chemical shifts of atoms within the protein is important in determination of 
protein structure by NMR or in characterisation of protein interactions. The first step involves a 
backbone assignment of amino acids within the peptide chain, followed by assignment of the side 
chains. Furthermore, the measurement of distances between protons, requires identification and 
assignment of the protons which give rise to the signals in the spectra. 
 
2.1.4.1   Backbone assignment 
Assignment of a protein backbone requires knowledge of the sequence of the peptide chain and 
involves determination of the chemical shifts of NH, Ca, Cb, and C’ atoms. Typical assignment 
involves an HSQC and triple resonance experiments, that correlate three nuclei (1H, 15N, and 13C) 
and provide sequential connectivities between amino acids so that the resonances can be linked 
to particular residues and sequentially assigned. This requires preparation of uniformly 
isotopically double labeled proteins (13C and 15N) by recombinant expression in minimal media 
using 13C6 glucose as the sole carbon source and 15NH4Cl (or -SO4) as the sole nitrogen source. 
 
The HSQC spectrum shows peaks of the correlated nitrogen and amide protons in the peptide 
bond of each residue of the protein, except for proline.  However, in practice not every peak is 
always visible due to several factors such as exchange with solvent. Furthermore, sidechains with 
nitrogen-bound protons can also generate peaks and can be easily recognised in the spectrum due 
to their characteristic shifts. For example, tryptophan side-chain Nε-Hε groups are typically 
shifted downfield and can be observed in the bottom left corner of the spectrum. Asparagine and 
glutamine side-chain Nδ-Hδ2/Nε-Hε2 groups appear as doublets in the top right corner of the 
spectrum, and an additional smaller and distinctive peak may appear above each peak due 
to deuterium exchange from the D2O typically added to NMR samples. The backbone amide 
peaks of glycine usually appear at the top of the spectrum. In addition, signals corresponding to 
Arg Nε-Hε can be observed, but as the Nε chemical shift is outside the region typically recorded, 
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the peaks are ‘folded’ which means that they appear as aliased ppm (often negative peaks). The 
HSQC spectrum of a folded protein shows well-dispersed peaks where single peaks can usually 
be distinguished. In contrast, a large area of not resolved and greatly overlapped peaks in the 
middle of the spectrum, indicates the presence of unstructured regions in the protein. Furthermore, 
the intensity of peaks varies with their flexibility and so the folded protein regions exhibit similar, 
fairly strong, peak intensities. In contrast more flexible regions, such as loops tend to exhibit 
lower or no peak intensities in the spectrum. However, highly flexible regions, such as the C-
terminus show very high peak intensities and appear in characteristic, lower positions in the 
HSQC spectrum. The assignment of the HSQC spectrum, normally requires the 
CBCANH and CBCA(CO)NH experiments and often, especially in a case of large 
proteins, HNCO and HN(CA)CO, HNCA, HN(CO)CA spectra. These experiments work in pairs 
following the concept that e.g., the CBCANH correlates each NH group with the Cα and Cβ 
chemical shifts of residue ‘i’ (producing a strong peak), and of the preceding residue ‘i-1’ 
(producing a weak peak). While, CBCA(CO)NH only correlates the NH group to the Cα and Cβ 
chemical shifts of the preceding residue i-1. This allows the identification of the sequential links 
of one NH group with the next one within the protein sequence (Figure 12). Furthermore, the Cα 
and Cβ chemical shifts adopt values characteristic for each particular amino acid, which is 
advantageous for the backbone assignment. For example, residues such as alanine, serine and 
threonine can be easily distinguished because their Cβ chemical shifts are very distinctive, while 
Glycine has no Cβ. The Cα chemical shifts of Valine, Isoleucine and Proline exhibit lower 
chemical shifts compared to those of other amino acids. The pair of 
HNCO and HN(CA)CO experiments show peaks of correlated NH group of each i residue with 
the C' of i-1 in the case of (HNCO) or, with C' of both, i and i-1 in the case of HN(CA)CO (Figure 
12). The HNCO experiment is more sensitive than the CBCANH and is often used to resolve 
ambiguous assignments from the CBCANH data. Other experiments often used in assignments 





Figure 12: The basic scheme of 3D experiments used in a backbone assignment indicating the 
direction of magnetization transfer. In the HNCO, HN(CA)CO and HSQC experiments, the 
magnetisation originates from an amide proton and, via J-coupling, is then transferred to the correlated 
nucleus for evolution, which may be 15N or 13C, via an INEPT. Next it is transferred back to the proton and 
the signal is then recorded. In these experiments, the 1H signal is detected in the directly measured 
dimension, while the chemical shift of 15N or 13C is recorded in the indirect dimension which is produced 
from the series of experiments. CBCANH and CBCA(CO)NH are recorded differently and the 
magnetisation originates at 1Hα and 1Hβ and is transferred to 13Cα and 13Cβ, respectively, followed by 
transfer from 13Cβ to 13Cα. It is then transferred first to 15NH and then to 1HN for detection. In CBCANH 
spectra, for each NH group, there are two Cα and Cβ peaks visible while in CBCA(CO)NH spectra there is 
only one peak of each. 
 
The typical assignment strategy is shown in Figure 13 A and involves using a uniformly 13C1H-






Figure 13: Strategies for sequential assignment. A) Step by step backbone assignment. B) An example 
of characteristic distances of which NOEs are generated in antiparallel strands of a b-sheet. b-sheet specific 
NOEs are in red and simple sequential NOEs in green. 
 
Interestingly, it is possible to predict secondary structure of the protein and dihedral φ and ψ 
angles directly from the chemical shift backbone assignment due to the strong correlation of 
chemical shifts with local structure. Chemical shift indexing (CSI) identifies the patterns of 
stretches of α-helix or β-strand by analysis of their chemical shifts. For example, Cα atoms in α-
helices, typically have positive secondary chemical shifts and Cα atoms in β-strands are likely to 
have negative secondary chemical shifts. In contrast, Cβ in β-strands are characterised by positive 
secondary chemical shifts and negative in α-helices. Furthermore, the chemical shifts of Hα HN, 
NH and C’ are also correlated with secondary structure, although to a lesser extent. The 
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Ramachandran plot of the φ and ψ torsion angles specifies that the secondary structure of a protein 
depends on the sequential residues comprising similar φ and ψ torsion angles, with a particular 
area of the plot being characteristic either for α-helices or for β-strands.  
 
2.1.4.2   Sidechain assignment 
A common experiment in protein sidechain assignment is a total correlation spectroscopy 
(TOCSY), which correlates all protons of 13C nuclei. The TOCSY experiment allows for the 
transfer of magnetization and correlation of 13C nuclei and all protons of protein sidechains. 
Hence, the spectra may become crowded due to a great amount of information especially in large 
proteins and may require additional experiments such as NOESYs. The assignments for sidechain 
resonances in the experimental part of this thesis were achieved via a combination of 
HBHA(CBCACO)NH [also called HBHA(CO)NH] and 3D HCCH-TOCSY, such as carbon 
observed (H)CCH-TOCSY and proton observed H(C)CH-TOCSY (Figure 14). The 
HBHA(CBCACO)NH experiment provides chemical shifts of 1Hα and 1Hβ protons and correlates 
their resonance to the following NH group. This experiment is analogous to the previously 
described CBCAC(CO)NH in which the magnetisation is transferred from 1Hα and 1Hβ to 13Cα 
and 13Cβ, respectively, and then from 13Cβ to 13Cα. Next the magnetisation is transferred to 13CO, 
and then to 15NH, followed by the final transfer onto 1HN for detection. While, the chemical shift 
is not evolved at any of the 13C nuclei, it is evolved on the 1Hα and 1Hβ, and also the 15NH and 1HN. 
The subsequent 3D spectrum possesses one nitrogen and two hydrogen dimensions. 
 
Generally, the practice of sidechain assignment involves using the Cα and Cβ chemical shifts 
assigned during the backbone assignment, and navigating to the corresponding peak in the 
HCCH-TOCSY. HBHA(CO)NH can be used to confirm the 1Hα and 1Hβ. This allows 
identification of Hα, Hβ, Hγ and Hδ chemical shifts linked to 13C shift which have peaks 
corresponding to the same H ppm values in this 3D experiment. It is also convenient to use an 





Figure 14: The basic scheme of 3D experiments for sidechain assignment indicating the direction of 
the magnetisation transfer. In the TOCSY experiment the magnetisation transfers from the hydrogen 
nuclei of sidechains to their corresponding 13C nuclei (i.e., Cβ, Cg) . After the subsequent isotropic 13C 
mixing, the magnetisation is transfered back to the hydrogen atoms of sidechain for detection. In 
HBHA(CO)NH the magnetisation is transferred from 1Hα and 1Hβ to 13Cα and 13Cβ, respectively, and then 
from 13Cβ to 13Cα. This is followed by magnetisation transfer to 13CO and then to 15NH and 1HN for detection. 
In order for the 13Cα and 13Cβ to appear in the same dimension, the chemical shift is evolved simultaneously 
on both nuclei. The magnetisation does not evolve on 13CO. 
 
 
2.1.4.3   NOE assignments 
NOESY experiments provide information about distances between protons (NOE distance 
restraints), which is used in protein structure calculations.  A crosspeak appears if protons are 
close in space and the intensities of the correlated signals are proportional to 1/r6, where r is a 
internuclear distance. NOESY experiments are often used in both backbone and sidechain 
assignments. NOE distance restraints in the experimental part of this thesis were derived from the 
most commonly used NOESY experiments such as 2D NOESY and a pair of 3D experiments: 
15N-edited NOESY-HSQC and 13C-edited NOESY-HSQC (Figure 15). 
 
The 2D NOESY spectrum is typically used in assignment (especially of aromatic residues) and 
to provide structural restraints. It shows signal for all protons which are in close proximity to one 
another. While for very large proteins the aliphatic region of the spectrum tends to be very 
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crowded, the NH and aromatic region provides valuable constraints for methyl and aromatic 
hydrogens. In addition, the edge of the spectrum often contains some well isolated methyl peaks. 
The 3D NOESY experiments are also used for both, to obtain restraints for structure calculations 
and for protein assignment. Each NOE strip of 15N- NOESY-HSQC spectrum contains NOE peaks 
linking one NH group with all other hydrogen atoms close in space. Valuable hydrogens peaks 
can be visible in the aliphatic and in the amide and aromatic regions. In addition, each strip of 
13C-edited NOESY-HSQC contains NOE signals connecting one CH group to all other 
neighboring hydrogens. In this spectrum, a double set of peaks usually occurs because a CH2 
group has two hydrogens with different chemical shifts. 13C-edited NOESY-HSQC is usually 
recorded in 100% D2O to reduce the signal of noise and artifacts. 
 
In practice the first step of NOEs assignment is to find the sequential neighbours to each residue 
using the NOEs between their NH groups. The next step is to determine the correct sequential 
order of the neighbouring residues using NOEs between the NH group of one residue and the 
sidechain of the other. Once several residues are connected, it is possible to identify where they 
are within the sequence. Furthermore, α-helices and β-sheets have slightly different patterns of 
NOEs and once identified, can help with the assignment. For example, characteristic cross peaks 
in a NOESY spectrum between protons connecting two strands in a β-sheet facilitate the 
assignment and building of two neighbouring strands in parallel Figure 13 B. NH-NH distance is 
around 2.8 Å in helices and 4.2 Å b-sheets. Additionally, the intensities of peaks are useful in 
identifying sequential and structural links. The NOEs linking sequential residues are the strongest 
and cover a short range distance NH (1.8-2.5 Å) while additional NOEs which can be intra- or 
interresidue are of medium range NH (1.8-3.5 Å) or long-range NOEs NH (1.8-5.0 Å). Especially 
in α-helical secondary structure it is possible to observe medium and long range NOEs and these 
are weaker and can be useful in linking several sequential residues. In β-sheet secondary long 
range NOEs connect to the neighbouring strand which may be of comparable strength to the short 
range NOEs in a parallel β-sheet or stronger in an antiparallel β-sheet. Generally short range 
NOEs are important in identifying elements of secondary structure while the long range NOEs 
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provide crucial information about the tertiary structure of a protein. Furthermore, to decide the 
direction in the sequential assignment it is useful to know that the Hα of residue i is usually much 
closer to the NH of the following residue i+1, than the NH of the preceding residue i-1. It is also 
practical to use a reference of hydrogen chemical shifts to compare the shifts with the average 
hydrogen chemical shifts. Some amino acids such as alanine, glycine and threonine have unusual 
patterns of sidechain hydrogen chemical shifts which can be easier to identify. However, not all 
resonances are always visible in the spectra. Overall, the more unambiguous NOE restraints are 
assigned, the more precise is the structure. Typically, there are about 15-20 NOE restraints 
including about 3.5 long range distance restraints per residue in a high-resolution NMR structure. 
In addition, there are some special NOESY experiments which are often used in structural studies 
of protein complexes. These include filtered, edited NOESYs which are based on selection of 
NOEs from two molecules with unique labelling patterns. They require a sample comprising a 
mixed labelled and unlabeled ligand and allow observation of signals which are only present at 





Figure 15: The basic scheme of 3D experiments of NOE assignment indicating the direction of 
magnetisation transfer. In 2D NOESY experiments, the magnetisation transfer occurs first between all 
hydrogen nuclei using the NOE. In 15N-edited NOESY-HSQC the magnetisation is subsequently transferred 
to neighbouring 15N nuclei and back to 1H for detection. In 13C-edited NOESY-HSQC the magnetisation is 
subsequently transferred to neighbouring 13C nuclei and back to 1H for detection. The direction of transfer 
depends on the 13C frequency used in the pulse sequence and occurs to/from the aliphatic 13C nuclei or 
to/from the aromatic 13C nuclei (but not both). 
 
2.1.5   Structure calculations 
Following the resonance assignment, the NMR data (through space correlation of NOE intensities 
and through bond correlation of J-couplings and chemical shifts) need to be converted into 
distances and torsion angles to generate the structural constraints which then can be used in 3D 
structure calculations. The torsion and dihedral angles for structural calculations are provided 
from the assignments and calculated by TALOS+ (305). Initially, only unique and unambiguous 
NOEs are assigned and proton-proton distance restraints are applied in structural calculations 
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using a restrained molecular dynamics (MD) or simulated annealing (SA). Hence, calculation of 
structures involves computational heating/cooling of structures to attempt to find a global energy 
minimum (in SA) or to satisfy structural restraints and determine the initial structure (in MD). 
This is followed by many cycles of finding and evaluating the violated NOE restraints in an 
iterative process. The starting set of structures can be used to filter ambiguous assignment. After 
completion of the assignment of the remaining NOEs, the water refined ensemble of structures is 
obtained which typically spans fairly narrow conformational space. Hence, the quality (resolution 
and precision) of a NMR structure can be judged by the root mean square deviation (RMSD) of 
each structure from this ensemble to describe how similar these structures are. The RMSD for 
both backbone and all heavy atoms are usually analysed and the high-resolution structure will 
have a backbone RMSD £ 0.8 Å and heavy atoms RMSD £ 1.5 Å. Sometimes only the RMSD of 
more ordered regions are reported. The NOE assignment is usually accomplished by a 
combination of automatic and manual methods. The structure calculations are performed using 
available software such as ARIA (Ambiguous restraints for iterative assignment) (306), CYANA 
(Combined assignment and dynamics algorithm for NMR applications) (307) or Rosetta (308). 
Furthermore, the structure is validated by inspecting the stereochemical quality of the protein 
including backbone phi and psi-angles favoured in a Ramacharndran plot and low deviation from 
idealised covalent geometry. These statistical parameters are then compared to other deposited 
structures using various software such as WhatIf or PROCHECK.  
 
2.1.6   Study of protein-protein interactions by NMR 
NMR is commonly used in studying protein-protein and protein-peptide interactions. This method 
is very sensitive and allows easy detection of an apparent change in signal between the free states 
and the complexes. In NMR, observable parameters such as the chemical shift, relaxation rate and 
J-coupling may all change upon binding of a ligand (e.g., another protein). Chemical shifts are 
sensitive to changes in the local magnetic field of a nucleus and can be perturbed by both changes 
in covalent structure and by non-covalent interactions with binding partners. Therefore, chemical 
shifts are well suited to identify binding interfaces of interacting protein complexes. Chemical 
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shift mapping or chemical shift perturbation (CSP) studies usually involve 1H-­‐15N correlational 
spectroscopy experiments such as HSQC and HMQC. The 1H-­‐15N HSQC is a sensitive experiment 
that generates well resolved peaks corresponding to each amino acid in the protein. In a good 
quality spectrum, it is easy to follow any peak changes caused by addition of a ligand. Typically, 
the perturbations of chemical shifts are monitored in a series of 1H-­‐15N HSQC experiments in 
which increasing amounts of a ligand (e.g. a peptide) is titrated in to a protein. The resulting CSPs 
belong to amino acids close to the binding interface. However, if the protein undergoes a 
conformational change upon complex formation this will reflect in widespread CSP, which can 
be away from the binding site. 
The effect on chemical shifts upon addition of a ligand depends on the type of chemical exchange 
that affects the nuclei. Overall, there are three exchange regimes: slow, intermediate and fast 
exchange. Fast exchange occurs in weak interactions (in the mM range) and the chemical shifts 
change continuously throughout the addition of a binding partner and until the binding site is 
saturated. These peaks usually shift in a straight line which makes the changes easy to identify. 
Since this interaction is weak, the rate of exchange between the state of a free and bound nucleus 
is high. Therefore, the observed single peak corresponds to the weighted average chemical shift 
in the NMR spectrum for the free protein and the complex. The intermediate regime, is 
characteristic in stronger interactions (µM range) in which protein resonance peaks may become 
weaker, then disappear and reappear again when increased amounts of a binding partner is added. 
Sometimes peaks may completely disappear from the spectrum. This effect is caused by the 
difference in the populations between the two (free and bound) conformations occurring during 
the recording of the NMR experiment. This can also result in line broadening and produce peaks 
so broad, that they are not observed in an NMR spectrum. In a slow exchange regimen, the binding 
between interaction partners is very strong (nM range) and results in appearance of new resonance 
peaks. While the intensity of the newly formed peaks increases upon the addition of a binding 
partner, some original peaks (free protein) gradually decrease in intensity until they disappear. 
This effect occurs because the binding is very strong and so the exchange rate between the two 
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conformations is also slow and therefore both, free and bound protein states can be observed 
simultaneously.  
 
In interaction studies between two proteins, it may be beneficial to isotopically label each of them 
and perform reciprocal chemical shift perturbation experiments. This allows comparison of the 
binding effect in both proteins and provides information on possible conformational changes. 
 
2.2   Protein Crystallography  
In crystallography the structural information is obtained from electrons. A single protein crystal 
is placed into a focused X-ray beam causing the electrons to oscillate in the electric field and 
scatter the X-rays. They produce diffraction images that are recorded on a detector. The electron 
density corresponding to the atomic structure of protein molecules within the crystal is 
reconstructed by Fourier transform techniques of the diffraction data and the atomic model is built 
into a three-dimensional electron density map. Over the past 100 years crystallography has grown 
significantly and the resolution dramatically improved reaching even 0.48 Å for some structures 
deposited in the protein data bank. High resolution structures (<1.5 Å) can provide additional 
information such as the positions of hydrogen atoms, distributions of valence electrons and 
orientations of bound waters, that is valuable in establishing the dynamic and chemical properties 
of proteins. In this section I will begin by briefly outlining the fundamental concepts of 
crystallography and then I will focus on the practical aspects and stages of solving protein 
structure by molecular replacement. 
 
2.2.1   Fundamental concepts in X-ray crystallography 
2.2.1.1   Crystal geometry and symmetry 
Protein crystals have the ability to diffract X-rays to produce valuable information about their 
atomic structures. The typical X-ray wavelength used in laboratories varies between 1.6 Å and 
78 
 
0.5 Å and uses molybdenum or a copper as a beam source. Protein crystals are formed from many 
copies of the same molecule organised in an ordered fashion.  The protein molecules repeat 
themselves in a self-assembled crystal lattice that can be arranged in many different ways. 
However, the number of arrangements the molecules can pack into is limited. The collection of 
all symmetry elements of a repeating pattern in a protein crystal is called a space group. There are 
65 possible chiral space groups in which proteins can construct their three-dimensional crystal 
structure. These different arrangements are possible through combination of symmetry operations 
such as translation and rotation. The repetitive order of the crystal lattice allows identification of 
positions that are equal.  These positions can be marked with an imaginary point, called a lattice 
point. In two dimensions, four neighbouring lattice points form a lattice plane. In three 
dimensions, the neighbouring lattice points can be connected to form a box called a unit cell. In 
a crystal, unit cells are stacked on a top of each other in every direction. Crystal contacts occur 
when intermolecular interactions connect the molecules within the crystal. These repeat with the 
same periodicity as the lattice. The unit cell is a basic building block of a crystal lattice that can 
be translated up, down or sideways through the lattice without changing the content. Since there 
is often more than one possible choice of selecting the lattice points and the unit cell, the general 
practice is to choose the smallest unit that exhibits the maximum symmetry of the structure. 
Furthermore, within the unit cell even smaller elements can be distinguished, known as the 
asymmetric unit. It is described as the smallest repeat unit from which the crystal is formed. Each 
unit cell has its parameters defined including the axes a, b and c and, connecting them, angles a, 
b and g which then form the faces A, B and C (Figure 16 A and B). 
 
 Considering the organisation of unit cells within a crystal lattice the crystal geometries are 
categorized into 7 basic crystal systems and 14 Bravais lattices. The seven crystal systems are 
cubic, tetragonal, orthorhombic, hexagonal, triclinic, monoclinic and triclinic (Table 2). The 
different unit cell lattices include P, primitive, F-face-centred, C-side-centred, I, body-centred. In 
the primitive lattice, the lattice points lie only at the corners of the unit cell. In the face-centred 
lattice, the lattice points lie at the corners of the unit cell and one lattice point lies in the middle 
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of every face of the unit cell. In the body-centred lattice, the lattice points lie at the corners of the 
unit cell and one lattice point lies in the middle of the unit cell. In the one side-centred lattice, the 
lattice points lie at the corners of the unit cell and also one lattice points lies at each of the two 
relevant faces. The 14 Bravais lattices are defined based on the variations of the parameters of the 
unit cell and different lattice points (Table 2).  For example, one of the most common crystal 
systems, orthorhombic, is characterised by all different lengths of the axes (a, b, c), although all 
angles are of 90°. The types of Bravais lattices occurring in the orthorhombic system are: the 
primitive, the body centred and face centred (Table 2).  
 
Table 2: The seven crystal systems and fourteen Bravais lattices (309). 
Crystal system Cell parameters Lattice types 
Cubic a = b = c, a = b = g = 90° P, I, F 
Tetragonal a = b ¹ c, a = b = g = 90° P, I 
Orthorhombic a ¹ b ¹ c, a = b = g = 90° P, I, F, C 
Hexagonal a = b ¹ c, a = b = 90°, g = 120° P 
Trigonal a = b ¹ c, a = b = 90°, g = 120° P 
Monoclinic a  ¹ b ¹ c, a = g = 90°, b ¹ 90° P, C 
Triclinic a  ¹ b ¹ c, a ¹ g ¹ b ¹ 90° P 
 
Within a unit cell, each asymmetric unit is related by symmetry. The lack of symmetry of the 
asymmetric unit poses limitations on its position within a unit i.e., it cannot be located at the 
symmetry elements. Hence in protein crystallography, non-crystallographic symmetry exists 
when more than one identical molecule is present in the asymmetric unit like in a case of dimers 
and higher oligomeric structures. There are two types of symmetry element in a crystal 
lattice,translational and non-translational. Translational symmetry which must be present for a 
crystal to diffract an X-ray beam and produce reflections is characterised by translation, that is 
moving an object in a direction (a,b,c). In this symmetry, rotation or reflection combined with 
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translation gives rise to screw axes (as opposed to simple rotation axes) and glide planes (as 
opposed to mirror planes), respectively. Screw axes combine a simple rotation with a translation 
along the direction of the axis. This type of symmetry cause absences in a diffraction data. 
Systematic absences are the absent reflections in diffraction data that appear when the observed 
intensity is zero.  Since, asymmetric chiral protein motifs limit possible symmetry operations of 
proteins, mirror planes or glide planes are not allowed. Non-translational symmetry does not cause 
absences in diffraction data and the symmetry operations include the inversion centre, reflection, 
rotation and rotation-inversion. 
 
Miller indices are part of the notation system that defines the orientation of a plane or a set of 
parallel planes of atoms in crystal lattices. These indices describe the position of a face or internal 
plane of a crystal and are determined on the basis of the reciprocal of the intercept of the face or 
plane on the crystallographic axes. The planes are determined by three integer values h, k, and l, 
referred as the Miller indices. The integers are written in brackets (hkl), and define the Cartesian 
coordinates or the axes of the unit cell, where h corresponds to the x-axis or a direction of the unit 
cell, k corresponds to the y-axis or b direction and l corresponds to the z-axis and c direction. 
Furthermore, if the intensities corresponding to a specific Miller index (hkl value) is zero, 
absences in diffraction data occur. 
 
While there are several different methods of describing crystal geometry, the one that is preferred 
by crystallographers for practical reasons is the Hermann–Mauguin notation. This system, 
commonly used to represent the symmetry elements in point groups, plane groups and space 
groups, includes translational symmetry elements and the directions of the symmetry axes. The 
first letter of the Hermann–Mauguin notation represents the type of lattice and the following three 
notations indicate the type of symmetry operation or operations along the corresponding axes x,y 
z. For example, the orthorhombic space group referred as P212121 indicates that the lattice is of a 
primitive type with a 21 screw axis along each of the x, y, z directions. A 21 screw axis indicates a 
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180° rotation followed by a translation upwards of half the unit cell. On the other hand, a space 
group P21 belongs to a monoclinic crystal system with a primitive lattice type while it also has a 
similar screw axis 21. For comparison, the P222 space group indicates a primitive lattice with two-
fold rotations along each of three axes. 
 
 
Figure 16: Unit cell. A) the parameters of the unit cell. The axes, angles and faces of the unit cell. A faces 
are the front and the back of the unit. B faces are the left and the right side of the unit. C faces are the top 
and the bottom of the unit. The unit cell volume, V = a • (b x c).  B) Within one unit cell, the position of an 
atom can be specified by a set of spatial coordinates x,y,z (309).  
 
2.2.1.2   Theory of X-ray diffraction by a crystal 
In crystallographic experiments, copper, molybdenum, silicon and germanium are the most 
common sources of X-rays. The X-ray generators may include X-ray tubes, rotating anodes and 
synchrotrons. Synchrotron radiation provides very high energy X-rays by bending the electron 
paths as they move through a storage ring of bending magnets. Initial X-rays are generated when 
accelerated electrons move from excited to relaxed states, emitting electromagnetic radiation 
(Figure 17 A). The excited state of electrons can be caused by a collision with a photon. The total 
amount of energy emitted corresponds to the energy difference between the excited and ground 
states and can be represented as a function of frequency: E = hv, where E is the energy emitted, 




As discovered by Laue and Bragg, X-rays are electromagnetic waves and, as a consequence, get 
diffracted by the periodically arranged atoms in a crystal. During an experiment, the X-rays enter 
a single crystal, and interact with oscillating electrons. This cause the beams to be scattered in all 
directions which forms a diffraction pattern of spots (also called images) on the detector. The 
intensities and angles of these beams are recorded as the crystal is gradually rotated. Spot are 
called reflections, because they correspond to the reflection of X-rays from a set of parallel planes 
passing through lattice planes. To define the plane, three numbers referred to as indices (hkl) are 
used to specify its orientation with respect to the rims of the unit cell. 
 
Bragg’s law introduced a simplified interpretation of X-ray diffraction that helps to understand 
how diffraction patterns and spots are generated in an incident X-ray beam (Figure 17 B). The 
scattering diagram can be interpreted as the reflection or diffraction of X-rays on a set of lattice 
planes in a crystal. The planes and lines are separated by a distance d. When the incident X-rays 
collide with the crystal lattice at specific points, the X-rays are reflected out from these points 
generating diffraction spots (Figure 17 B). Bragg’s equation indicates that diffraction spots 
appear when 2dsinq = nl, that is the incident X-ray wavelength is twice the d distance (also called 
spacing or dhkl) multiplied by the sine of the diffraction angle (Figure 17 B). Individual diffraction 
spot is the sum of the diffraction from Miller planes and so can be defined with a hkl value that 
corresponds to Miller indices. Furthermore, each spot can be characterised by an intensity value 
that depends on the strength of the X-ray diffraction. Some spots are missing if the intensity is 
zero and these are called absences. Thousands of spots are mathematically reconstructed to 
produce a diffraction map and subsequently an electron density map. Electrons that scatter the X-
rays in an atom are not steady but move around the nucleus in defined orbits. The amplitude of 
scattered wave depends on how many electrons scatter from a particular position in an atom, 




The reconstruction or processing of the sets of diffraction data produces the reciprocal form 
(Table 3). It relies on the concept that for each set of Miller planes (hkl) in real space there is a 
point in reciprocal space and the collection of all of these points can be defined as the reciprocal 
space (Table 3). In X-ray crystallography, the intensities of points are experimentally measured 
in reciprocal space during data collection. These data are used to generate an electron density map 
from a crystal in real space which then can be used to solve a protein structure (Table 3). 
 
 
Figure 17: X-ray diffraction. A) Emission of X-rays. When a photon travelling as a wave collides with 
an electron in an atom, the electron is promoted into an excited state. X-rays are generated when an excited 
electron relaxes back into its ground state. This causes energy emission that includes X-ray radiation. K, L, 
M are the atomic shells between which the electron moves and, in an X-ray diffraction experiment, the 
most valuable energy comes from an electron moving from the L to K shell. This wavelength is called a 
‘characteristic X-ray’. B) Diffraction according to Bragg’s law. The interpretation of scattering as relates 




Furthermore, the Ewald sphere introduced by Paul Ewald, (310) demonstrates the relationship 
between the wave vector of the incident and diffracted x-ray beams, the diffraction angle for a 
given reflection and the reciprocal lattice of the crystal. It allows us to visualize the properties of 
Bragg's law and it shows that the form of a diffraction condition: d*hkl = 2sinq/l, where d* is a 
distance in a reciprocal space, can be effectively visualised by a geometrical construction. The 
relationship between the Ewald sphere and Bragg's law (Figure 18) shows that diffraction can only 
occur when a reciprocal lattice point intersects the Ewald sphere (Figure 18 B, C and D).  
Moreover, the detector is flat and therefore the reciprocal lattice points near the rotation axis never 
pass through the Ewald sphere and hence they contribute to the ‘blind region’.  In practice, the 
construction of the Ewald sphere predicts which diffracted waves satisfy Bragg’s law, when the 
information of the beam wavelengths, the angle, the details of the lattice, the distance from 
detector and the orientation of lattice relative to the detector is provided. Furthermore, the position 
and intensity of each reflection (spot) in a diffraction pattern, corresponding to the angle at which 
it reached the crystal, is used to provide three-dimensional stryctural information of proteins, such 
as atom positions, bond lengths and angles, torsion angles and non-bonded distances . Also, the 
absences in crystal data relate to lattice types and symmetry elements. They can be used to 
determine the space group of a crystal lattice as the absences are specific for a particular group 
(except for a primitive lattice). There are two types of absences in diffraction patterns: general 
absences that are linked to lattice types and systematic absences, linked to translational symmetry. 
General absences appear on a diffraction pattern due to destructive interference of X-rays (as 
opposed to constructive) for non-primitive lattices (I, F, C). The rules characterizing these 
absences affect all reflections in the diffraction pattern (for all hkl values). Systematic absences 
also appear due to destructive interference of X-rays in relation to specific translational symmetry 
elements (i.e., screw axes). Therefore, systematic absences are found only in diffraction patterns 
for translational symmetry. Additionally, intensities in crystal data are associated with the 
structure factors. X-rays are waves that are scattered (diffracted) by electrons and share the 
properties of waves such as amplitude, wavelength and the phase. Therefore, a structure factor is 
applied to describe each reflection including its position, intensity and phase. 
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Table 3: Correlations between the real space and the reciprocal space (309). 
Real space Reciprocal space 
Crystal structure Diffraction pattern 
Electron density (atomic parameters) Amplitudes and phases (X-rays) 
Crystal lattice and unit cell Reciprocal lattice 






Figure 18: The relationship between the Ewald sphere and Bragg's law. A) Diffraction from a lattice 
plane. The angles between the primary and diffracted beams and the plane, both equal q. B) The angles 
between the lattice plane and the primary and diffracted beams are always q and diffracted beams are always 
on a circle. Different colours correspond to different q angles. C) The construction of the Ewald sphere 
respects the properties of Bragg's law. The angle between the primary and diffracted beams is always 2q. 
A vector connecting the points where the diffracted beam and the primary beam lie on the edges of the 
circle (S in red). If the radius of the circle equals 1/, l then the red vector has a length of 2sinq/l. The center 
of the circle is the (real space) origin of diffraction and the point where the horizontal beam exits the circle 
is the origin of reciprocal space. D) Diffraction occurs when a reciprocal lattice point intersects the Ewald 
sphere. The corners of each rectangle indicate points of the reciprocal lattice. E) The reflections in a ‘blind 
region’ (yellow) do not intersect the reciprocal sphere and are not recorded or detected. Rotating (red arrow) 
and tilting the crystal helps to increase the number of detected reflections. 
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2.2.2   X-ray crystallography in practice 
2.2.2.1   Crystallisation of proteins 
There are several techniques applied in growing protein crystals such as vapour diffusion (hanging 
drop or sitting drop), evaporation, and seeding. A typical multi-well assay plate contains a 
reservoir in one well which is the crystallisation solution and a drop of the mixture of protein and 
reservoir in the second well. Since the plate is sealed, the system equilibrates by slow water 
vapour diffusion (and other volatile reagents), from a protein solution drop into the reservoir, 
increasing the concentration of the drop (including the protein). During this process, the drop 
becomes supersaturated and nucleation can begin which then promotes the crystal growth. 
Crystallisation solutions include precipitants, additives, detergents and others which aim at 
reducing protein solubility when it reaches supersaturation. These can be methyl-pentane-diol 
(MPD), glycerol, phosphate, sulfate and metal cations which often participate in in intermolecular 
contacts and sometimes are even essential for crystal formation. MPD salts are common 
precipitants that affect protein solubility in such a way that small amounts often increase it (salting 
in) and large amounts reduce it. Mild organic precipitants such as polyethylene glycol (PEG) of 
varying chain lengths (between 200-15 000 Da average molecular weight) are commonly used 
also as a mild denaturant or even cryprotectant. Crystals come in different forms and 
morphologies that may or may not reflect in a different space group. 
 
2.2.2.2   Strategy of solving the structure  
Prior to the structural data collection, it is beneficial to obtain the unit cell of the selected protein 
crystal and determine the data collection strategy. This can often be achieved by a combination 
of experimental and computational methods. The diffraction data are collected by rotating a 
crystal mounted onto a goniostat and exposed to a focused X-ray beam. The rotation of a crystal 
is necessary to collect the full set of data. Diffraction images are recorded on a detector during 
small rotation increments (oscillation) of a crystal and combined into a dataset. Fourier transform 
is used to mathematically transform the diffraction images from reciprocal diffraction space into 
direct molecular space. Phases of each diffraction spot are acquired separately and together with 
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FT allow synthesising or reconstructing the electron density. The position and intensity of each 
spot is fairly easily calculated, whereas the phases of the waves which formed each spot are more 
challenging to determine but are necessary to produce an electron density map. In practice solving 
protein structures by crystallography involves several main steps: indexing, data reduction, 
molecular replacement and refinement. 
 
Collecting good diffraction data is very important in later stages of structure determination. To 
allow the data collection the crystal can be rotated to 360° around a single axis in small 
increments. A diffraction image (also called a frame) is recorded at each stage of rotation. 
Rotation around a single axis (often perpendicular to the X-ray beam and referred to as j) is 
usually sufficient to collect many symmetry related reflections and obtain good multiplicity of a 
full dataset. For example, it is common to collect 1800 images of 360° crystal rotation with 0.2° 
increments. However, an initial screening of the data collection parameters can help to optimise 
the strategy according to the predicted symmetry of a reciprocal space. This is done by a short X-
ray exposure time for the crystal and small portions of diffraction data being collected at various 
angles (i.e., 3 x 45° rotation range for 40msec) followed by data analysis and initial inspection of 
the diffraction image. 
 
2.2.2.3   Indexing 
Based on the Ewald sphere and crystal orientation, the hkl reflections are collected on the detector. 
However, to measure the intensities, the reflections from the reciprocal lattice have to be 
transformed into real space (Table 3). The intensities are determined by the contents of the crystal 
lattice and unit cell. The intensities (I) of all unique reflections (Bragg peaks) are collected in a 
diffraction experiment and allow the reconstruction of the electron density map of the protein. At 
this stage it is possible to calculate the dimensions of the unit cell (a,b,c and a, b, g) and indicate 
the probable space group. However, the precise space group is only confirmed after the structure 
of a protein has been solved. Indexing is essentially an assignment of a consistent set of unit cell 
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vectors matching a diffraction pattern where the diffraction from each Miller plane is integrated 
across all frames of data and therefore possesses the intensity value (from the multiplicity). A list 
of intensities can be indexed using several different software such as IMOSFLM, XDS, Xia2. The 
algorithms applied in these calculations rely on a spot finding routine and a Fourier analysis to 
find a consistent set of spot positions on different images.  
 
The initially indexed diffraction spots are transformed into a list of appropriately scaled intensities 
and their estimated standard errors. The integrated data consist of a list of indices, the reflection 
intensity of each individual reflection, the standard error, and additional batch information for 
each frame. Following data integration and several iterations of the background, polarization and 
absorption corrections, the resulting file is referred to as the scaled, unmerged data file or the hkl 
file. 
 
2.2.2.4   Data reduction 
Once the complete diffraction dataset is indexed, the data are reduced. The data reduction includes 
merging and scaling of multiple measurements of equivalent reflections according to the initial 
indexing. The programs used in this methods, such as AIMLESS, SCALA or TRUNCATE 
produce a .mtz file. The merging statistics allow the analysis of the data quality at a given 
resolution. These include the R-merge value, signal-to-noise ratio (I/d) and completeness factor. 
The data can be reindexed if some of the data have to be removed (cut). To estimate where to 
‘cut’ the data and decide on the appropriate resolution it is common to access the following 
parameters: I/sigma, to assess background to noise signal, R-merge to assess data consistency 





The reduced data are used to determine the space group. The diffraction spots and intensities 
signify the lattice and the unit cell geometry of the crystal system. To determine the symmetry of 
the unit cell and the space group of collected data it is necessary to analyse both the position of 
spots and their absences. Systematic absences are locations of missing h,k,l reflections that are 
absent due to destructive wave interference. The missing reflections are important in assigning 
the space group because for specific space groups there is a pattern of missing reflections defined. 
In general, the recommended unit cell is usually the smallest unit that displays the maximum 
symmetry of the structure. In practice, it is useful to analyse the statistics provided by the software 
in a table with suggested possible space groups. For example, it is worth analysing how much the 
RMSD changes between the P1 space group and the preferred, higher symmetry group (this means 
how much it is necessary to ‘bend’ the cell unit to fit in the data). If the initially chosen space 
group was incorrect, the data can be reprocessed with correct symmetry. 
 
When analysing the data quality, we can also assess factors such as the Wilson plot and the 
presence of twinning or non-crystallographic symmetry (NCS). The Wilson plot is used to 
determine the absolute scale of the diffracted intensities and to obtain the temperature factor, 
therefore its value depends on the resolution. Twinning occurs when two separate crystals share 
some of the same crystal lattice points in a symmetrical manner and two overlapping spots may 
be detected in a dataset. NCS occurs when there is more than one copy of a molecule in the 
asymmetric unit. The Matthews coefficient calculator is used to estimate the number of molecules 
in a volume of the asymmetric unit considering the molecular weight of a molecule.  
 
Data reduction essentially converts intensities (Ihkl) into structure factor amplitudes |Fhkl|. The 
structure factor is a description of each reflection including its position, intensity and 
phase. Reconstruction of electron density from these structure factors is crucial to visualize the 
map in structure determination. To calculate the electron density ρ (xyz) and to determine the 
atomic positions inside the unit cell, we require phases of the various diffracted beams, Φ (hkl). 
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However, phase information is lost during the physical detection of the diffracted photon 
experiments (there is currently no experimental technique available to measure the phases) and is 
called the phase problem. The X-ray phase angle for each reflection (in centrosymmetric 
structures: 0° or 180°; positive or negative) is therefore supplied from the phasing experiment 
which involves the calculation of a molecular model that represent the contents of the crystal 
lattice. The phase angle indicates the angle at which the incident X-ray beam reaches the crystal. 
The electron density map is created, where the electron density is a Fourier transform of the 
structure factors, amplitudes and phases at a point (x,y,z) in the crystal lattice.  
 
There are different electron density maps and map coefficients which can be reconstructed from 
structure factors and amplitudes (Fcalc), calculated phases (jcalc) and simulated noise intensity data 
observed from structure factor amplitudes (Fobs). These maps employ different combinations of 
Fourier coefficients and include basic difference density maps (Fobs -Fcalc) • exp (ijcalc) and 
combined (2Fobs-Fcalc) • exp (ijcalc), where Fobs is the observed structure factor amplitude, and both 
Fobs and jcalc come from the initial phasing model. 2Fobs-Fcalc map or 2mFobs–DFcalc is usually 
visualised in blue and Fobs-Fcalc  or mFobs - DFcalc  are usually shown in red and green; m and D are 
‘de-biasing’ coefficients. These maps allow for efficient model building in structural analysis. 
The maps are usually contoured in units of sigma (RMSD), typically 1.0s for 2Fobs -Fcalc and ±3s 
for Fobs -Fcalc. Other modifications involve changing the coefficients and include, for example, 
omit maps.  
 
2.2.2.5   Molecular replacement 
To determine the structure of proteins by crystallography it is essential to solve the phase problem 
which is referred to as phasing. Techniques for phasing include direct methods (using heavy 
atoms), experimental phasing, molecular replacement (MR), multi-wavelength anomalous 
diffraction (MAD) or single-wavelength anomalous diffraction (SAD).  Molecular replacement 
(MR) is beneficial in a situation where there is a previously determined, structurally similar 
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protein model available, which can be used to calculate initial phases which then can be applied 
in the reconstruction of the electron density. In MR the pdb file of a similar protein is used a 
search model, where the sidechains are often removed and a polyalanine backbone chain is 
created. The starting model, provided using an automated model building software such as an 
Autobuild, is included in phasing calculations using for example PHASER. MR requires a search 
for a correct orientation and location of a search molecule with regard to the unknown structure. 
In the MR calculations, at each grid point of an asymmetric unit of the unknown cell, there is a 
search model placed in varying orientations and a structure-based correlation score is computed 
against the observed data. The scored solutions are ranked with the preferred solution having the 
highest correlation coefficient.  
 
The output files generated by the molecular replacement software are the .pdb file and the .mtz 
file. The .pdb file contains the atomic coordinates and secondary structure information and the 
.mtz file contains the electron density map into which the protein structural model is built in real 
space. 
 
2.2.2.6   Refinement 
The building of a structural model of a protein can be done using visualisation software such as 
Coot and involves local real space fitting of residues into an electron density map using global 
restrained reciprocal space refinement. The cycles of refinement involve ‘fitting’ the model 
against the experimental diffraction data (often performed by Refmac5 or PHENIX) using 
difference maps. The iterations of refinement involve implementing small changes of positional 
atom coordinates to find the overall energy minima and atomic displacement parameters. 
Restrained reciprocal space refinement facilitates the correction of the protein’s bond lengths and 
angles, backbone geometry and torsion angles during the model building and the refinement 
cycles. The model is also improved by building in water molecules and appropriate bound ion 
metals throughout the refinement. 
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Furthermore, statistical methods provide measures of how well the model fits the experimental 
data. One parameter of refinement is the temperature factor (B-factor) that is annotated to each 
atom in the final model. A high temperature factor can suggest disorder or thermal motion. 
Disorder indicates that the atom occupied various conformations in different molecules within the 
crystal, while ‘thermal motion’ means a vibration of an atom about its static position. Portions of 
flexible protein chains produce areas of low electron density in the map, making it difficult to 
assign the positions of corresponding atoms. Therefore, often the tails and loops of a protein chain 
are sometimes missing from a crystallographic atomic coordinate file. Also, oxygen and nitrogen 
atoms have similar numbers of electrons and therefore look similar in electron density maps, thus 
it is sometimes difficult to assign these atoms in sidechains such as asparagines and glutamines. 
Furthermore, partial occupancy always requires building of a model with care to avoid model 
bias. For instance, B-values under 10 create a model of the atom that is sharp and values greater 
than 50 produce a weaker signal or may have missing coordinates. This is common in particular 
for atoms at the surfaces of proteins, since they can have long sidechains exposed which are free 
to move in the surrounding water. Furthermore, in some crystals, there are slight differences 
between each of these molecules. For example, a sidechain on the surface may move between 
several conformations, or a ligand may bind in two different orientations, or a metal ion may be 
bound only to a subset of the molecules. The 2Fobs-Fcalc and Fobs-Fcalc density maps used in model 
building indicate the missing or additional portions of a model we are building in. They can also 
show errors in the position of a built atom, errors in occupancy and errors in B-factor. 
 
The are several extra parameters that can be employed in structural refinement. These include 
non-crystallographic symmetry (NCS) restraints, Translation/Libration/Screw (TLS) refinement 
and refinement of individual coordinates, B-factors, and occupancies for some atoms. NCS 
refinement is typically used in non-symmetrical molecules such as dimers, where different copies 
of a molecule in the asymmetric unit have different overall displacements. TLS is defined as a 
possible mean square displacements of groups of atoms in the protein model. The refinement of 
TLS parameters can be used to define a TLS group for rigid side chains. TLS refinement is often 
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useful if the NCS is present. Additionally, the anomalous difference for anomalous Fourier 
(DANO) is a difference Patterson electron density map that can be used in determination of the 
positions of heavy atoms such as metal ions within the structure. 
 
The alternative methods to MR for estimating phases, called isomorphous replacement, involve 
the addition of a few electron-dense atoms, such as metal ions, to the crystal. The resulting 
diffraction pattern is compared with that of a similar crystal that does not have the heavy atoms. 
Comparing the differences, facilitates location of the heavy atoms, and estimation of the phases 
based on their positions. Other methods include single-wavelength anomalous dispersion (SAD) 
and multi-wavelength anomalous dispersion (MAD). 
 
2.2.2.7   Structure validation 
To assess the quality of a protein model, it is useful to analyse structural features such as the 
crystal packing (contacts between symmetry molecules), chemical bonds within peptide chains 
(lengths, angles, chirality, planarity and torsions) and consider possible rotamers, crystallographic 
parameters (real space fits, B- factor) and statistical parameters (CC ½, R-free). 
Cross-validation using the R-free and R-work parameters is a useful method to assess the model. 
It measures how well the structural model fits the experimental data. The cross-validation relies 
on the concept of splitting the data into two sets: a first set that is not used in any model 
optimisation (~5-10% of randomly selected data, R-free), and a second set (the rest of the data, 
R-work) used for calculations in model building and refinement. It allows two factors, R-free and 
R-work, to be observed throughout the structure refinement. In a good model ~90% of the work 
set should fit 10% of the excluded data (random set) well. Since the random set data do not 
participate in refinement, R-free > R-work. The difference R-free – R-work depends on resolution 
and ranges from 5-7% (at medium to low resolution) to ~0.15% (at high resolution). Typical 
values should be approximately 0.20%. However, even if the R-factor (the difference between R- 
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free and R- work) is appropriate and one would expect a good model it is always crucial to check 
model-to-map fit, to avoid overfitting.  
 
The CC ½ coefficient is another good parameter that helps to estimate the quality of a model. 
Thus, CC ½ values greater than ~0.5-0.8 indicate good correlation but may also give high 
correlation for weak densities. The CC½ is correlated with the B-factor: poorly defined regions 
typically have low CC½ and high B-factors.  
 
Furthermore, the crucial measure of the accuracy of an atomic model is its resolution, which 
describes the amount of detail that may be observed in the experimental data. High-resolution 
structures (resolution of 1 Å or lower) are highly ordered and allow visualisation of each atom in 
the electron density map. In contrast, lower resolution structures (resolution of 3 Å or higher) 
display only contours of the protein amino acid chain. 
 
A very useful software to validate crystal structures is Molprobity. It analyses all-atom contacts 
and geometry and inspects the chemical bonds within peptide chains (lengths, angles, chirality, 
planarity and torsions). These are compared in a Ramachandran plot, and inspected for outliers. 
Typically, the presence of some outliers (1-3%) is normal. 
 
The submission of a final model of a crystal structure to the PDB archive usually involves two 
types of data. The coordinate file (pdb) describes atomic positions of the final model of the 
structure while the data files (mtz or mmcif) describe the structure factors (the phases and the 
intensities of the X-ray spots in the diffraction pattern) obtained from the structure solution. As 
part of the service, the PDB generates validation reports that provide an assessment of structure 
quality using broadly accepted standards and criteria. 
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2.3   ITC overview 
Isothermal titration calorimetry is a label-free technique used to obtain 
the thermodynamic parameters of interactions between biomolecules in solution. It is frequently 
used to study the interaction between proteins, peptides and DNA. ITC directly measures the heat 
that is either released or absorbed throughout the binding event. It is a quantitative method and 
measuring the heat transfer during binding allows determination of the binding affinity (Ka), 
enthalpy changes (DH) and binding stoichiometry (n) of the interaction between molecules in 
solution. From these measurements the Gibbs free energy (DG) and entropy changes (DS) can be 
calculated using the formula: DG = - RTlnKa = DH  - TDS,  where R is the gas constant and T is 
the absolute temperature. The dissociation constant (Kd) can be calculated using the relationship, 
1/Ka.  
 
The measurement relies on the principle that a binding event causes heat to either be absorbed or 
released and this is measured by a sensitive calorimeter during gradual titration of the protein into 
the sample cell containing the binding partner. The microcalorimeter is composed of two cells, 
one of which is a reference cell and contains water or buffer, while the second cell contains the 
sample. The microcalorimeter retains these two cells at the same temperature throughout the time 
of the titrations. The heat sensing circuits detect the temperature difference between the cells 
when binding occurs and this triggers the response of the heaters, which return the cells to equal 
temperature. The instrument calculates how much power is required to maintain identical 
temperatures between the sample and reference cells. In an exothermic reaction, the temperature 
in the sample cell rises when the reactant is titrated and this requires lower power resulting in a 
downward peak in the signal. When the temperature of the two cells returns to equilibrium, the 
signal returns to the baseline. In contrast, an endothermic reaction, requires more power which is 
shown as an upward peak in the signal. The resulting experimental (raw) data present a series of 
injections over a period of time, where each heat signal corresponds to one injection of a reactant. 
The heat signal reaches baseline as the limiting reactant becomes saturated. The area of each peak 
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is integrated and plotted versus the molar ratio of binding partner/protein. The resulting isotherm 
is fitted to an appropriate binding model from which the binding affinity and a reaction 
stoichiometry can be derived. 
 
2.4   Summary 
NMR spectroscopy, X-ray crystallography and cryoelectron microscopy (not discussed here) are 
the main methods for determining high resolution atomic structures of proteins and their 
complexes. These methods are used independently or in combination to supplement each other 
with the complementary information that they provide. 
 
NMR spectroscopy and X-ray crystallography, each have their unique strengths and weaknesses. 
Protein structures solved by both techniques are often similar, however NMR focuses on 
structural studies of proteins in solution or in their solid state while crystallography studies 
proteins in their crystal form. NMR is particularly useful for characterising the structures of well 
folded proteins with lower molecular weights (<40kDa) as well as proteins with large intrinsically 
disordered regions. In contrast flexible proteins are far more difficult to study by crystallography 
because it relies on having many molecules aligned in exactly the same orientation (a repeated 
pattern in a crystal lattice). It means that the flexible parts of proteins will often be invisible in 
crystallographic electron density maps. Moreover, some proteins are difficult or impossible 
to crystallise, because of factors such as intrinsically disordered regions and the heterogeneous 
conformational properties of samples. Unlike NMR, X-ray crystallography provides limited 
information about protein dynamics, in the form of the crystallographic B-factor. Furthermore, 
unlike NMR, X-ray crystal diffraction typically cannot assign the positions of hydrogen atoms or 
reliably distinguish nitrogen from oxygen and carbon. This means that the chemical identity of 
the terminal side chain atoms can be unclear, for example for Asp, Gln and Thr. Furthermore, 
there is a risk that the crystals and protein will be damaged by the X-ray radiation. This is caused 
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because the electrons from inner atomic shells can be released and the resulting free electrons can 
directly interact with atoms, break bonds or generate free radicals. 
On the other hand, crystallography has the great benefit of being able to study larger proteins and 
their complexes at high resolution, given that they crystallise. Interestingly, new techniques have 
developed recently to improve and speed up the screening of protein crystals. This method 
includes in situ data collection. This can be achieved by collecting data directly from crystals 
growing in thin screen plates without the need for mounting and freezing the crystals. The 
possibility of using a grid scan and collecting data from a multiple positions of a crystal from 
different angles allows not only inspection of whether the crystal is formed of protein or salt, but 
also full data collection. For example, data collected from three different positions on the crystal 
and from three different angles can be merged into one dataset. 
Similarly, NMR has its weak points and one of the main disadvantages of NMR is the limiting 
size of proteins which nowadays usually cannot be bigger than 40-50kDa. Another drawback is 
the lack of automated software for the otherwise time consuming methods used in unambiguous 
assignment of peaks in a spectrum which is required for protein structure solution.  
 
Overall, both crystallography and NMR are effective in studying macromolecular complexes and 
also the dynamics of binding in the case of NMR. ITC and other biophysical methods are great 
tools for quantifying interactions and providing thermodynamic and kinetic details by delivering 
parameters like stoichiometry of binding partners and binding affinity.  
 
X-ray crystallography and NMR spectroscopy have constantly been developing and are now able 
to provide very high resolution structural data on very complex biological assemblies. Combining 
them is also highly beneficial in studying structures and functions of proteins and their complexes. 
Moreover, NMR models can be used as molecular replacement search models or to assess the 
folding of proteins prior to crystallization. Furthermore, cryo-electron microscopy is gaining 
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momentum in structure determination, especially of big complexes and the quality is dramatically 
improving reaching atomic resolution. 
The following books have been used as reference to describe the techniques in this chapter. NMR 
references included: Keeler, J. Understanding NMR Spectroscopy (Second Edition) (Wiley, 
2010), Rattle, H. An NMR Primer for Life Scientists (Partnership Press, 1995), Hore, P.J. Nuclear 
Magnetic Resonance (Oxford University Press, 1995), NMR: The Toolkit by P. J. Hore, J. A. 
Jones, S. Wimperis Oxford University Press (2000) Rule, G. S., and Hitchens, T. K. 
Fundamentals of Protein NMR Spectroscopy (Springer, 2006). J. Cavanagh, W. Fairbrother, A.G. 
Palmer III and Skleton N.J. Protein NMR Spectroscopy – Principles and Practice (Academic 
Press). Crystallography sections were based on Clegg W. X-Ray Crystallography 2/e (Oxford 
Chemistry Primer, 2015), Li-ling, O. X-ray Crystallography (Oxford University Press, 2010), 
Blow, D. Outline of Crystallography for Biologists (Oxford University Press, 2002), Rupp, B. 
Biomolecular Crystallography (Garland Science, 2010). 
 
2.5   Experimental material and methods 
2.5.1   Cloning and mutagenesis 
Proteins described in Chapter 3 and Chapter 4 were constructed using the following method. Gene 
fragments encoding human RNF126 (Uniprot code Q9BV68, constructs 1-40, 1-100, 142-218 
and 219-289 and RNF full-length) and N-terminal SGTA (Uniprot code O43765, construct 1-86) 
were PCR amplified from cDNA (Life Technologies), codon optimised for E.coli, and cloned into 
the BamHI/XhoI site of a home-modified pET28 vector which includes a N-terminal thioredoxine 
A tag followed by a hexahistidine peptide and tobacco etch virus (TEV) protease cleavage site. 
DNA inserts were PCR-­‐amplified using primers that introduced 5’ BamHI and 3’ XhoI restriction 
sites. Both, inserts and pET-­‐28 vector were digested with restriction enzymes to create compatible 
overlapping ends. Vector and insert were subsequently joined together in a ligation process using 
T4 DNA ligase. The RNF126 (1-40) construct is later called RNF126_NZF (for N-terminal Zinc 
finger) in all experiments.  GFP versions of RNF126 (1-40) were cloned following a similar 
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strategy but using a pET28 vector variant containing a N-terminal GPF tag instead of thioredoxine 
A. The RNF126 mutants (H14A, F36A, E38K and E39K) were obtained by PCR mutagenesis 
reaction using pET28-GFP-RNF126 (1-40) vector as template and overlapping complementary 
primers carrying the mutated codons at the centre of the oligonucleotides. The mutagenesis PCR 
conditions used in this work are described in (Table 4) and (Table 5). Following PCR 
amplification, parental, methylated DNA was removed by digestion with 10U of DpnI enzyme at 
37oC.  
 
Sequences corresponding to the N-terminal SGTA (1-69) and the UBL domains of BAG6 
(Uniprot code P46379, residues 17-101, named BAG6_UBL) and UBL4A (Uniprot code P11441, 
residues 1-74, named UBL4A_UBL) were cloned using ligation-independent Ek/LIC cloning 
(Novagen) into pET-46 vector containing a T7lac promoter and an amino-terminal His-Tag 
coding sequence immediately followed by an Ek/LIC cloning site. DNA inserts were produced in 
a PCR amplification with appropriately designed primers that include the 5' LIC extensions and 
generating vector compatible overhangs by treating purified PCR product with T4 DNA 
Polymerase. Target inserts were then joined with linearised pET46 vector in an annealing process 
by 5 min of incubation, followed by a transformation. RNF126_FL was cloned via Sequence and 
Ligation-Independent Cloning (SLIC) (312) because LIC and classic cloning methods have failed. 
The cloning was performed following the protocol reported here (312). This method involved 
designing primers with extensions which will produce specific sticky-ends in a PCR followed by 
the T4 polymerase digestion of 3’ ends (similar to the LIC cloning). However, unlike the LIC 
cloning it does not involve nucleotide addition and instead it is stopped after a time equal for 
insert and a vector. The insert with sticky ends self-assembly with a vector that also comprises 
sticky ends upon mixing. Furthermore, the construction process does not involve a ligase addition 
and during the transformation the nicks in DNA are repaired by processes of E.coli. In the case 
of yeast constructs of Sgt2 (Uniprot code Q12118, presented in Chapter 5), gene fragments 
encoding the Sgt2_TPR (residues 93–229 and 96-225 for the shorter construct) from 
Saccharomyces cerevisiae were PCR amplified and cloned into the home-modified pET28 vector 
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containing thioredoxin and hexahistidine tags (described above). The Sgt2_TPR (93-229) 
construct was used in structure determination by crystallography and also used in NMR titrations 
and ITC experiments. The shorter construct (96-225) was used to solve the structure of the 
Sgt2_TPR/PTVEEVD complex.  
 
Table 4: PCR reaction mixture. 
Reagents Volume in µl 
10X QuickChange Lightening Multi reaction buffer 2.5 
double-distilled H2O 18.5 
ds- DNA template 1.0 
mutagenic primers 1.0 
dNTP mix 1.0 
QuickChange Lightning Multi enzyme blend 1.0 
 
The reactions were cycled in a thermocycler using the parameters outlined in the table below. 
Table 5: PCR reaction conditions. 
Segment Cycles Temperature Time 
1 1 95°C 2 minutes 
2 30 95°C 20 seconds 
55°C 30 seconds 
65°C 30 seconds/kb of 
plasmid length 
3 1 65°C 5 minutes 
 




2.5.2   Protein expression  
E. coli was used as an expression host to produce all recombinant proteins described in this work. 
SGTA (1-69) and UBL4A_UBL were transformed into Rosetta cells, while BAG6_UBL, and all 
plasmids carrying RNF126 and Sgt2_TPR, were transformed into the BL21 (DE3) strain. The 
transformation protocol involved using a standard method, where 50 µl of E. coli cells were 
incubated with 0.5-2µl of plasmid and heat shocked at 42  °C for 45 seconds. The mixture was 
plated onto Lysogeny Broth (LB) agar containing the appropriate antibiotic for plasmid selection 
(50 µg/ml of carbenicillin for the pET46 vector, 30 µg/ml of kanamycin for the pET28 vector and 
34 µg/ml chloramphenicol for Rosetta cells). Transformed cells were used to inoculate 10 or 50 
ml of medium (LB or M9 accordingly) containing the necessary antibiotic and the overnight 
culture, was used to innoculate larger expression cultures. Typically, protein expression was 
induced by adding 0.3-0.5 mM isopropyl-β- D-thiogalactopyranoside (IPTG) to 1000ml of 
bacterial cultures at OD600 ≈ 0.8, followed by either 4 hours’ incubation at 37  °C (for SGTA, 
SGT2, UBL4A and BAG6) or overnight incubation at 18  °C (for RNF126). 15N-, 15N/13C-, and 
2H/15N/13C-labelled protein samples were expressed in M9-based minimal media supplemented 
with labelled ammonium chloride (>98 % 15N, Sigma-Aldrich) and/or glucose (> 99% U-13C, 
Sigma-Aldrich). For RNF126 expression, the cultures were supplemented with 10  µM ZnCl2. The 
cultures were harvested by centrifugation at 5000g and stored at -­‐80 oC. 
 
2.5.3   Protein purification  
Typically, harvested cells were resuspended in lysis buffer (20 mM potassium phosphate, pH 8.0, 
300 mM NaCl, 10 mM Imidazole, 250 µM TCEP), supplemented with 1mM PMSF and protease 
inhibitors (a mix of 0.3 µM Aprotinin, 10 µM Leupeptin and 1 µM Pepstatin A) or Protease 
Inhibitors EDTA-free tablets (Merck). Cells were lysed by sonication on ice or using a cell 
disruptor (Constant Systems Ltd). Cell debris and insoluble material were clarified by 
centrifugation at 17,000 g for 60 mins and overexpressed protein was recovered in a soluble 
fraction. Recombinant proteins included a his tag and therefore could be purified using nickel 
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affinity chromatography (HisTrapTM HP 5 ml, GE Healthcare). Typically, proteins were eluted 
with buffer containing 300 mM imidazole. For proteins containing a TEV cleavage site (all 
RNF126 constructs, SGT2 constructs and SGTA (1–86)), protein samples were dialyzed against 
cleavage buffer (20 mM potassium phosphate, pH 8.0 and 300 mM NaCl) and simultaneously 
digested with homemade TEV protease (≈ 100 µ g/ml) at 4 °C overnight. Following TEV cleavage 
a second nickel affinity chromatography step was performed to remove fusion protein, his tags, 
uncleaved protein and TEV protease; the target protein was then recovered in the flow through 
and loaded onto a gel filtration HiLoad 16/60 Superdex 75 column (GE Healthcare), previously 
equilibrated in buffer containing 10 mM potassium phosphate pH 6.0, 100 mM NaCl and 250 µ 
M TCEP (or 20mM Tris-HCl pH 7.5 in the case of Sgt2 used in crystallisation experiments and 
100 mM pH 6.0 MES buffer, 150 mM KCl in the case of NMR titration and structural experiments 
of SGTA (1-69) with UBLs). Proteins were concentrated using Vivaspin concentrators (Sartorius 
Stedin) and sample purity was checked by SDS-PAGE after addition of 5x loading dye and boiling 
for 10 minutes. The SDS-PAGE was typically run at 160V for 45 minutes using 12-15% gels and 
stained for 60 min using Quick Coomassie Stain (Generon). Protein concentration was determined 
from the absorbance at 280 nm (or using a BCA assay) and molecular weights confirmed by mass 
spectrometry. The lyophilized peptides: PTVEEVD (corresponding to Ssa1 C-terminal; residues 
634-640), MEEVD (corresponding to C-terminal of Hsp82; residues 705-709) and SLEEDLNLD 
(corresponding to C-terminal of Ybr137wp; residues 171-179) were purchased from Alpha 
BioScience (Birmingham, UK) and resuspended in water or an appropriate buffer before use. All 
peptides were purified and verified by HPLC (high pressure liquid chromatography) and mass 
spectrometry. 
 
2.5.4   Estimation of protein concentration by BCA assay 
The Thermo Scientific Pierce BCA Protein Assay was used to determine total protein 
concentration of SGTA (1-69), UBL4A_UBL and BAG6_UBL samples with reference to a series 
of bovine serum albumin (BSA) protein standards between 25 and 2000 µg/ml. Samples and 
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protein standards were prepared with BCA reagent according to the manufacturers protocol and 
their absorbances were measured at 562 nm (A562) after a 15-minute incubation period at 37˚C. 
 
2.5.5   Native PAGE mobility shift assay  
The native PAGE mobility shift assay was employed to analyse of protein-protein interactions. 
The experiment involved incubating 25  µM GFP-tagged RNF126_NZF (wild type and mutant 
variants) with increasing amounts of BAG6_UBL or UBL4A_UBL (at a concentration range from 
0 to 4 molar equivalents) for 10  min at room temperature in a final volume of 20  µl. In the case 
of competition experiments, GFP-tagged RNF126 was added to the SGTA (1-86) and 
BAG6_UBL protein mixture at increasing concentrations (between 0 to 4 molar equivalents). In 
vice-versa titrations, increasing amounts of SGTA (1-86) were added to the RNF126/BAG6_UBL 
complex. The visualisation of fluorescent bands on the gel was performed using an Amersham 
Imager 600 (GE Healthcare) with a light source of Epi-RGB green light at 520  nm and Cy3 
emission filter. The gels were also stained using Coomassie to detect protein bands. Native gels 
were made using 10% polyacrylamide in 0.45  M Tris-HCl pH 8.8, 1% ammonium persulphate 
and 0.02% TEMED and run under native conditions (no SDS), in buffer containing 25  mM Tris, 
200mM glycine at 100  V for 180  min 
 
2.5.6   NMR titrations 
Protein samples of SGTA (1-69), UBL4A_UBL and BAG6_UBL for NMR titrations were 
dialysed overnight into 100 mM MES, pH 6.0 with 150 mM KCl. All RNF126 constructs, 
UBL4A_UBL, BAG6_UBL, SGTA (1-86), Sgt2_TPR (93–229) and peptides were prepared in 
10  mM potassium phosphate pH 6.0, 100  mM NaCl and 250  µM TCEP). Spectra were recorded 
in the absence and presence of a binding partner in a suitable range of molar ratios and keeping 
the concentration of the labelled protein constant. Shift changes were monitored by 1D 1H- and 
2D 1H-15N HSQC spectra and experiments were typically recorded for each titration point at 25°C 
except for SGTA (1-69)/UBL titrations, which were performed at 30  °C. Chemical shift 
105 
 
perturbation (CSP) was calculated for every amide signal using the following formula, where 
Δδ1H and Δδ15N are the chemical shift differences for the same amide in its free and bound 
spectra (δfree-δbound) and for proton and nitrogen values respectively: 
Δ𝛿#$ = ∆𝛿'( ) + ∆𝛿'+, 5 ) · 0.5 
Competition binding experiments of SGTA (1-69), UBL4A_UBL and BAG6_UBL were carried 
out by titrating 15SGTA (1-69) with BAG6_UBL, followed by the addition of UBL4A_UBL in 
1:1 molar ratio. In the reverse titration scenario, 15N SGTA (1-69) was titrated with UBL4A_UBL, 
followed by the addition of BAG6_UBL. Prior to the NMR binding experiments, the 
concentration of all the proteins was measured, by comparing the integrated methyl peak of 100 
µM DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) to that of isolated methyl peak of the 
protein on 1D spectra.  
 
CSP results were mapped onto the structures using the PyMOL software DeLano Scientific LLC, 
Palo Alto, CA, USA). For the RNF126 titration with UBL4A_UBL, chemical shift perturbation 
data were analysed and fitted using the Dynafit software (313). 
 
2.5.7   NMR structural experiments 
Samples of SGTA (1-69), UBL4A_UBL and BAG6_UBL used in experiments described in 
Chapter 3 were buffer-exchanged by dilution/re-concentration into 100 mM pH 6.0 MES,150 mM 
KCl buffer. NMR experiments were performed on samples at a concentration between 200 and 
1000 µM of 15N, 13C-labelled protein in either 5 mm Shigemi (Sigma-Aldrich) or standard 5 mm 
NMR tubes at 35 or 30°C for SGTA and BAG6/UBL4A samples respectively. SGTA protein 
backbone assignments were carried out using experiments – HNCO, HN(CA)CO, 
CBCA(CO)NH, and HNCACB. Assignments for sidechain resonances were executed using a 
combination of HBHA(CBCACO)NH, (H)CCH-TOCSY, H(C)CH-TOCSY, and amide detected 
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H(CCCO)NH-TOCSY and (H)C(CCO)NH-TOCSY experiments. NOE distance restraints and 
assignment of aromatics rings were derived from 3D 15N-NOESY-HSQC and 3D 13C-separated, 
(13C, 15N-F1)- filtered edited NOESY experiments. Data were mostly collected on 600 MHz 
Bruker Avance lll and 800 MHZ Bruker Avance II spectrometers at Imperial College London 
with TCI and TXI cryoprobes respectively, controlled by Topspin3 (Bruker Biospin Ltd). The 
15N-filtered NOESY experiment was recorded on a Bruker 700 MHz Avance spectrometer with 
a cryoprobe at Kings College London. The 3D, 15N-HSQC-NOESY was collected on a homebuilt 
950 MHz spectrometer equipped with triple-resonance, triple-axis gradient probehead at the 
University of Oxford. Data were processed using NMRPipe (314) and analysed in NMRView 
(315) (One Moon Scientific) and with CcpNMR Analysis (316). The structure calculation was 
performed using ARIA2 (50) by generating 100 conformers in the final iteration and selecting the 
20 best structures with lowest restraint energies for a final step of refinement in water. 
 
NMR experiments described in Chapter 4, including BAG6_UBL and RNF126_NZF proteins, 
involved using samples prepared at concentrations between 100 and 1000  µM in 10% or 100% 
D2O (Sigma Aldrich), 10  mM potassium phosphate pH 6.0, 100  mM NaCl and 250  µM TCEP 
buffer (also containing 10  µM DSS for proton chemical shift referencing). NMR experiments 
were recorded in 5  mm NMR tubes at 25  °C on Bruker Avance spectrometers at 500  MHz and 
700  MHz equipped with cryoprobes, controlled by the TopSpin 3.1 software package. Backbone 
assignments were performed using 3D experiments (HNCO, HN(CA)CO, CBCA(CO)NH, and 
CBCANH and sidechain resonances were assigned using 3D HCCH-TOCSY experiments for 
both RNF126_NZF and for the RNF126_NZF/BAG6_UBL complex. All NMR spectra were 
processed with NMRPipe followed by examination with CcpNMR Analysis. For RNF126_NZF, 
NOE distance restraints were obtained from the following NOESY experiments: 2D NOESY (in 
90% H2O and 100% D2O). The complex study involved using either 15N, 13C labelled 
BAG6_UBL or RNF126 1–40 and acquiring the two pairs of 15N-edited NOESY-HSQC, 13C-
edited NOESY-HSQC and 12C, 14N-filtered-13C-edited NOESY-HSQC experiments. Dihedral 
constraints (ϕ and Ψ angles) were extracted from the chemical shift values using TALOS+ (305). 
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The structure calculation was performed using ARIA2 (306) by generating 100 conformers in the 
final iteration followed by selecting 20 best structures with lowest restraint energies for a final 
step of refinement in water. The coordination of the zinc atom in RNF126 structure was 
determined in a first round of calculations using only NOE based distance restraints and once it 
was confirmed, the zinc atom coordination was added as an additional restraint in calculations 
that involved using ARIA2 tools. The final ensemble of each structure was deposited with the 
PDB - accession numbers:2N9O; RNF126_NZF, 2N9P; RNF_NZF/BAG6_UBL. 
 
The samples of Sgt2_TPR used in NMR experiments described in Chapter 5 were prepared at 
concentrations between 500-3000  µM in 90% H2O/10% D2O (Sigma Aldrich), 10  mM potassium 
phosphate pH 6.0, 100  mM NaCl and 250  µM TCEP buffer. Similarly, to above, NMR 
experiments were acquired in 5  mm NMR tubes at 25  °C on Bruker Avance spectrometers at 
500  MHz and 700 MHz equipped with cryoprobes at Kings College London, operated by the 
TopSpin 3.1 software package. Backbone assignments were carried out using 3D experiments 
(HNCO, HNCA, HN(CA)CO, CBCA(CO)NH, and CBCANH) for Sgt2_TPR. All NMR spectra 
were processed with NMRPipe and analysed with CcpNMR Analysis. Chemical shifts were 
deposited in the STAR format created in CCPN Analysis at BMRB accession number 27044.  
 
All structures were analysed and represented using PyMOL (317). 
 
2.5.8   Complex docking with HADDOCK 
2.5.8.1   SGTA/UBL complex assembly using HADDOCK 
The CSP studies provided the information about the interaction surface of SGTA 
(1_69)/UBL4A_UBL and SGTA (1-69)/BAG6_UBL complexes. These data were implemented 
in structural calculation of the complex using the HADDOCK approach (318). Assignment of 
intermolecular NOE provided additional restraints. Calculations of complex structures involved 
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using the PDB-deposited structures of UBL4A_UBL (2DZI) and BAG6_UBL (4EEW) and our 
lowest energy NMR structure of SGTA (1-69) dimer. Ambiguous Interaction Restraints (AIRs) 
were added in HADDOCK according to the standard protocol and included the most perturbed 
residues in CSP experiment. These were chosen from 20 amino acid residues in SGTA (1-69) (in 
both titrations) and 26 and 21 in UBL4A_UBL and BAG6_UBL, respectively, which were 
detected to have chemical shift changes higher than the averages of: 0.055 or 0.083 ppm for SGTA 
(1-69) and 0.222 and 0.148 ppm for UBL4A_UBL and BAG6_UBL and were used as suitable 
cut-off values. Following the filtering for a solvent exposed residues greater than 25%, as 
calculated using the program Naccess, 14 and 8 residues in each SGTA (1-69) monomer, for the 
UBL4A and BAG6 titrations respectively, were defined as active. These were 34, 38, 40, 41, 43, 
44, 47, 48, 51, 54, 55, 60, 62, and 64 for the UBL4A titration and 39, 45, 47, 51, 54, 55, 58, and 
60 for the BAG6 titration. Similarly, for UBL4A_UBL 14 residues, namely 15, 16, 17, 18, 19, 
21, 23, 49, 54, 55, 56, 73, 75, and 78 were active. Finally, for the BAG6_UBL 16 residues, 22, 
23, 24, 25, 26, 58, 62, 63, 65, 67, 76, 83, 85, 86, 87 and 88 were identified as active residues. 
Filtered NOESY experiments using a 3D 13C F1-filtered, F3-edited NOESY-HSQC pulse 
sequence were performed on samples comprising unlabeled SGTA (1-69) and 15N, 13C-
UBL4A_UBL or 15N, 13C-BAG6_UBL. Obtaining unambigous distance restraints to support 
docking was not possible due to the ambiguity of the cross peak resonances. This could be due to 
the chemical shift perturbations upon protein binding.  Additional AIRs were used instead as 
shown in tables in Chapter 3.6. Solvent exposed residues neighbouring the active residues were 
automatically defined as passive residues by the HADDOCK software. One thousand initial 
complex structures were produced by rigid body energy minimization, and the top 200 structures 
defined by total energy were selected for torsion angle dynamics and subsequent Cartesian 
dynamics in an explicit water solvent. Following the standard benchmarked protocol, cluster 





2.5.8.2   RNF126_NZF/UBL4A_UBL complex assembly using HADDOCK 
To generate a model of RNF126_NZF complex with UBL4A, the same HADDOCK approach 
was used as for SGTA/UBL complex. For HADDOCK calculations, PDB-deposited structures of 
UBL4A_UBL (2DZI) and the lowest energy NMR structure from RNF126_NZF structural 
ensemble were used. AIRs were implemented based on the chemical shift perturbation data and 
allowed identification of 14 amino acid residues in RNF126_NZF and 21 in UBL4A_UBL with 
chemical shift changes greater than 0.15  ppm. After sorting for a relative solvent accessibility 
higher than 45%, 10 residues in RNF126_NZF and 14 in UBL4A respectively, were identified as 
active. These were RNF126_NZF residues 14, 27, 34, 36, 38, 39 and UBL4A residues 8, 44, 48, 
49, 68, 70. Solvent exposed residues near the active residues were automatically named passive 
residues by the HADDOCK. Following the same protocol as for SGTA/UBL, cluster analysis 
produced 175 structures in 5 cluster ensembles. The top scoring cluster (lowest energy) was 
selected as the most reliable result as shown by HADDOCK benchmark testing. 
 
2.5.9   Isothermal Titration Calorimetry 
ITC experiments were performed at 30°C for SGTA (1-69) binding assays with UBL4A_UBL 
and BAG6_UBL and at 25 °C for RNF126_NZF interacting with UBLs and for Sgt2_TPR 
interacting with peptides. The experiments were carried out using ITC-200 MicroCal 
microcalorimeter (GE Healthcare) following the standard procedure. The samples of SGTA (1-
69), UBL4A_UBL and BAG6_UBL were prepared in 100 mM MES, pH 6.0, 200 mM KCl and 
the titrations involved 20 injections of 2 µL of SGTA (1-69) (dimer), at a concentration of 500 
µM, added to a sample of BAG6_UBL or UBL4A_UBL respectively at 50 µM (monomer).  
 
RNF126_NZF and UBL domains were prepared in 10  mM potassium phosphate pH 6.0, 100  mM 
NaCl, 250  µM TCEP. In each titration, 20 injections of 2  µL of RNF126_NZF (wild-type or 
mutant), each at a concentration of 500  µM, were added to a sample of BAG6_UBL or 
UBL4A_UBL at 50  µM in the reaction cell. In Sgt2_TPR binding experiments with peptides, 
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proteins were prepared in 10 mM potassium phosphate pH 6.0, 100 mM NaCl, 250 µM TCEP 
and 20 injections of 2 µL of peptide solution at a concentration of 500 µ M, were added to 
Sgt2_TPR (residues 93–229) at 50 µM in the reaction cell.  
 
Integrated heat data acquired for the titrations were corrected for heats of dilution and fitted using 
a nonlinear least-squares minimization algorithm to a theoretical titration curve, using the 
MicroCal-Origin 7.0 software package. ΔH (reaction enthalpy change in Kcal/mol), Kb 
(equilibrium binding constant per molar), and n (molar ratio between the proteins in the complex) 
were the fitting parameters. The reaction entropy, ΔS, was calculated using the ΔG = −RT ⋅lnK 
b (R = 8.314 J/(mol⋅K), T 298 K) and  ΔG  = ΔH −T ΔS.  Dissociation constants (Kd) are shown 
for each interaction. 
 
2.5.10   Microscale Thermophoresis 
Microscale thermophoresis was used in protein-protein interaction studies and performed on the 
Monolith NT.115 (Nanotemper Technologies, Munich, Germany) with fluorescently labelled 
proteins as described (319). 
 
In binding assays of SGTA (1-69) with UBL4A_UBL and BAG6_UBL, purified UBLs were 
labelled using the Monolith NT protein labeling kit RED-NHS (Amine Reactive) dye 
(NanoTemper Technologies GmbH). The labelling reaction was completed in 100 mM MES pH 
6.0, 150 mM KCl, 0.5 mM TCEP buffer using a concentration of 20 µM protein (molar dye : 
protein ratio ≈2∶1) at RT for 30 min. Unbound dye was removed with the dye removal columns 
which were supplied in a reaction kit. The concentration of labelled proteins was adjusted to 0.8 
µM using buffer comprising 100 mM MES pH 6.0, 150 mM KCl, 0.5 mM TCEP, 0.0% 
TWEEN20. Samples of unlabelled SGTA (1-69) were prepared in serial dilutions of equal 
volumes (1∶1) using the same buffer and yielding SGTA (1-69) concentrations ranging from 800 
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µM to 48.8 nM. For thermophoresis, each SGTA (1-69) dilution was mixed in 1:1 ratio with one 
of the labelled UBL proteins, producing a final concentration of 0.4 µM fluorescently labelled 
protein and final SGTA (1-69) concentrations ranging from 400 µM to 24.4 nM. Following 15 
min incubation, approximately 5 µl of each solution was loaded into Monolith NT Standard 
Capillaries (NanoTemper Technologies GmbH). Thermophoresis rates were measured using a 
Monolith NT.115 instrument (NanoTemper Technologies GmbH) at room temperature of 25°C 
with 5 s/30 s/5 s laser off/on/off times, respectively. Instrument parameters used in the 
experiments were: 10% LED power and 40% IR-laser power. Data from three independently 
pipetted measurements were analysed (NT Analysis software version 1.2.101, NanoTemper 
Technologies) using the signal from Thermophoresis + T-Jump. 
 
MST studies of RNF126_NZF with BAG6_UBL and UBL4A_UBL were performed using GFP 
tagged construct of RNF126_NZF in buffer comprising 10  mM potassium phosphate, pH 6.0, 
100  mM NaCl, 250  µM TCEP. Samples for the reaction were prepared by mixing GFP tagged 
RNF126_NZF with either BAG6_UBL or UBL4A_UBL and maintaining the concentration of 
RNF126 constant (0.125 or 0.250  µM), while UBL domain concentrations ranged from 25  µM to 
0.8  nM (BAG6_UBL), or 50  µM to 1.5  nM (UBL4A_UBL) using 1:1 serial dilutions. Followed 
15  minute incubation, ~5  µl of each solution was loaded into Monolith NT Standard Capillaries. 
Thermophoresis was measured at 25  °C with 5s/30s/5s laser off/on/off times and instrument 
parameters were adjusted with 10–20% LED power and 20% IR-laser power. Data from three 
independently pipetted measurements were compared (NT Analysis software version 1.2.101, 
NanoTemper Technologies) using the signal from Thermophoresis + T-Jump. 
 
2.5.11   Crystallisation  
Sgt2_TPR (residues 93–229) was concentrated to 35 mg/ml in 20mM Tris-HCl pH 7.5 buffer and 
crystals were obtained after four days by the vapor-diffusion method at 293K using MRC plates 
in 0.1M SPG, pH 6.0, 25% w/v PEG 1500 (ICL7 screen plate from Imperial College London, 
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based on PACT premier from Molecular Dimensions) at 20°C (drop volume = 400nl). In the case 
of Sgt2_TPR (96-225)/PTVEEVD complex, protein/peptide mixture was co-eluted from a 
HiLoad 16/60 Superdex 75 column and concentrated to 20 mg/ml in 20mM Tris-HCl pH 7.5 
followed by a further peptide addition (up to protein: peptide =1:3 ratio) preceding crystallization. 
The lyophilized peptides: PTVEEVD (corresponding to Ssa1 C-terminal; residues 634-640), 
MEEVD (corresponding to C-terminal of Hsp82; residues 705-709) and SLEEDLNLD 
(corresponding to C-terminal of Ybr137wp; residues 171-179) were purchased from Alpha 
BioScience (Birmingham, UK) and resuspended in water or in the same buffer as the protein 
before use. All peptides were purified and verified by HPLC and mass spectrometry. The complex 
was crystallised after seven days by the vapor-diffusion method at 293K in 0.2M Zinc Acetate, 
pH 6.3, 20% w/v PEG 33500 (ICL3 screen plate from Imperial College London, PEG/Ion screen 
from Hampton Research) producing needles. These were optimised and rod crystals were 
produced by the vapor-diffusion method in 0.2M Zinc Acetate, pH 7.2, 30% w/v PEG 3350 after 
7 days). All crystals were harvested in reservoir solution with 20% glycerol before flash cooling 
in liquid nitrogen. 
 
2.5.12   Crystallography (Data collection and processing) 
A complete dataset was collected from a single crystal on Diamond Beamline I04 for the free 
Sgt2_TPR dataset and I03 for the Sgt2_TPR/PTVEEVD complex using a Pixel Array Detector 
(PAD): Pilatus 6M-F detector and a single wavelength 0.920 Å. Data were processed using Xia2 
(320) followed by scaling and merging with Aimless and the asymmetric unit contents were 
estimated using the Matthews coefficient with CCP4 suite (321). In the case of the complex data 
were reduced with Xia2 and scaled with Aimless. The scaled and unmerged data were selected 





2.5.13   Crystallography (Structure solution and refinement) 
The crystal structure of Sgt2_TPR (93–229) was determined by molecular replacement using 
Phaser (322) with human SGTA_TPR crystal structure (PDB accession number: 2VYI) used as a 
search model. The Sgt2_TPR (96-225)/PTVEEVD complex structure was determined by 
molecular replacement using Phaser and mammalian model (PDB accession: 2VYI) as a search 
model. The free Sgt2_TPR structure was refined using REFMAC5 (323) and the complex 
structure, using PHENIX (324) with manual model building using Coot (325). PHENIX was run 
using a script with automatic NCS and TLS (10 final TLS groups). Before submission, data were 
extracted into the correct format using PDB_EXTRACT 3.20. A free R-value of 4.9% was used 
as a cross-validation method for Sgt2_TPR and 4.8% for Sgt2_TPR (96-225)/PTVEEVD. Water 















Chapter 3.   Structural and binding studies of SGTA, BAG6 and UBL4A 
This chapter aimed to contribute to better understanding of the way in which hydrophobic proteins 
have their fate decided by the collaboration between SGTA and the BAG6 complex. First, a 
solution structure of the SGTA dimerisation domain was solved. This was followed by using 
biophysical techniques to investigate the interaction of SGTA’s UBD with two different 
ubiquitin-like domains (UBL) from the BAG6 complex. Moreover, a combination of structural 
and interaction data was implemented including the HADDOCK protein-protein interaction 
docking tool to generate models of the SGTA-UBL complexes. 
 
3.1   Protein production 
The domains of SGTA (1-69), SGTA (1-86) and UBL4A_UBL constructs were designed based 
on the previous studies in Isaacson lab. Proteins were successfully overexpressed in E. coli 
Rosetta cells and BAG6_UBL was expressed in BL21 (DE3). The purification steps proved all 
proteins were well expressed, soluble and found to be stable. The SDS-PAGE profile shows bands 
corresponding to the correct proteins sizes of approximately 9.3kDa for SGTA (1-69), 9.6kDa for 
UBL4A_UBL and 10.4kDa for BAG6_UBL, with the BAG6 band consistently running higher 
than expected on a gel (Figure 19). In all cases, overexpressed protein was recovered in the 
soluble fraction. Enrichment of expressed protein was achieved by affinity purification and size 
exclusion chromatography (SEC), prepared in a buffer at a pH that was distant from the pI of the 
individual proteins. Final yields of purified proteins were typically 50-100 mg/L for expression 
in LB and in M9 minimal media. The high yields of SGTA (1-69) did not bind to the His-Trap 
column efficiently and protein was typically present in the elution and also wash fraction possibly 
due to overloading the His-Trap column or non accessible His-tag obscured by the dimer interface 





Figure 19: Purification of SGTA (1-69), BAG6_UBL and UBL4A_UBL. Left, SDS-­‐PAGE analysis of 
purification by affinity chromatography of SGTA (lanes 1-5) and BAG6 (lanes 6-10). 1), 6) uninduced cell 
control 2), 7) flow through after column loaded with the cell lysate, 3), 8) wash with 5 CV of wash buffer 
(20 mM potassium phosphate pH 8.0, 300 mM NaCl and 250 µ M TCEP), 4), 9) wash with 2 CV of wash 
buffer 2 (20 mM potassium phosphate pH 8.0, 300 mM NaCl and 250 µ M TCEP, 20mM Imidazole)  5), 
10) elution with 2 CV of elution buffer (20 mM potassium phosphate pH 8.0, 300 mM NaCl and 250 µ M 
TCEP, 300mM Imidazole). Right, SDS-­‐page analysis of UBL4A_UBL purification 1) uninduced cells 
control 2) flow through after column loaded with the cell lysate, 3) wash with 5 CV of wash buffer, 4) 
elution with 2 CV of elution buffer. 
 
3.2   SGTA (1-86) 1H, 13C, and 15N Chemical Shift backbone and side chain 
assignment 
The backbone and side-chain assignments of SGTA (1-69) construct were mostly assigned by a 
Master’s student Mr Newran Sriskandarajah employing NMRView modules which provided 
rapid input for MARS automated assignment (326) and facile handling of sidechain data (327). 
These assignments for side-chain resonances were performed from a combination of 
HBHA(CBCACO)NH, (H)CCH-TOCSY, H(C)CH-TOCSY, and amide detected H(CCCO)NH-
TOCSY and (H)C(CCO)NH-TOCSY experiments. I have completed the backbone assignment of 
N-terminal SGTA (residues 1-86) using CCPN analysis, including the assignment of the linker 
between the N-terminal domain with the TPR domain. The chemical shifts were deposited at 
BMRB with Accession Number: 19779. The complete set of 3D NMR experiments (HNCA, 
HN(CO)CA, HNCACB, HN(CO)CACB and also 2D NOESY experiment) were acquired at 
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was prepared for NMR spectroscopy in 100 mM MES, pH 6, 150 mM KCL and 10% D2O buffer. 
Under these conditions the number and dispersion of the peaks displayed the features of a 
homogeneous folded protein. 15N HSQC peaks were picked manually and the NH assignment for 
all missing residues was completed except for Prolines. The full 15N HSQC spectrum with 
assigned peaks is shown in Figure 20. The overlay between SGTA (1-69) and SGTA (1-86) is 
shown in Figure 21. By the analysis of the HSQC spectrum, residues 69-86 were likely to be 
flexible therefore construct 1-69 was used in structural calculations. 
 
Figure 20: 1H-15N HSQC spectra of 15N-labelled SGTA (1-86). The assignment of SGTA (1-69) was 
propagated or reassigned onto the longer construct of SGTA including the missing 17 residues of the linker. 
‘He’ corresponds to side chain protons. 
 




















































































Figure 21: An overlay of 1H-15N HSQC spectra of 15N-labelled SGTA (1-69) in dark blue and 15N-
labelled SGTA (1-86) in light blue. 
 
3.3   The NMR solution structure of SGTA (1-69)  
The SGTA (1-69) construct was used in all structural calculations which have been done in 
collaboration with Dr John Darby using ARIA2. The backbone and side chain assignment 
chemical shift lists, dihedral constraints (ϕ and Ψ angles), extracted from the chemical shift values 
using TALOS+ and manually assigned NOE restraints, were used to calculate the structure of a 
SGTA (1-69) dimer. NOE distance restraints and assignment of aromatics rings were derived 
from 3D, 13C-NOESY-HMQC, 3D, 15N-NOESY-HSQC and 3D, 13C-separated, (13C, 15N-F1)-
reject filtered NOESY and 15N-filtered NOESY experiments. In the initial Aria runs we also 
allowed for automated nuclear Overhauser effect (NOE)-derived assignment. In each of many 
cycles of structure calculations with water refinement, we inspected the restraints violations and 
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manually corrected them. The final Aria run generated 100 conformers in the final iteration and 
the 20 best structures with lowest restraint energies were selected for a final step of refinement in 
water. The final ensemble was deposited at the PDB with the Accession Number: 4CPG. The 
structural statistics including those obtained from PROCHECK are presented in Table 6. Like its 
yeast homologue, SGTA (1-69) forms a tight symmetrical homodimer (Figure 22). Each 
monomer consists of four alpha helices (α1 =  N3-H21; α2 =  S26-F43; α3 =  V47-L52; α4 =  L58-
T67) connected by short loops with helices from each subunit arranged in a head to tail fold form, 
analogous to that of the Sgt2 N-terminal. The first two helices are of similar length and mediate 
homodimerization with the third, shorter helix packing against their other side, away from the 
dimer interface (Figure 22 B). The dimer interface is highly hydrophobic resembling the core of 
a globular protein and spans an area of 1266 Å2 as calculated by PISA (328). The dimer contacts 
mainly via the α2 helices and includes the interaction of small and conserved residues (Ser31, 
Ala35, Cys38, and Ala42), resulting in close packing between the main chains of the two subunits. 
Also, residues with larger hydrophobic side chains (Leu24, Leu39, Thr41, Phe43 and Val34 on 
α2 and Ile11 and Leu15 on α1) contribute to the formation of the dimer hydrophobic core (Figure 
22 F). The conserved acidic residues Asp27 and Glu30, Glu33 and Glu40, result in a negatively 
charged ring surrounding the hydrophobic core (Figure 22 C). Our SGTA (1-69) structure aligns 
with the yeast homologue with an RMSD of 2.4 Å. Minor structural differences are present at 
helix α3 and the loop between helices α2 and α3 which form part of the UBL interaction site. A 
structural overlay with the equivalent yeast domain is shown in Figure 22 D. The equivalent 
conserved residues of N-terminal SGTA and Sgt2 of which some are involved in formation of the 
binding interface with UBL domains are shown in Figure 22 G and H and the sequence alignment 





Figure 22: Orthogonal views of NMR structures of SGTA (1-69) dimer. A) Ensemble views showing 
20 lowest energy ARIA-calculated structures as deposited in the PDB (Accession code: 4CPG); monomers 
indicated by red and green. B) Cartoon views of a dimer with monomers coloured as in A. C) Electrostatic 
views ranging from −10 negative charge in red to +10 positive charge in blue modelled using ccp4mg (329) 
which calculates the charge distribution present on the solvent accessible surface of the protein. D) 
Structural alignment of SGTA (1-69) (red/ green) with Sgt2 N-terminal (lilac/blue; PDB: 4ASV) 
superimposed using secondary-structure matching in ccp4mg. The structures align with RMSD of  2.41Å. 
E)  Sequence alignment of SGTA (1-69) homologs. The species are Homo sapiens, S. cerevisiae Aspergillus 
fumigatus , Drosophila melanogaster. Alignment was made using Clustal and asterisks indicate sequence 
identity and dots indicate sequence similarity. Residue coloring is based on similarity (grey), 
hydrophobicity (purple) and charge (blue). The residues are numbered according to the human SGTA 
sequence. The helices are shown as red cylinders. F) Details at the dimer interface showing small, conserved 
residues (left) and bulky, hydrophobic residues (right) with side chains highlighted as sticks. G) Conserved 
residues are shown as sticks on SGTA and equivalent residues on Sgt2 (H) (82). 
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Table 6: Summary of SGTA (1-69) dimer solution structural statistics of ensemble of 20 structures.  
Distance and Dihedral Restraints  
NOEs:  Intra-residue  518 
             Sequential 345 
             Short range 232 
             Medium range 106 
             Long range 183 
             Inter-monomer 136 
             Total unambiguous 1520 
             Ambiguous 694 
             Total NOE-derived 2214 
Hydrogen bond restraints (applied to each monomer) 68         (34 H-bonds) 
Dihedral angles (φ + ψ) (applied to each monomer) 126       (63 residues) 
Structural Statistics  
Ramachandran Plot (%)  (from Procheck-NMR)  
             Most favoured 92.2 
             Additionally allowed 7.2 
             Generously allowed 0.6 
             Disallowed 0.0 
RMSD from experimental restraints  
             Distances (Å) 0.027 ± 0.018 
             Dihedrals (o) 1.24 ± 1.32 
RMSD from idealized geometry  
             Bonds (Å) 0.0034 ±  0.0007 
             Angles (o) 0.53 ± 0.101 
             Impropers (o) 1.78 ± 0.718 
NOE Violations > 0.5 Å 0 
                            > 0.3 Å 0 
                            > 0.1 Å 7.7 ± 3.5 
Structural Precision  
RMSD from average structure (Å)  
  Backbone (all/2ndary structure) 0.95 ± 0.35 / 0.50 ± 0.16 




3.4   Probing the binding interface for SGTA (1-69)/UBL4A_UBL by 
chemical shift perturbation 
The NMR structure of the UBL domain from UBL4A which we used in our experiments has been 
solved by Zhao and colleagues as part of the RIKEN Structural Genomics Initiative and deposited 
in the Protein Data Bank (Accession Number: 2DZI) with no associated publication to date. Since 
the NMR chemical shifts were not originally published, we used the backbone assignments of 
UBL4A_UBL reassigned by Aline Simon in our lab (90) in our interaction experiments. 
Reciprocal chemical shift perturbation studies (CSP) were carried out by titrating unlabelled 
UBL4A_UBL into 15N-labelled SGTA (1-69) and vice versa to probe the binding interface 
between the two domains (Figure 23 and Figure 26 peak list can be found in appendix. The 
interaction was monitored by recording a series of 1H/15N-HSQC experiments until the binding 
reaction was saturated and no further chemical shift perturbation was observed. The spectra 
showed binding in a fast and fast-intermediate exchange regimen and CSPs were calculated for 
each residue in its free and bound position (δfree-δbound) for proton and nitrogen values 
respectively (Figure 24 and Figure 29) and plotted on the structure, with the most perturbed 
residues shown in dark red (Figure 27A and C). The results showed that the interface is 
analogous to the equivalent complex in yeast Sgt2/Get5 (90), although with some differences. 
While, only one set of NMR signals from the two domains of the SGTA homodimer was observed 
in the bound state, it would be expected that a single UBL domain, binding at the homodimer 
interface should disrupt the chemical equivalence of some NMR signals from the two halves of 
each dimer, resulting in two sets of signals. This was a similar result to the yeast complex of 
Sgt2_NT/Get5_UBL. In the Sgt2_NT/Get5_UBL complex, we, and others (263) found that 
exchange of the UBL between the two equivalent binding sites on the Sgt2 dimer is faster than 
the NMR chemical shift timescale causing averaging of the frequencies at the elevated 
temperatures required for analysis (310 K) and it is probable that we observe a similar event in 
the mammalian complex (82). The 1∶1 (SGTA dimer: UBL monomer) stoichiometry was 





Figure 23: Full 1H-15N HSQC spectra of 15N-labelled UBL4A_UBL titrated with unlabelled SGTA 
(1-69). The 15N-labelled UBL4A_UBL: SGTA (1-69) protein ratio was used at 1:0 (maroon), 1:0.3 (blue), 





Figure 24: Normalized CSP of 15N-labelled UBL4A_UBL titrated with unlabelled SGTA (1-69). The 
graph shows the CSP plot for each residue. 
 
3.5   Probing the binding interface for SGTA (1-69)/BAG6_UBL by chemical 
shift perturbation 
We aimed to investigate the interaction of SGTA (1-69) with the second UBL domain from the 
BAG6 complex, which belongs to the BAG6 protein itself. Since UBL domains of both, BAG6 
and UBL4A, are highly conserved and represent ubiquitin-like folds, we wanted to compare the 
SGTA-UBL interactions. The solution structure of the UBL domain from BAG6 (residues 17-
101) was previously solved by Zhao and colleagues and deposited in the Protein Data Bank 
(Accession Number: 1WX9) and the BMRB (Accession Number: 11263). Furthermore, a crystal 
structure of this domain was also solved and deposited by Kozlov et al. (PDB Accession Number: 
4EEW). Neither of these structures is yet associated with a publication. We therefore used the 
published BMRB assignments in our reciprocal CSP studies. We used the BAG6 STAR file from 
the BMRB and converted it into an NMRView file (XPK). The numbering we use here 
corresponds to the BMRB entry. Leu8 is the first relevant amino acid and this corresponds to the 
first amino acid in the UBL domain or the 17th amino acid in the full length protein. The first 7 
amino acids in the BMRB sequence are a Gly/Ser linker from the construct but most of these 
haven't been assigned. The CSP binding experiments were carried out by titrating 15N-labelled 
BAG6_UBL into unlabelled SGTA (1-69) and vice versa (Figure 25 and Figure 26; the peak list 
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can be found in the appendix. Similarly, to the NMR titrations of SGTA and UBL4A, the 
interaction of SGTA with BAG6_UBL is mostly in a fast exchange rate in the NMR timescale 
with the same pattern of peak shifts. CSPs were plotted onto the SGTA (1-69) and BAG6_UBL 
structures (Figure 28) and the comparison of shift perturbations highlighted in red in Figure 27 
shows that SGTA (1-69) binds the BAG6 and UBL4A UBLs at the same binding site. However, 
in contrast to UBL4A_UBL binding, we do observe peak splitting for several residues located in 
α2 and in the loop connecting α1 and α2 (His21, Gly22, Ala28, Ala35, Gln37 and Ala42), as 
shown in Figure 27E and Figure 30 and Figure 37. The residue A28 is presented here as an 
example and the remainder of the residues displaying peaks splitting are later displayed on the 
complex structure. The peak splits may suggest that that exchange of the UBL between the two 
binding sites on the SGTA (1-69) homodimer is slower than the NMR chemical shift timescale 
in the case of BAG6_UBL binding. This interesting, although subtle, difference in the dynamic 
properties of the SGTA/UBL complexes may contribute to further characterization of their 





Figure 25: Full 1H-15N HSQC spectra of 15N -labelled BAG6_UBL titrated with unlabelled SGTA (1-
69). The 15N-labelled BAG6-UBL: SGTA (1-69) protein ratio was used at 1:0 (maroon), 1:0.1 (yellow), 






Figure 26: Full 1H-15N HSQC spectra of 15N-labelled SGTA (1-69) before (black) and after (red/blue) 
titration with saturating quantities (1:2 molar ratio) of unlabelled BAG_UBL (bottom) and 




Figure 27: Chemical shift perturbation data for SGTA (1-69)/UBL interactions. A–D: Cartoon views 
coloured according to reciprocal CSP upon addition of a binding partner. Residues whose shifts are higher 
than one standard deviation above the mean chemical shift are coloured darkest red. Those below the mean 
are coloured white and shifts between these points are coloured pink. A) BAG6_UBL B) UBL4A_UBL C) 
SGTA (1-69) upon binding BAG6_UBL D) SGTA (1-69) upon binding UBL4A_UBL; E–F: Region of 1H-
15N HSQC spectra of 15N-labelled SGTA (1-69) before (black) and after (blue/maroon) titration with 
saturating amounts of unlabelled BAG_UBL (E) and UBL4A_UBL (F) Residue Ala28 splits upon binding 
to BAG6_UBL but not upon binding UBL4A_UBL. Residues Leu7 and Asp49 are displayed on the SGTA 
structure to show where the neighboring peaks on an HSQC spectrum of the A28 splitting peak are localised 





Figure 28: Normalized CSP of 15N-labelled BAG6_UBL titrated with unlabelled SGTA (1-69). The 




Figure 29: Normalized CSP of 15N-labelled SGTA (1-69) titrated with unlabelled UBLs of UBL4A 





Figure 30: Fragments of 1H-15N HSQC spectra of 15N-labelled SGTA (1-69) before (black) and after 
(blue/red) titration with saturating amounts of unlabelled BAG_UBL (left) and UBL4A_UBL (right). 
The selected fragments of the spectra indicate amide backbone peaks which show peak splitting, possibly 
due to the slower exchange of BAG6_UBL between its two orientations on the dimer of SGTA (1-69) (82). 
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3.6   SGTA (1-69)/UBL4A_UBL and SGTA (1-69)/BAG6_UBL complexes by 
HADDOCK 
The structures of SGTA (1-69) and the UBL domains display high similarity to the yeast 
equivalent studied previously. However, the CSP experiments indicate some subtle differences in 
UBL domains which include residues at the start of strands β3 and β5 (residues 39–42 and 66–68 
in the sequence alignment shown in Figure 33 G). This showed large perturbations in the 
mammalian but not the yeast system. The binding interface is very similar in both SGTA-UBL 
complexes although with some differences in the positions of the conserved and charged residues 
known to be important for the Sgt2/Get5_ubl interaction from previous mutagenesis experiments. 
Therefore, we aimed to investigate this structurally, by generating models of the SGTA (1-
69)/UBL4A_UBL and SGTA (1-69)/BAG6_UBL complexes using HADDOCK-based semi-
rigid, data-driven docking. Ambiguous interaction restraints (AIRs) for HADDOCK (330) were 
defined using the chemical shift perturbation data and residue solvent accessibility analysis. 
Additionally, we acquired filtered 3D NOESY experiments on complex samples consisting of 
labelled SGTA (1-69) dimer bound to unlabelled _UBL or unlabelled SGTA (1-69) dimer bound 
to labelled _UBL to identify distance restraints within the binding surface. These experiments 
involved using 15N, 13C-UBL4A_UBL or 15N, 13C-BAG6_UBL protein samples. The data 
generated additional ambiguous restraints which were used in our HADDOCK calculations. We 
have recorded 3D 13C F1-filtered, F3-edited NOESY-HSQC experiments which allow selection 
of intermolecular NOEs. However, the signal: noise ratio of these experiments was low even on 
the most sensitive instrument available to us (a 700 MHz spectrometer equipped with cryoprobe). 
This was somewhat expected due to the increased T2 relaxation rate of the complex, which causes 
signal loss during the additional filter elements of the pulse sequence. Of the handful of resolvable 
peaks observed, we were able to obtain 3 (UBL4A complex) and 4 (BAG6 complex) useful 
intermolecular NOEs. The NOE restraints are listed in Table 7. In HADDOCK runs we used our 
SGTA (1-69) deposited ensemble, NMR structure of UBL4A_UBL (PDB accession number: 
2DZI) and x-ray structure of BAG6_UBL (PDB accession number: 4EEW, A chain). Previously 
deposited complexes of Sgt2/Get5_ubl (PDB accession number 3ZDM, 4ASW and 2LXC) were 
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used in comparisons. The input in HADDOCK included CSP residues selected from the 15N 
BAG6_UBL/SGTA (1-69) titration with peak shifts in HSQC experiments greater than one 
standard deviation above the mean and solvent accessibility above 25%. The final input for 
HADDOCK combined the following active residues: 22, 23, 24, 25, 26, 58, 62, 63, 65, 67, 76, 
83, 85, 86, 87, 88. In the case of 15N UBL4A _UBL/SGTA (1-69), residues were selected by the 
same method and final HADDOCK input included: 15, 16, 17, 18, 19, 21, 23, 49, 53, 54, 55, 56, 
73, 75, 78, 79. The passive AIRs were assigned automatically.  
 
Table 7: HADDOCK ambiguous interaction restraints (AIRs) obtained from filtered NOE 
experiments for the SGTA (1-69) and UBL4A_UBL and the SGTA (1-69) and BAG6_UBL complex. 
AIR UBL4A detected residue SGTA NOE 
1 L15 S26,E30,S31,C38,L39 
2 L15 E30,E35,Q37 
3 R55 T41 
AIR BAG6 detected residue SGTA NOE 
1 V64, V80, V84 E30,E35 
3 R63,V64 D27,E40 
4 R63,V80 V34 
 
We analysed the four lowest energy HADDOCK clusters of SGTA (1-69)/UBL4A_UBL and 
SGTA (1-69)/BAG6_UBL from our experimentally restrained docking. The top-ranked first two 
clusters of SGTA (1-69) /UBL4A_UBL and SGTA (1-69) /BAG6_UBL were similar to each 
other and also the most comparable to the experimentally-derived N-terminal Sgt2/Get5_ubl 
complex structure. However, cluster 3 and 4 display differences in UBLs orientation on SGTA 
(1-69)/UBL4A_UBL and SGTA (1-69) /BAG6_UBL models (Figure 31 and Figure 32 





Figure 31: Four top scoring clusters of the SGTA (1-69)/UBL4A_UBL models generated by 
HADDOCK. The selected cluster 2 displayed the best Z-score and the lowest energy. 
 
Table 8: The statistics of the top 4 clusters SGTA (1-69)/UBL4A_UBL HADDOCK models. The top 
cluster is the most probably according to HADDOCK. Its Z-score shows how many standard deviations 
from the average this cluster is located in terms of score (the more negative the better). 
 
 
Figure 32: Four top scoring clusters of the SGTA (1-69)/BAG6_UBL models generated by 








































41.7 +/- 6.1 -1.5 
Cluster2 -121.7 +/- 
9.2 










37.7 +/- 6.4 -1.9 












34.6 +/- 2.1 -0.5 
Cluster4 -95.8 +/- 
13.8 










38.3 +/- 4.2 -0.1 
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Table 9: The statistics of the top 4 clusters of SGTA (1-69)/BAG6_UBL HADDOCK models. The top 
cluster is the most probably according to HADDOCK. Its Z-score shows how many standard deviations 
from the average this cluster is located in terms of score (the more negative the better). 
 
The final HADDOCK models of SGTA (1-69)/UBL4A_UBL, chosen based on the lowest energy 
scores, and similarities of the orientation of conserved residues at the interface to homologue 
complexes are shown in Figure 33 A and Figure 35 and SGTA (1-69)/BAG6_UBL complexes 
are shown in Figure 33 B and Figure 36. The structural analysis showed that the orientation of 
the SGTA binding helices relative to the UBL partner in the SGTA mammalian complexes was 
slightly different and rotated by approximately 45 degrees in comparison to the yeast complex, as 
highlighted in Figure 33.  Since the binding was driven by electrostatic interactions, this reflected 
some differences in the negative charge distribution of the α2 central binding helices of SGTA 
(1-69) and Sgt2 N-terminal and also in the differences in positive charge distribution on the 
surface of the UBLs (Figure 33).  Furthermore, Lys85 in the Get5_UBL corresponds to Glu12 in 
human UBL4A_UBL and therefore do not form the same salt bridge. Alternatively, 
UBL4A_UBL Lys66 and Lys46 can tweak the SGTA_NT domain around slightly to satisfy the 
charge interactions. From the SGT perspective, the four negatively charged amino acids are 
spread along the helix differently in Sgt2 and SGTA, with Sgt2 displaying two at each end 
(Asp28/Asp31 and Asp38/Asp42) and SGTA showing three at one end (Asp27/Glu30/Glu33 
where the Lys85 interaction was lost) and one at the other (Glu40). The minor differences in 
charge distribution of important interacting residues can support the slight differences in binding 



























Cluster1 --107.0 +/- 
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34.0 +/- 7.8 -1.5 
Cluster2 -102.6 +/- 
5.7 










27.7 +/- 5.3 -1.1 
Cluster3 -97.5 +/- 
18.8 











37.5 +/- 3.9 -0.7 











28.3 +/- 9.0 -0.4 
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The binding interfaces of SGTA (1-69)/UBL4A_UBL and SGTA (1-69)/BAG6_UBL 
HADDOCK models are similar however, the BAG6_UBL binding site displays a slightly 
narrower surface spanning 1–2 fewer amino acids at the N-terminal of α2 which is central to the 
interaction. All of the residues that were identified to be involved experimentally are found at the 
interface (Figure 34). The interface is comprised of the few hydrophobic residues on 
UBL4A_UBL (Ile61, Leu8) and BAG6_UBL (Leu24 and Val65), that docks against the 
Val34 and Thr145 from the SGTA (1-69) dimer. The conserved lysine residues on UBL4A_UBL 
are 6, 46, 42, 48, and 66 and their equivalents on BAG6_UBL 22, 58, 64, 80 make electrostatic 
contacts with the charged residues on SGTA (1-69), Asp27, Glu30, Glu33, and Glu40. The 
equivalent of Lys 46 is missing in the BAG6_UBL and is replaced by Gln62. The residues which 
split in the NMR titration experiments of SGTA (1-69) during the interaction with BAG6 are 
shown in Figure 37. Some of those residues are present at the binding interface and we suggest 
that they split because of differences in contact with BAG6_UBL on each SGTA protomer. 
However, some of them are located away from the binding interface and perhaps split due to 





Figure 33: Cartoon views of the lowest energy complexes of A) SGTA (1-69)/UBL4A_UBL, B) SGTA 
(1-69)/BAG6_UBL and C) Sgt2_NT/Get5_UBL (90) as calculated by HADDOCK from chemical shift 
perturbation data and intermolecular NOEs. SGTA (1-69) is shown in red/ green and SGT2 N-terminal 
in lilac/blue; the UBLs of UBL4A, BAG6 and GET5 are in purple, grey and yellow respectively. The 
complexes are aligned according to the SGT domain and detailed views in boxes indicate specific residues 
involved in each interaction at one side of the SGT dimer. D), E) and F) show the vacuum electrostatic 
views of the equivalent aligned UBL domains. Surfaces are coloured according to electrostatic charge, 
exhibiting the positively charged residues (blue) that faciliate the interaction. The binding helices from the 
relevant SGT proteins are superimposed to show the relative orientations of binding. G) Sequence 
alignment between the three UBL domains with boxes indicating conserved residues and red highlighting 
sequence identity. Structural motifs are labelled across the top with ‘TT’ indicating a β turn. Sequences are 
numbered according to the UBL4A sequence. Graphic was generated using the ESPript 3.0 server (331). 





Figure 34: Two detailed views of the binding interface between SGTA (1-69) and (A) UBL4A or (B) 




Figure 35: HADDOCK-generated structural ensembles showing the 10 lowest energy structures from 
the top-scoring cluster for the complex between SGTA (1-69) and UBL4A_UBL aligned according to 





Figure 36: HADDOCK-generated structural ensembles showing the 10 lowest energy structures from 
the top-scoring cluster for the complex between SGTA (1-69) and BAG6_UBL aligned according to 






Figure 37: SGTA (1-69)/BAG6_UBL model indicating the residues which split in NMR titration 
experiments. These residues (His21, Gly22, Ala28, Ala35, Gln37 and Ala42) are shown as sticks. 
 
3.7   BAG6_UBL and UBL4A_UBL competition for the same binding site on 
SGTA (1-69) 
We also wanted to investigate whether the two different UBLs from the BAG6 complex can bind 
to the SGTA (1-69) dimer simultaneously or if they compete for the same binding site. We 
recorded an HSQC NMR experiment of 15N-labelled BAG6_UBL titrations with unlabelled 
SGTA (1-69) up to a 1:2 molar ratio and analysed the characteristic NMR chemical shift 
perturbations that occurred upon binding (Figure 38 C). Next, we added unlabelled 
UBL4A_UBL to the protein mixture which resulted in the BAG6_UBL peaks shifting back 
towards their unbound state as the availability of SGTA_NT decreased (Figure 38 D). 
Additionally, we ran the reciprocal experiment by titrating unlabelled SGTA (1-69) into 15N-
labelled UBL4A_UBL (Figure 38 A) followed by the addition of unlabelled BAG6_UBL 
(Figure 37 B). This indicated that, in excess, the two UBL domains displace each other from 
140 
 
SGTA and compete for the same binding site and do not bind simultaneously. Under the 
conditions used, the binding affinity of both SGTA/UBL complexes appears similar as observed 
by analysing the 1D spectra, although it is possible that in vivo the relative affinities are influenced 
by additional cofactors or other domains of BAG6 or UBL4A. 
 
Figure 38: Detailed view of 1H-15N HSQC NMR titrations. A) 15N-labelled UBL4A_UBL free (black) 
and titrated with increasing concentration of unlabelled SGTA (1-69) in red/green/blue/magenta. B) 
Saturation point of A with binding competed out through addition of unlabelled BAG6_UBL. C) 15N-
labelled BAG6_UBL free (black) and titrated with increasing quantities of unlabelled SGTA (1-69) 
(red/green/magenta). B) Saturation point of C with binding competed out through addition of unlabelled 
UBL4A_UBL. In B and D the bound UBL peaks move back towards their free state as their unlabelled 
competitor binds the SGTA (1-69). 
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3.8   Interaction study of SGTA (1-69) and UBLs by ITC, MST and SEC 
To further characterize the interaction of SGTA (1-69) and UBL domains, we examined the 
stoichiometry and the binding affinity of the complexes empirically. In the case of UBL4A and 
SGTA (1-69) binding, we performed Isothermal Titration Calorimetry (ITC) and indicated that, 
just like in the equivalent yeast system, one UBL4A_UBL monomer interacts with one SGTA (1-
69) dimer (N  of  0.949 ± 0.013; ΔH  of  5.9 ± 110 kcal/mol; Figure 39) albeit with a dissociation 
constant (Kd) of 3.0 µM, an order of magnitude weaker than in the yeast system. In addition, the 
binding affinity was verified using microscale thermophoresis (MST) which monitors changes in 
hydration shell, charge and size of molecules across a laser-induced temperature gradient (332). 
MST produced a comparable Kd value of 3.7 µM for the interaction between SGTA (1-69) and 
UBL4A_UBL (Figure 39).  
 
In the case of BAG6_UBL, ITC experiments confirmed the interaction between SGTA (1-69) and 
BAG6_UBL and resulted in a sigmoid-shaped binding curve. However, the value of N deviated 
from 1 and an accurate Kd could not be determined as these data did not fit 1:1 stoichiometry. 
However, by assuming n of 1, we arrived at a Kd of 6.0 µM, a result fairly similar to the 
UBL4A/SGTA binding affinity (1-69) (Figure 40). Initially, we tried the same parameters as were 
used for UBL4A_UBL (50mM MES pH 6, 150mM KCl) with 50µM BAG6_UBL in the cell and 
500µM SGTA (1-69) in the syringe at 30 ºC. Analysed data indicated an interaction (Figure 40), 
however, fitting the isotherms using either a single-site or two-site model still did not generate a 
binding curve at n=1 molar ratio. A set of experiments, designed to optimise the method was 
performed by extensively varying the following parameters alone and in tandem: buffer (20mM 
Tris pH 7.5, 100mM NaCl, 50mM MES pH 6, 200mM KCl and adding TWEEN at a range of 
concentrations between 0.04% and 0.1%); temperature (25 ºC and 30 ºC); protein concentration 
(adding 150-1500 µM of the sample in the syringe to the cell containing protein at concentrations 
between 15-150 µM and testing each protein in the cell and syringe). Unfortunately, none of these 
attempts yielded data that could be fitted appropriately. Similarly, MST experiments at different 
protein concentrations were performed as well as fluorescent labelling either SGTA (1-69) or 
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BAG6_UBL. A series of dilutions for unlabelled BAG6_UBL was prepared between 80 µM and 
2.4 nM (or 20 µM to 0.6 nM respectively) in the presence of labelled SGTA (1-69) at a 
concentration of 0.4 or 0.2 µM. In addition, we tested the binding by using labelled BAG6_UBL 
at a concentration of 0.4 µM with SGTA (1-69) serially diluted from 400 µM to 24.4 nM. 
Unfortunately, no interaction between BAG6_UBL and SGTA (1-69) was observed in any of 
these experiments. This is despite the NMR chemical shift mapping and filtered NOESY data 
which indicate a bindingbetween SGTA_NT and BAG6_UBL and the competition titrations 
which qualitatively indicate a similar binding affinity for the two UBLs. The interaction between 
SGTA (1-69) and BAG6_UBL can also be seen by size exclusion chromatography as 
demonstrated in Figure 41. 
 
Figure 39: ITC data showing binding of one Ubl4A_UBL domain per dimer of SGTA (left) and MST 
data showing binding of Ubl4A_UBL domain to SGTA (1-69) (right). In the MST data, the top panel 
shows raw fluorescence signals during the reaction and the bottom panel shows normalised binding curves 
plotted against the SGTA concentration. Affinity constants (Kd), determined by ITC and MST respectively 





Figure 40: ITC data showing interaction between BAG6_UBL and SGTA (1-69) domains. If n is fixed 
at 1, Kd = 6.0 µM. 
 
 
Figure 41: Chromatogram of size exclusion chromatography using Superdex 75 16/60 showing 




















3.9   Summary 
The backbone and side chain assignment of the N-terminal SGTA dimer, together with NOE 
assignment were used to determine the structure of SGTA (1-69). Moreover, the backbone of the 
linker connecting SGTA (1-69) with the TPR domain has also been assigned. The structure of 
SGTA (1-69) aligned well with the yeast homologue with some minor structural differences, 
present at helix α3 and the loop between helices α2 and α3 which form part of the interaction site 
with UBLs. 
 
The analysis of the interaction between SGTA and the UBL domains of BAG6 and UBL4A 
showed that they do not bind simultaneously but compete for the same binding site. This has been 
shown in a reciprocal titration experiment, where CSP peaks, where shifting back to the unbound 
state upon the addition of the competitive protein. Additional biophysical techniques were used 
to determine binding affinities of these complexes. ITC showed the binding affinity of 3.0 µM 
for SGTA (1-69)/UBL4A_UBL complex that is an order of magnitude weaker than in the yeast 
system (Sgt2/Get5_UBL). Furthermore, the binding affinity was confirmed using MST which 
showed a comparable Kd value of 3.7 µM. In the case of SGTA (1-69)/BAG6_UBL complex, 
ITC experiments confirmed the interaction but an accurate Kd could not be determined as these 
data did not fit 1:1 stoichiometry. Therefore, n was fixed to 1, giving a Kd of 6.0 µM that is fairly 
similar to the UBL4A/SGTA binding affinity (1-69). In addition, HADDOCK, used to generate 
models of SGTA-UBL complexes showed that the binding interfaces of the two models are 
similar as the BAG6_UBL binding site exhibited a slightly narrower surface spanning 1–2 fewer 







Chapter 4.    The structure and interactions of RNF126, E3 ubiquitin 
ligase with BAG6 and UBL4A 
RNF126 E3 ligases comprises two zinc finger domains: an N-terminal zinc-finger domain and a 
C-terminal RING domain (75, 173). The N-terminal zinc-finger domain has been shown to be 
involved in the interaction with the UBL domain of BAG6 (75) while the RING domain is 
required for the E3 ubiquitin ligase activity (173). The work described in this chapter, is a 
structural and biophysical characterisation of RNF126 and its complex with the UBL domains of 
BAG6 and UBL4A. Furthermore, to expand our understanding of the ubiquitination and rescue 
triage mechanism of hydrophobic substrates, we study the competitive interaction between 
RNF126, SGTA and UBLs of BAG6 and UBl4A using ITC, MST and NMR.  
 
4.1   Construct design of RNF126  
The N-terminal region of RNF126 (residues 1–100) was predicted to be a theoretical Zinc finger 
domain and previously defined as the BAG6-interacting module (75). Therefore, this construct 
was cloned and used in the preliminary experiments (Figure 42). However, the secondary 
structure prediction using PsiPred showed random coil predisposition for residues 38–100 
(Figure 43). Thus, a shorter construct was also produced (residues 1–40, hereafter named 
RNF126_NZF) and later used in structural and interaction studies. To further characterise 
RNF126 E3 ligase, the following RNF126 constructs were also made: full length RNF126 (named 
RNF126_FL), a construct containing a predicted hydrophobic region of RNF126 (named RNF126 
142-218), and a RING finger domain (construct excluding the Serine rich region, residues 219-
289), of which an NMR structure has previously been solved using the mouse sequence (PDB 
accession 2ECT). The boundaries for the constructs were chosen based on secondary structure 
prediction (Figure 43) and a primary sequence alignment of RNF126 from several species to 
identify conserved domains (Figure 44). The alignment shows that the constructs share two 
distinct regions of similarity present at their N- and C- termini which are also similar to the 
equivalent regions in RNF115, a homologue of RNF126 (Figure 44). All constructs were cloned 
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into a pET28 vector which includes a N-terminal thioredoxine A tag and a hexahistidine tag. 
Furthermore, an N-terminal GFP-fusion of RNF126_NZF was also constructed to be used in MST 
experiments. 
 
Figure 42: Construct design of RNF126. The boundaries of RNF126 constructs used in this project are 
shown with residue number of N and C termini. The constructs were designed based on previously reported 
results and new data, including secondary structure prediction and sequence alignment. The two distinct 
regions of RNF126 include a C-terminal RING domain, responsible of the ubiquitination activity and a N-




Figure 43: PSIPRED secondary structure prediction and construct boundaries of the human 
RNF126. The software predicts b-sheet features (yellow arrow) in the N-terminal region (residues 1-40) 
followed by a largely disordered section and hydrophobic region (a-helices shown as pink cylinders) for 
resides 142-218. The C-terminal region displaying b-sheet predisposition belongs to the RING domain 







Figure 44: ClustalW multiple sequence alignment of RNF126. 1) Homo sapiens, against 2) Mus 
musculus, 3) Brugia malayi, 4) Xenopus laevis, 5) Arabidopsis thaliana, 6) Drosophila melanogaster, 7) 
Schizosaccharomyces japonicas and 8) RNF115 (Homo sapiens). The level of conservation is rated from 
0%(blue)-100%(red). Primary sequence alignments were performed using PSI-BLAST and ClustalW and 











4.2   Expression and purification of RNF126 
During the overexpression of RNF126_NZF, the cultures were supplemented with 10  µM ZnCl2 
to support protein folding and solubility. Enrichment of expressed protein was achieved by 
affinity purification and size exclusion chromatography (Figure 45). In the case of RNF126_NZF 
with a GFP tag, expression and purification including the tag removal step were also monitored 
by the GFP fluorescence. (Figure 45 B). A typical purification profile shows a diffuse 
RNF126_NZF sample on SDS-PAGE, despite denaturation and the presence of a reducing agent 
in the loading dye (Figure 45 A and C). However, the protein in solution is fairly stable and 
produces sufficient yields for the required experiments. Moreover, we have noticed that other zinc 
finger proteins in the lab have a similar SDS-PAGE profile.  
 
Figure 45: Purification of RNF126_NZF. A) SDS-­‐page analysis of purification and the removal of the 
fusion/histidine tag by affinity chromatography of RNF126_NZF 1) uninduced cells control 2) flow through 
after column loaded with the cell lysate, 3) wash with 5 CV of wash buffer (20 mM potassium phosphate 
pH 8.0, 300 mM NaCl and 250 µ M TCEP), 4) elution with 2 CV of elution buffer (20 mM potassium 
phosphate pH 8.0, 300 mM NaCl and 250 µ M TCEP, 300mM Imidazole), 5) additional elution step, 6) 
total cleavage reaction, 7) flow through after column loaded with total cleavage reaction (cut 
RNF126_NZF), 8) wash with 2 CV of wash buffer 9) elution with 2 CV of elution buffer (uncut protein 
and tag). B) Expression and purification of RNF126_NZF_GFP. C) SDS-­‐page analysis and D) 
Chromatogram of size exclusion chromatography using Superdex 75 16/60. Lanes are identified with 
elution volume in ml. 
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4.3   Backbone and sidechain assignment of RNF126_NZF by NMR 
4.3.1   Backbone 1H, 13C, and 15N Chemical Shift Assignments of RNF126_NZF 
The following triple resonance experiments, HNCA, HN(CO)CA, HNCACB, HN(CO)CACB 
were acquired at 700 MHz using the shorter construct, RNF126_NZF, to facilitate the full 
backbone and side-chain assignments. 15N HSQC peaks were picked manually and the NH 
assignment for all residues except for five prolines was completed using CCPN Analysis. The full 
15N HSQC spectrum with assigned peaks is shown in Figure 46. The chemical shifts of 1HN, 15N, 
13Cα and 13Cβ, and 13C’ were deposited in the BMRB (Accession Number: 25913). Validation 
Software (AVS) was run automatically after we deposited the assignments and the full report can 
be seen in Appendix. The 1H15N HSQC spectrum of RNF126 (1-100) indicated a partially folded 
protein and backbone assignment of residues 1–66 showed that residues 1–40 constitute the 
structured region while the remainder exhibits the chemical shift dispersion typical of disordered 
proteins. A shorter, RNF126_NZF construct displays comparable spectra to the longer version, 
showing that the additional truncation has no effect on the folding of the zinc finger region 
(Figure 47). Therefore, this construct was used in full backbone and sidechain assignments, 



















































Figure 47: An overlay of 1H-15N HSQC spectra of 15N-labelled RNF126 (1-100) and (1-40). 1H-15N 
HSQC spectra of 15N-labelled RNF126 (1-100) in black and the shorter construct RNF126_NZF (1-40) in 
red. Assigned peaks from region 1-40 are labelled in red. The comparison of the peaks chemical shifts 
indicates that the folding of longer and shorter RNF126 constructs is conserved. 
 
4.3.2   Sidechain assignment of RNF126_NZF 
Side chain resonances were assigned using 3D HcCH-TOCSY and hCCH-TOCSY together with 
13C HSQC and 2D NOESY experiments. The chemical shifts were deposited, together with the 
backbone assignments (BMRB Accession Number: 25913, and the validation report is shown in 
appendix). Overall, chemical shifts assignments for all residues were assessed as consistent except 
for 24 Pro which was marked as suspicious because of the unusual shift of atom HG2 = 0.816, 
where the expected shift should be 1.93 (Std = 0.31). However, after an additional assessment the 


































































shifts of 15N and 261 chemical shifts of 1H. Overall, 85% of side chain H were assigned, including 
97% of Ha and 90% of Hb (Figure 48). The remaining residues were unassigned due to the poor 
quality signal to noise ratio in this area of the spectrum and spectral overlap. 
 
 
Figure 48: Chemical shift assignment for heavy atoms of RNF126_NZF. The completed assignment for 
the heavy atom is shown in black circles, highlighting with where 1H-15N HSQC (blue), 13C-HSQC (pink) 
and 2D NOESY were used. Figure was created using CCPN Analysis. A line shows the NOE assigned 
between atoms. 
 
4.3.3   Chemical Shift Index Analysis 
The secondary structure of RNF126_NZF was predicted from the chemical shifts of C¢, Ca, Cb 
and Ha atoms using the chemical shifts index (CSI) method (304, 333) in CCPN Analysis (Figure 
49). These chemical shifts are combined to give the CSI values indicating the secondary structure 
type; -1 indicates alpha-helix and +1 beta-strand. The chart is the graphical representation of the 
secondary structure prediction for each residue indicating the difference of recorded chemical 
shift from (sequence adjusted) random coil chemical shift. The structure shows three main b-
strands, which is in agreement with the PSIPRED secondary structure prediction, and one 




Figure 49: Secondary structure analysis of RNF126_NZF using chemical shift index of Ca, Cb, C’ 
and Ha. CSI values indicate the secondary structure type; -1 indicates a-helix and +1 b-strand. Residues 
with chemical shifts indicating b-strands are shown as arrows. 
 
 
4.3.4   TALOS 
TALOS+ was used to determine the RNF126 dihedral angle restraints from the chemical shift 
assignment using standard methods (305). In total there were 34 pairs of dihedral angles (Φ+Ψ) 
derived by TALOS and used in structure determination (section 4.4). 
 
4.3.5   NOE Distance constraints in intra- and inter-residue assignments 
NOE distance restraints were derived from different NOESY experiments: 2D NOESY (in 90% 
H2O and 10% D2O) for RNF126_NZF. Manual assignments of NOESY cross peaks were 
performed using CCPN starting with the identification of amino acids, with a characteristic 
pattern of cross signals, i.e. of glycine, alanine, threonine, valine, leucine and isoleucine, and 
continuing to the neighbouring residues. The NOEs were assigned for proton cross peaks between 
b-strands and for cysteines coordinating a zinc atom. All NOE distance restraints were grouped 
into several classes and a final count includes 719 NOEs including 326 intra-residue signals,119 




4.4   NMR structure of RNF126 
The solution structure of RNF126_NZF was solved in collaboration with Dr Santiago Martinez-
Lumbreras. The structure calculation was performed using the ARIA2 program (306) providing 
spectra with chemical shift lists, dihedral constraints (ϕ and Ψ angles) extracted from the chemical 
shift values using the TALOS+ program and manually assigned NOE restraints. In the initial Aria 
runs we also allowed for automated NOE assignment. In each of many cycles of structure 
calculations with water refinement, we inspected the restraints violations and manually corrected 
them. The final Aria run generated 100 conformers in the final iteration and the 20 best structures 
with lowest restraint energies were selected for a final step of refinement in water. The 
coordination sphere of the zinc ion in the structure of RNF126 was obtained in a first round of 
calculations using only NOE based distance restraints and, once it was confirmed, the zinc 
coordination was added as an additional restraint in structural calculations by ARIA2. The final 
structure is in agreement with the structure prediction from PSIPRED and CSI and the structural 
assembly was deposited in the PDB after validation with PROCHECK-NMR (PDB Accession 
Number: 2N9O). The statistical parameters are presented in Table 10 and the structure is shown 
in Figure 50 A. The folded domain comprises residues Arginine 10 to Leucine 40. This region 
contains a three-stranded short antiparallel β-sheet (β1  =  Y11-C13; β2  =  V18-I20; β3  =  I37-E39) 
and a zinc finger comprising four cysteines; one pair from the β1-β2 short loop (C13; C16) and 
the other pair from the long structured region between strands β2 and β3 (C29; C32). 
Identification of cysteines that coordinate zinc can be supported by the analysis of chemical shift 
data of 13Cα and 13Cβ. These can be compared to previously documented characteristic shifts of 
zinc-ligated cysteines (334). In RNF126_NZF structure the first zinc coordination shell contains 
four cysteine side-chains in tetrahedral conformation (Figure 50 B) whose chemical shift values 
for 13Cα (~59  ppm) and 13Cβ (~31  ppm) compared well to predicted shifts of zinc-binding 
cysteines (334). The second coordination shell is produced by the formation of three hydrogen 
bonds between the cysteine sulphur atoms (C13, C29 and C32) and the amide group of the residue 
at position +2 (C15, R31 and S34 respectively) (Figure 50 B). All parameters of the zinc 
coordination are presented in Table 11. A stable hydrophobic core is formed by the long 
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structured loop β2-β3 folded against one side of the β-sheet that buries several non-polar residues. 
The opposite side of the β-sheet is solvent exposed and comprises some glutamic acid side-chains 

























Table 10:  NMR and refinement statistics for the final 20 structure ensembles of RNF126_NZF. The 
asterisk means data were obtained from PROCHECK-NMR.  
NMR distance and dihedral restraints 
 Distance restraints 
  Total NOE 719 
  Intra-residue 326 
  Sequential (|i-j|  =  1) 119 
  Medium-range (1  <  |i-j|  <  4) 55 
  Long-range (|i-j|  >  5) 219 
 TALOS derived dihedral restraints 
  Total dihedral restraints (Φ+Ψ) 34 
    Structure statistics 
 Violations (mean and s.d.) 
  Number of violated distance restraints per structure (>0.15  Å) 1.2  ±  0.9 
  Max. distance restraint violation (Å) 0.19 
  Number of violated dihedral angle restraints per structure (>2°) 5.1  ±  0.6 
  Max. dihedral angle restraint violation (°) 2.8 
  Ramachandran Plot analysis (%)* (1–40) (10–40) 
  Residues in most favoured regions 77.4 84.8 
  Residues in additionally allowed regions 19.8 15.2 
  Residues in generously allowed regions 0.9 0.0 
  Residues in disallowed regions 1.8 0.0 
 Derivation from idealized geometry 
  Bond length (Å) 0.0041  ±  0.0001 
  Bond angles (°) 0.58  ±  0.01 
  Averages RMSD to mean structure (range) (10–40) 
  Backbone (Å) 0.19  ±  0.05 




Table 11: Geometry of the RNF126_NZF zinc coordination centre. Averaged distance (Å) and angular 
(º) values for first and second coordination shell across the NMR ensemble. Two hydrogen bonds are 
established in the outer shell of coordination on Cys13 and Cys29 and possibly Cys32. 
 Cys 13 Cys 16 Cys 29 Cys 32 
First coordination shell     
Sg-Zn distance 2.29 ± 0.01 2.29 ± 0.01 2.29 ± 0.01 2.29 ± 0.01 
Cb-Sg-Zn angle 110.0 ± 0.3 109.9 ± 0.3 105.7 ± 0.5 110.1 ± 0.3 
Second coordination shell     
Sg-HN (i+2) distance 2.42 ± 0.08 5.24 ± 0.04 2.49 ± 0.04 3.08 ± 0.07 







Figure 50: NMR solution structure of RNF126_NZF. A) Two views of ensemble backbone (left) and 
cartoon diagram (right) showing the 20 lowest energy ARIA-calculated structures as deposited in the PDB 
(Accession number: 2N9O). B) Detailed representation of the zinc finger coordination shell showing the 
cysteines coordinating the zinc cation; hydrogen bonds in the second coordination shell are shown as yellow 
dashed lines. C) Detailed view of the solvent-exposed β-sheet interface. Polar and hydrophobic residues 
present at this interface are illustrated using ball-and-stick. Carbon atoms are coloured in grey, oxygen 





4.5   Binding study of RNF126_NZF with UBL domains of UBL4A and BAG6 
To characterise and compare the interactions between RNF126 and UBL domains, we used a 
range of biophysical methods including chemical shift perturbation (CSP), ITC, MST and 
mutagenesis.  
 
4.5.1   Chemical Shift Perturbations of RNF126_NZF interaction with BAG_UBL 
CSP studies were carried out to analyse the binding interface between RNF126 and BAG6. The 
unlabelled N-terminal RNF126 (both constructs: 1–40 and 1–100) was titrated into 15N-labelled 
BAG6_UBL and vice versa. Both RNF126 constructs have the same effect on the BAG6_UBL 
spectrum and show similar shifts upon BAG6_UBL binding. This confirms that residues 1–40 are 
necessary and sufficient for the interaction (Figure 51). Hence we used the 1–40 construct in 
most subsequent experiments. The spectra displayed binding in a slow exchange regime 
characterised by two independent chemical shifts, one for the residue in the free state and one for 
the residue in the bound state (for 1H-15N-labelled RNF126_NZF see Figure 52  and for 1H-15N-
labelled labelled BAG6_UBL see Figure 53). This type of CSP suggests a high-affinity binding 
with a saturation point close to a 1:1 molar ratio. CSPs were calculated for each residue in its free 
and bound spectra (δfree-δbound) for proton and nitrogen values respectively (Figure 54) and 
plotted onto the structure, with the most perturbed residues shown in dark red (Figure 55). We 
used our backbone assignments described in Section 4.3 together with the assignments for 
BAG6_UBL deposited by another research group in the BMRB (Accession Number: 11263). The 
assignment of the bound state spectra (described in Section 4.6) indicated that the β-sheet 
(predominantly the β3 strand) of RNF126_NZF is influenced upon titration, together with some 
residues from the β2-β3 loop. The binding region in BAG6_UBL is found along its exposed β-
sheet; β3, β4, β5 strands, the loop between β1 and β2 and also includes part of the C-terminal 




Figure 51: NMR experiments showing that RNF126_NZF is sufficient for BAG6_UBL interaction. 
A) 1H-15N HSQC spectra of 15N-labelled BAG6_UBL in free form (black with assignments), 15N-labelled 
BAG6_UBL bound to unlabelled RNF126_NZF (1-40) at 1:1.5 molar ratio (green) and 15N-labelled 
BAG6_UBL interacting with unlabelled RNF126 (1-100) construct at the same molar ratio (red). Bound 
states of BAG_UBL to both RNF126 constructs are similar. B) 1H-15N HSQC overlapping spectra of 1H-
15N-labelled RNF126_NZF (green) and RNF126_1-100 (red) in free form and bound to unlabelled 
BAG6_UBL at a 1:1.5 molar ratio (NZF construct in sky blue and 1-100 in purple). Both RNF126 




Figure 52: The 15N-1H  HSQC spectrum of 15N- RNF126_NZF titrated with BAG6_UBL. 15N-1H 
HSQC spectra of free RNF126_NZF (black, assigned peaks) and RNF126_NZF bound to BAG6_UBL (1:1 


























































Figure 53: The 15N-1H  HSQC spectrum of 15N- BAG6_UBL titrated with RNF126_NZF. 15N-labelled 
BAG6_UBL at different titration points with unlabelled RNF126_NZF (1:0, 1:0.25, 1:0.5, 1:0.75, 1:1, 1:2; 
in corresponding colours: red, orange, light green, cyan, blue, dark blue). On the right a detail of a spectral 





Figure 54: Normalized CSP of 15N-labbeled RNF126 titrated with unlabelled BAG6_UBL (top) and 
15N-labelled BAG6_UBL titrated with unlabelled RNF126_NZF (bottom). The graph shows the CSP 




Figure 55: Orthogonal cartoon views of RNF126_NZF and BAG6_UBL (PDB: 1WX9). The structures 
are coloured according to reciprocal CSPs with the most perturbed residues shown in red. 
 
4.5.2   ITC of RNF126_NZF interaction with BAG_UBL 
The binding between RNF126_NZF and BAG6_UBL was confirmed and characterised using ITC 
(Figure 56). The results display 1:1 stoichiometry with a dissociation constant of 0.40  ±  0.05  µM 
in agreement with the slow exchange regime of the NMR titration data. The favourable enthalpy 
and entropy values obtained from ITC (ΔH  =  −4.52  ±  0.04  kcal/mol; ΔS  =  14.1  ±  0.4 cal/mol·K, -
TΔS = -4.21 ±  0.2 kcal/mol, ∆G  =  −8.73 ±  0.05  kcal/mol) suggest that the complex formation 
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between RNF126 and BAG6 is driven by the establishment of both hydrogen bonds and 
hydrophobic interactions. 
 
Figure 56: ITC data showing binding of RNF126_NZF to BAG6_UBL. The affinity constant, 
determined by ITC was: Kd = 0.40  ±  0.05  µ. All integrated heat data obtained for the titrations were 
corrected for heats of dilution (top panel) and fitted using a nonlinear least-squares minimization algorithm 
to a theoretical titration curve, using the MicroCal-Origin 7.0 software (bottom panel). 
 
4.5.3   Probing the binding interface of RNF126_NZF/BAG_UBL complex by 
mutagenesis 
To further characterize the interface, RNF126_NZF mutants were designed, considering the 
largest chemical shift perturbations. ITC results showed that the RNF126_NZF binding with UBL 
domain was driven by hydrophobic and hydrophilic interactions. H14 and F36 residues with 
exposed side chains at the b-sheet and highly perturbed were selected as good candidates, in 
addition to E38 and E39 which are involved in electrostatic interactions. The following mutants 
were produced by mutagenesis: single mutants of H14A and F36A and also a E38R/E39R double 
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mutant to reverse the charge. The effect of RNF126 mutations on BAG6_UBL interaction were 
studied using ITC (Figure 57), native PAGE mobility shift assay (Figure 58) and NMR (Figure 
59). All mutations result in a drop in binding affinity of at least an order of magnitude, and binding 
was not detected in the case of a double mutant E38R/E39R, proving that these residues are 
involved in the interaction with BAG6. The wild-type structure is retained in each mutant, as 
judged by 1D NMR (Figure 60). 
 
Figure 57: ITC data indicating binding of RNF126_NZF mutants to BAG6_UBL. Affinity constants, 
determined by ITC were: Kd of F36A mutant  =  5.0  ±  0.3  µM; Kd of H14A mutant  =  >50  µM and Kd of 
E38E39/R mutant could not be calculated. In comparison, Kd of wild type RNF126_NZF  =  0.40  ±  0.05  µM. 
 
Figure 58: Native PAGE of GFP-tagged RNF126_NZF. Native PAGE of GFP-tagged 
RNF126_NZF_WT and mutants visualised by fluorescence (top) and Coomassie (bottom) titrated with a 
increasing concentration of BAG6_UBL. The red asterisk indicates the complex formation in the case of 
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RNF126_NZ WT. However, the RNF126_NZF_H14A and RNF126_NZF_F36A and E38E39/R mutants 
present lower or no affinity. 
 
Figure 59: 1H-15N HSQC spectra of labelled BAG6_UBL upon titration with RNF126_NZF_WT, 
RNF126_NZF_H14A and RNF126_NZF_F36A. Chemical shift perturbation occupies a slow chemical 
exchange regime in the case of both wild type and the F36A mutant and a fast chemical exchange regime 
in the case of mutant H14A indicating a lower affinity (red arrows show the CSPs). The protein 
concentration of E38E39/R mutant was too low to be used in NMR titrations after it precipitated. 
 
 
Figure 60: 1D 1H NMR spectra of RNF126_NZF_WT and mutants, showing characteristic shifts of 
the folded protein. 








4.5.4   Chemical Shift Perturbations of RNF126_NZF interacting with 
UBL4A_UBL 
Since both subunits of the BAG6 complex, BAG6_UBL and UBL4A_UBL, each bind to SGTA 
(82), we considered that RNF126_NZF and UBL4A_UBL might also interact. First, the 
interaction was studied using chemical shift perturbations. Upon NMR titration with unlabelled 
UBL4A_UBL, 15N-labelled RNF_NZF displayed CSPs within the first forty residues that agreed 
with those shifts that occur upon BAG6_UBL binding (Figure 61). The analysis of the reciprocal 
titration with 15N-labelled UBL4A_UBL was completed using assignments from the BMRB 
database (Accession Number: 11279) and CSPs were calculated (Figure 63) and mapped onto 
the UBL4A_UBL structure, deposited previously by another group (PDB: 1WX9). The analysis 
showed that the binding interface on UBL4A is equivalent to the one obtained for BAG6: β3, β4, 
β5 strands and the loop between β1 and β2 are perturbed upon binding RNF126 (Figure 62 and 
Figure 65). Both titrations occur in a fast exchange timescale suggesting that this interaction has 
a lower affinity than that of BAG6_UBL binding. Furthermore, plotting the CSP data against the 
concentration of RNF126_NZF and fitting the curve to a simple 1:1 equimolar binding model 
produces a dissociation constant (Kd) in the order of 20  µM, around 50 times higher than that of 





Figure 61: 1H-15N HSQC spectra of 15N-labelled RNF126 1-100 (black) titrated with unlabelled 
UBL4A_UBL. UBL4A_UBL was added at different molar ratios (RNF126:UBL4A): 1:0 (red), 1:0.125 
(brown), 1:0.25 (green), 1:0.75 (light blue) and 1:1 (navy). The residues of RNF126 assigned in orange 
































































Figure 62: Cartoon views of RNF126_NZF and UBL4A_UBL coloured according to reciprocal CSP 
data. The most perturbed residues are presented in red. UBL4A_UBL PDB accession is 1WX9. 
 
 
Figure 63: Normalized CSP of 15N-labelled UBL4A_UBL titrated with unlabelled RNF126_NZF. The 










Figure 64: Plot representing the normalized CSP data of the most perturbed UBL4A_UBL amino 
acids. The perturbed UBL4A_UBL residues upon titration with different concentrations of RNF126_NZF 
were 20, 21, 22, 23, 24, 25, 26, 28, 57, 58, 59, 61, 62, 63, 64, 81, 82, 83, 84, 85, 86. Fitting was performed 
using the DynaFit program yielding a Kd of 16.6  ±  2.7  µM (174). 
 
Figure 65: 15N-labelled UBL4A_UBL titrated with RNF126_NZF. RNF126_NZF was used at molar 
ratio equivalents (1:0, 1:0.25, 1:0.5, 1:0.75, 1:1, 1:2; in corresponding colours: red, orange, light 




4.5.5   Comparison of the RNF126_NZF interaction with UBL domains of UBL4A 
and BAG6 probed by MST, ITC and native gel electrophoresis 
We compared the interaction of RNF126_NZF with UBL domains using ITC, MST and native 
gels. Microscale thermophoresis (MST) of RNF126_NZF and UBLs binding were performed 
using GFP tagged version of RNF126_NZF. GFP tagged RNF126_NZF was kept at a constant 
concentration, while BAG6_UBL concentrations ranged from 25 µM to 0.8 nM and UBL4A at 
50  µM to 1.5  nM. The Kd values derived from MST are approximately an order of magnitude 
lower than the values obtained by ITC indicating higher affinity (Figure 67). Experimental 
constraints necessitated using the labelled protein at a similar concentration to the expected Kd, 
meaning that small errors in GFP protein concentration have disproportionate impact on the 
results, potentially leading to overestimation of the affinity. We used 0.25 or 0.125 µM GFP 
protein while the Kd is 0.4 µM (ITC). We made many attempts to resolve this including using 
lower GFP concentrations to move away from the Kd value but we were unable to observe 
sufficient fluorescence signal (even after increasing the LED power). ITC however, proved not 
sensitive enough to detect the binding of RNF126_NZF with UBL4A_UBL in any of the tested 
conditions. In the same experimental conditions as were used for BAG6, the observed transition 
was small and impossible to fit, in keeping with the reduced affinity that we observed (Figure 
66). The concentration optimization we attempted (500-1000  µM for RNF126_NZF and 25,50  or 
100µM in the reaction cell for UBL4A_UBL) failed to improve the results.  
 
Figure 66: ITC data showing a titration curve of RNF126_NZF into UBL4A_UBL. 
















Figure 67: Binding of RNF126_NZF to UBL domains. A) Native PAGE of GFP tagged RNF126_NZF 
binding assay with UBLs (BAG6_UBL on the left, UBL4A_UBL on the right) visualised by fluorescence 
(top) and Coomassie (bottom). Values on the top of the gel indicate RNF126:UBL molar equivalents. The 
red asterisk indicates complex formation. B) MST data showing the interaction of GFP tagged 
RNF126_NZF at two different concentrations (0.125 and 0.250 µM) with BAG6_UBL (blue) and 
UBL4A_UBL (red). The change in normalized fluorescence is plotted against the concentration of 
unlabelled ligand and the affinity values obtained from fitting with Dynafit are displayed in the figure.  
 
NMR, MST and native PAGE mobility shift, collectively demonstrate a lower affinity (or no 
binding detected in the case of ITC and native gels), between UBL4A and RNF126 as compared 
to the BAG6 binding. However, more sensitive technique of NMR shows that, RNF126 is capable 




4.6   Backbone and sidechain assignment of RNF126_NZF and Bag6_UBL 
bound states in RNF126_NZF/Bag6_UBL complex 
To study the RNF126_NZF and BAG6_UBL interaction in greater detail and to investigate 
whether there are any structural rearrangements upon complex formation we aimed at solving the 
structure of the complex by NMR. The stability of the complex and the high quality of the NMR 
data allowed the experimental structure solution of the complex with no need to resort to in silico 
methods. The backbone and sidechains were assigned for both free and bound protein. Since the 
RNF126_NZF and BAG6_UBL interaction displays binding in a slow exchange regime, two 
independent chemical shifts can be observed (one for the residue in the free state and one for the 
residue in the bound state). Therefore, peaks corresponding to backbone and sidechain atoms of 
the bound state of RNF126_NZF and Bag6_UBL in RNF126_NZF/Bag6_UBL complex had to 
be assigned. We acquired complete triple resonance experiments for backbone and side-chain 
assignment of the bound state for each protein (by mixing labelled and unlabelled protein) and 
assigned them in the same way as the free RNF126_NZF. The assignments of 1H, 13C, and 15N 
chemical shift were deposited at BMRB with the Accession Number: 25914. The Validation 
Software (AVS) was run automatically after the assignment deposition and the full report can be 
seen in Appendix. 
 
4.6.1   NOE Distance constraints in intra- and inter- molecular assignments 
Filtered NOESY experiments were run on complex samples consisting of 15N13C-labelled 
RNF126_NZF bound to unlabelled BAG6_UBL or unlabelled RNF126_NZF bound to 15N13C–
labelled BAG6_UBL to identify distance restraints within the binding interface. NOE restraints 
were derived from the two pairs of 15N-edited NOESY-HSQC (to see both intra- and 
intermolecular NOEs), 13C-edited NOESY-HSQC (intra- and intermolecular) and 12C, 14N-
filtered-13C-edited NOESY-HSQC (to see only intermolecular cross-peaks) experiments for the 
complex using either 15N, 13C -labelled BAG6_UBL or RNF126_NZF. Manual assignments of 
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NOESY cross peaks were performed using CCPNanalysis.  In total 48 intermolecular distance 
constraints were assigned and the numbers of NOE distance restraints are shown in  
Table 12. 
 
4.7   NMR structure of the RNF126_NZF/BAG6_UBL complex 
The backbone and sidechain assignments of bound states of RNF126_NZF and BAG6_UBL, 
together with NOE restraint assignments from 3D NOESY experiments, and dihedral constraints 
(ϕ and Ψ angles), extracted from the chemical shift values using TALOS+, were used in complex 
structure calculations using the ARIA2. The final Aria run generated 100 structures and the 20 
structures with the lowest energy are represented as an ensemble (Figure 69A) and were 
deposited in the PDB with the Accession Number: 2N9P. The statistical parameters are shown in 
Table12. The reciprocal intermolecular NOEs between RNF126 and BAG6 were unambiguously 
assigned to ensure the accuracy of the structure calculation. The complex structure exhibits 
overall conservation of the original fold for each protein and a strong match between the binding 
interface of the obtained structure and the CSP analysis (Figure 69A and Figure 54). RMSD 
values between the free form of RNF126_NZF (this work) and the bound state are low (backbone 
RMSD  of  0.62Å) indicating lack of major conformational changes and the zinc coordination 
parameters are conserved (Table 13). BAG6 also presents low values of RMSD comparing free 
(PDB: 1WX9) and bound states (backbone RMSD  of  1.43Å), with a minor alteration of the 
arrangement of loop β1-β2 (Figure 68). Interactions observed at the binding interface of 
RNF126_NZF/BAG6_ubl complex include hydrogen bond formation and electrostatic and 
hydrophobic interactions, which agrees with ITC data. Hydrogen bonds are formed between the 
guanidinium groups of three arginine residues of BAG6 and the carboxyl group of two glutamic 
acids of RNF126. The side-chain of Arg64 connects with Glu39 via hydrogen bond while Arg58 
and Arg87 create a hydrogen bond with Glu38. Furthermore, the Glu38 amide is involved in 
hydrogen bond formation with the backbone carbonyl group of Gly63 from BAG6. Tyr27 from 
RNF126 is aligned with Gln62 from BAG6 and stabilises its aromatic ring. Tyr27 also interacts 
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with Arg64 through its hydroxyl group. Additional interactions are identified for imidazole 
groups of His14 (RNF126) and His83 (BAG6) (Figure 69 B). Hydrophobic contacts are shown 
for the two components: the aliphatic side-chain of Glu38 from β3 of RNF126 packed against 
Ile60, Val65 and side-chain of Arg58 from BAG6, and Phe36 in β2 of RNF126 fitted neatly within 
a hydrophobic pocket formed by Leu24, His83 and Val85 of BAG6 (Figure 69 C). 
 
 
Figure 68: Structural alignment of RNF126_NZF and BAG6_UBL in free and bound states. A) free 
RNF126_NZF (grey) and bound to BAG6_UBL state (orange). B) free BAG6_UBL (grey, PDB: 1WX9) 
and bound state to RNF126 (blue, this work). Backbone RMSD values are: RNF126_NZF (10-40) RMSD 




Figure 69: RNF126_NZF/BAG6_UBL complex structure. A) Two views of cartoon representations 
(left) and ensemble backbone (right) showing the 20 lowest energy ARIA-calculated complex structures as 
deposited in the PDB (Accession number: 2N9P). RNF126_NZF is coloured orange and BAG6_UBL is 
coloured blue with the coordinated zinc cation shown as magenta sphere. B) Binding interface of the 
complex displaying interactions. Residues shown in ball and stick representation are involved in the 
formation of hydrogen bonds or electrostatic interactions (indicated as yellow dashed lines). C) Details of 
the hydrophobic core at the binding interface. Apolar residues and hydrophobic regions of Glu38 and Arg58 








































Table 12: NMR and refinement statistics for the final 20 structure ensembles of 
RNF126_NZF/BAG6_UBL complex. 
NMR distance and dihedral constrains 
 Intramolecular distance constrains RNF126_NZF BAG6_UBL 
  Total unambiguous NOEs 461 1283 
  Intra-residue 252 689 
  Sequential (|i-j|  =  1) 58 266 
  Medium-range (1  <  |i-j|  <  4) 23 115 
  Long-range (|i-j|  >  5) 128 213 
  Ambiguous constrains 2 51 
 Intermolecular distance constrains 48 
 TALOS derived dihedral constrains RNF126_NZF BAG6_UBL 
  Total dihedral constrains (Φ+Ψ) 33 90 
Structure statistics 
 Violations (mean and s.d.) 
Number of violated distance restraints per structure 
(>0.25  Å) 
1.2  ±  0.5 
  Max. distance constraint violation (Å) 0.28 
Number of violated dihedral angle restraints per 
structure (>5°) 
1.3  ±  0.8 
  Max. dihedral angle violation (°) 7.6 




  Residues in most favoured regions 65.3 72.3 
  Residues in additionally allowed regions 28.6 22.5 
  Residues in generously allowed regions 3.9 3.8 
  Residues in disallowed regions 2.2 1.3 
 Derivation from idealized geometry 
  Bond length (Å) 0.0086  ±  0.0003 
  Bond angles (°) 0.84  ±  0.02 
 Averages RMSD to mean structure (range) RNF126 (10–40)/BAG6 (17–88) 
  Backbone (Å) 0.97  ±  0.25 
  Heavy (Å) 1.64  ±  0.22 
  *Obtained from PROCHECK-NMR. 
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Table 13: Geometry of the zinc coordination centre of RNF126_NZF in the 
RNF126_NZF/BAG6_UBL complex. 
 Cys 13 Cys 16 Cys 29 Cys 32 
First coordination shell     
Sg-Zn distance 2.29 ± 0.01 2.29 ± 0.01 2.30 ± 0.01 2.29 ± 0.01 
Cb-S-Zn angle 108.0 ± 1.5 110.0 ± 1.0 106.4 ± 1.0 108.9 ± 1.0 
Second coordination shell     
Sg-HN (i+2) distance 3.02 ± 0.76 4.74 ± 0.48 2.60 ± 0.58 2.97 ± 0.81 
Sg-H-N (i+2) angle 122.5 ± 7.2 137.3 ± 6.3 129.3 ± 5.0 143.0 ± 9.1 
Averaged distance (Å) and angular (º) values for first and second coordination shell across the NMR 
ensamble. Similar values compared with free form are obtained. 
 
4.8   HADDOCK models of RNF126_NZF/UBL4A_UBL complex 
Due to the similarities in interactions between RNF126_NZF and UBL domains of BAG6 and 
UBL4A in our NMR studies, we aimed at generating a structural model of the 
RNF126_NZF/UBL4A_UBL complex using HADDOCK-based semi-rigid, data-driven docking 
(330) rather than experimental structure solution. The CSP data of bound RNF126_NZF and 
UBL4A_UBL were used as ambiguous restraints and included 10 residues of RNF126_NZF and 
14 of UBL4A_UBL with chemical shift changes greater than 0.15  ppm and filtered for a relative 
solvent accessibility higher than 45%. In calculations we provided PDB-deposited structures of 
UBL4A_UBL (2DZI) and the lowest energy NMR structure from our family of RNF126_NZF. 
The three lowest energy HADDOCK clusters of RNF126_NZF/UBL4A_UBL are shown in 
Figure 70 A and parameters are presented in Table 14. The top-ranked cluster 1 is highly similar 
to the experimentally-derived RNF126_NZF/BAG6_UBL structure (Figure 70 B) indicating that 
residues forming contacts with RNF126_NZF are conserved between UBL4A_UBL and 
BAG6_UBL (Figure 71 A, Figure 70 C and D). The UBL4A_UBL residues shown in the binding 
interface with RNF126 are Leu8, Arg42, Leu44, Lys48, Ala49, Asn68 and Val70 of UBL4A 
(Figure 70 C), which align with residues Leu24, Arg58, Ile60, Arg64, Val65, His83 and Val85 
of BAG6_UBL (Figure 70 D). Both of these groups of UBL residues make contact with His14, 
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Tyr27, Phe36, Glu38 and Glu39 in RNF126_NZF. The positively charged Lys48, Arg42 and 
Lys72 of UBL4A (equivalent to Arg64, Arg58 and Arg87 in BAG6) form electrostatic 
interactions with Glu39 and Glu38 in RNF126_NZF (Figure 71 B). Phe36 of RNF126_NZF 
inserts into a pocket formed by Leu8, Asn68 and Val70 of UBL4A forming hydrophobic contacts 
between aliphatic portions of the side-chains (Figure 71 C and D).  
 
 
Figure 70: RNF126_NZF/UBL4A_UBL complex structure modelling results. A) Three top scoring 
clusters of the RNF126_NZF/UBL4A_UBL complex generated by HADDOCK. B) Overlay of 
RNF126_NZF/BAG6_UBL complex structure as calculated using ARIA with the HADDOCK-generated 
top scoring cluster 1 of RNF126_NZF/UBL4A_UBL complex. C) and D) Details of the binding interface 







Table 14: Energetic parameters obtained for the three best clusters of RNF126_NZF/UBL4A_UBL 



























Cluster1 -91.7 ± 2.7  119 1.5 ± 
1.2  
-32.9 ± 7.4 5.0 ± 2.0  1017.7 
± 74.4  
-297.3 ± 64.4  0.2 ± 4.0  -1.3  
Cluster2 -79.1 ± 3.6  23 5.9 ± 
0.8  
-31.3 ± 5.4  3.3 ± 1.8  1031.1 
± 98.6  
-302.9 ± 21.8  12.5 ± 2.8  -0.7  
Cluster3 -73.9 ± 6.7  21 9.7 ± 
0.8  














Figure 71: Structural analysis of RNF126_NZF and UBLs complexes. A) Structure-based sequence alignment 
of BAG6_UBL and UBL4A_UBL with the most perturbed residues from the CSP analysis labelled with asterisks; boxes 
indicate conserved residues while red indicates sequence identity, structural motifs are labelled across the top with ‘TT’ 
indicating a β turn. Figure was produced using ESPript 3.0 server. B) Superimposition of the BAG6_UBL complex with 
RNF126_NZF (experimentally calculated using ARIA) with the HADDOCK generated complex of UBL4A_UBL and 
RNF126_NZF indicating possible differences in electrostatic interactions at the binding interface. RNF126 is coloured in 
green, BAG6 in cyan and UBL4A in magenta, with polar residues at the interface shown in ball and stick representation. C) 
Vacuum electrostatics view of UBL binding pockets (BAG6 on the right and UBL4A on the left) highlighting higher 
hydrophobicity of BAG6_UBL compared to that of UBL4A_UBL. RNF126 is shown in cartoon representation (green) with 
the zinc cation shown as a sphere (blue); RNF126 residues involved in interactions are displayed as sticks. D) Detailed cartoon 
view of RNF126_NZF/UBL hydrophobic interactions showing key differences between residues lining the hydrophobic 
pocket. The backbone NH group of Leu24 and the aliphatic part of the His83 sidechain that lines the cavity in BAG6_UBL 
suggests stronger hydrophobic interactions with Phe36 in RNF126_NZF (right panel) compared to those of UBL4A. At the 
RNF126_NZF/UBL4A_UBL binding interface, the sidechain NH group of Asn68 lines the cavity in UBL4A_UBL and the 


























       TT                                    TT    TT                       
UBL4A_UBL    1     VK L        V     V   K         P   QRL   G  L D K L  Y  G          P   M L    S  P   V LNV    LF  KA   R SD SI P L  Q T A QGREC LQ EDEL STL QL SEK VRQ K A G NSKLN VVK LEK
BAG6_UBL    17     VK L        V     V   K         P   QRL   G  L D K L  Y  G          P   L V    T  G   I VSI    IY  RV   K QE NV G V  E L T DSQTR FI AQMN KEF EH AAS SEK Q Q D KVIHL ERA PQT
β1 β2 α1 β3 β4 η1 β5 
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4.9   Competition between SGTA (1-86) and RNF126_NZF for the same 
binding site on BAG6_UBL 
Since the RNF126 binding site on BAG6 exhibits some overlap with its SGTA interaction 
interface (82, 99) we examined whether there is a possibility of simultaneous or competitive 
binding between these three proteins using NMR and native PAGE mobility shift assay. 
 
4.9.1   CSPs in competitive binding study of SGTA (1-86), RNF126_NZF and 
BAG6_UBL 
First, the direct binding between SGTA (1-86) and RNF126_NZF was tested by reciprocal NMR 
titrations. It showed unperturbed spectra of each protein upon addition of the other, to a molar 
ratio of 1:4 (SGTA dimer: RNF) (Figure 72), indicating the lack of interaction. Next we analysed 
the CSP of 15N-labelled SGTA (1-86) upon titration with BAG6_UBL, followed by the addition 
of RNF126_NZF until saturated. The peaks that are perturbed upon BAG6_UBL binding 
incrementally return to their free state upon RNF126_NZF addition (detailed panels are shown in 
Figure 73 A and full spectra in Figure 74. Similarly, 15N-labelled BAG6_UBL protein was 
titrated with SGTA and then saturated with RNF126_NZF resulting in the characteristic shifts for 
SGTA binding pattern changing into the RNF126_NZF binding state upon saturation. 
Furthermore, the reverse titration was performed by adding RNF126_NZF followed by SGTA, 
with similar results (Figure 73 B) except for the BAG6/RNF126 complex signals not fully 




Figure 72: 1H-15N HSQC spectra of 15N-labelled SGTA (1-86) dimer titrated with RNF126_NZF. 1H-
15N HSQC spectra of 15N-labelled SGTA_NT dimer (assignment extracted from BMRB accession number 
19779) in free form (black), and with a four-fold molar excess of unlabelled RNF126_NZF (red). SGTA 









































































Figure 73: CSPs in competitive binding study of SGTA, RNF126_NZF and BAG6_UBL. A) Upper 
panel - detailed views of overlapping 1H-15N HSQC spectra showing 15N-labelled SGTA (1-86) protein 
titrated with unlabelled BAG6_UBL at ratios: 1:0 (black), 1:1 (purple) and 1:2 (blue). Lower panel – 
equivalent views of 1H-15N HSQC spectra of 15N-labelled SGTA in complex with unlabelled BAG6_UBL 
(1:2 molar ratio) titrated with unlabelled RNF126_NZF at ratios: 1:2:0 (blue), 1:1:1 (magenta) and 1:0.5:1.5 
(red). B) Detailed views of 1H-15N HSQC spectra of 15N-labelled BAG6_UBL (black) titrated with 
RNF126_NZF (red, far left) at a ratio of 1:1 and then saturated with unlabelled SGTA (1-86) (purple) to 
reach a BAG6:RNF126:SGTA ratio of 1:1:4; or 15N labelled BAG6_UBL titrated first with unlabelled 
SGTA (1-86) (green) at 1:2 ratio and then saturated with unlabelled RNF126_NZF (orange, far right) at 
ratios of 1:2:2 (BAG6:SGTA:RNF126). Since SGTA (1-86) dimerises, a two-fold concentration of this 























































































Figure 74: Expanded 1H-15N HSQC spectra corresponding to the detailed views in Figure 73A. A) 
15N-labelled SGTA (1-86) titration with unlabelled BAG6_UBL. B) 15N-labelled SGTA (1-86) in complex 
with unlabelled BAG6_UBL titrated with unlabelled RNF126_NZF. Molar ratios and colours as described 






















4.9.2   Native PAGE in competitive binding assay of SGTA (1-86), RNF126_NZF 
and BAG6_UBL 
Native PAGE mobility shift assays were employed to further analyse the competition between 
RNF126_NZF and SGTA (1-86) for BAG6_UBL binding. First, SGTA (1-86) was saturated with 
BAG6_UBL and a band shift was detected indicating a complex formation. Then, GFP-tagged 
RNF126 was added into the protein mixture at increasing concentrations which resulted in 
characteristic band shifts for the free form of SGTA and subsequent complex formation between 
BAG6_UBL and RNF126. On the contrary, in the reverse titration where 
BAG6_UBL/RNF126_NZF complex was formed followed by addition of SGTA, the release of 
RNF126 from the RNF126/BAG6_UBL complex upon competition with SGTA_NT was not 
observed (Figure 75).  
Collectively, these experiments are consistent and indicate that RNF126_NZF competes with 
SGTA (1-86) for the same binding region in BAG6_UBL (and on UBL4A_UBL, Figure 76) and 
exclude the possibility of RNF126 and SGTA binding to BAG6 simultaneously. Furthermore, 
BAG6_UBL binds more tightly to RNF126_NZF than it does to SGTA (1-86) as the former 
interaction has Kd ≈ 0.4 µM as calculated from ITC while the ITC data for the latter interaction 
could not be sufficiently fitted, despite trying a number of experimental conditions. The binding 
could only be demonstrated by NMR chemical shift perturbation in fast exchange and size 






Figure 75: Native PAGE of GFP-tagged RNF126_NZF competitive binding assay with BAG6_UBL 
and SGTA_NT visualised by fluorescence (top) and Coomassie (bottom). Left panel: lane 1 - free GFP-
tagged RNF126_NZF, lanes 2–4 - GFP-tagged RNF126_NZF titrated with BAG6_UBL at 0.2, 0.3 and 1 
molar equivalents, lanes 5–12 – GFP-tagged RNF126_NZF in complex with BAG6_UBL (1:1 ratio) titrated 
with SGTA_NT dimer at 0.1, 0.2, 0.3, 0.5, 1, 2, 3 and 4 molar equivalents, lane 13 – free SGTA_NT, lane 
14 – SGTA_NT in complex with BAG6_UBL (1:1) and lane 15 – free BAG6_UBL. Right panel: lane 1 – 
free SGTA, lanes 2 and 3 – SGTA_NT titrated with BAG6_UBL at 0.3 and 1 molar equivalents, lanes 4–8 
- SGTA_NT in complex with BAG6_UBL (1:1) titrated with GFP-tagged RNF126_NZF at 0.2, 0.5, 1, 3 
and 4 molar equivalents, lane 9 - free GFP-tagged RNF126_NZF, lane 10 - GFP-tagged RNF126_NZF in 
complex with BAG6_UBL (1:1), and lane 11 – free BAG6_UBL. Free GFP-tagged RNF126_NZF (green), 
free BAG6_UBL (red) and free SGTA_NT (yellow) are labelled with asterisks; GFP tagged 
RNF_126_NZF/BAG6_UBL complex with a green square and SGTA_NT/BAG6_UBL complex with a 
red square. 
C
SGTA_NT       -  -  -  -                          +  +  -   +  +  +   +  +  +   +  +  -  -  -
BAG6_UBL    -           +  +  +  +  +  +  +  +  -  +  +           +  +  +   +  +  -  +  +
RNF_NZF       +  +  +  +  +  +  +  +  +  +  +  +  -  -  -   -  -  -        +  +  -  
 1      2      3       4      5      6       7      8      9    10    11   12    13    14    15     1      2      3       4       5      6       7      8       9     10   11









Figure 76: SGTA_NT and RNF126_NZF interact with the same region of the UBL domains of BAG6 
and UBL4A. A) and B) Cartoon representations of BAG6_UBL in complex with SGTA (A-HADDOCK 
model (82), Chapter 3) and with RNF126_NZF (B -solution structure). C) and D) UBL4A_UBL in complex 
with SGTA_NT (C -HADDOCK model (82), Chapter3) and RNF126_NZF (D -HADDOCK model).  
 
4.10   Preliminary expression and purification trials of RNF126_FL and 
RNF126 (142-218) 
The full length RNF126 constructs and hydrophobic region (142-218) constructs were produced 
to characterise the full length protein and contribute to understanding how RNF126 E3 ligase 
selects its substrates for ubiquitination. Proteins were expressed in both, Bl-21 and C41 cells to 
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test expression conditions. Both constructs were not stable after the purification and solubility tag 
removal and several purification trials yielded none or little protein. The purification and mass 
spectrometry analysis of both samples are shown on Figure 77. Overall the results are not fully 
conclusive to decide if all the protein sample precipitated or whether the tag removal was not 
entirely successful. More purification trials are needed in order to find better 
purification/expression condition.  
 
 
Figure 77: Mass spectrometry results and SDS-PAGE of RNF126 full length (top) and RNF126 (142-
218) purification trials. Left: annotated mass spectrometry analysis. Right: SDS- PAGE 1) uninduced cells 
control 2) flow through after column loaded with the cell lysate, 3) wash with 5 CV of wash buffer (20 mM 
potassium phosphate pH 8.0, 300 mM NaCl and 250 µ M TCEP), 4) elution with 1 CV of elution buffer 
(20 mM potassium phosphate pH 8.0, 300 mM NaCl and 250 µ M TCEP, 300mM Imidazole), 5) additional 
elution step with 1CV of elution buffer, 6) total cleavage reaction, 7) flow through after column loaded 
with total cleavage reaction (cut RNF126), 8) elution with 2 CV of elution buffer (uncut protein and tag). 





4.11   Preliminary study of RNF126 interaction with Frataxin 
Recently, in vivo studies have shown that the N-terminal portion of Frataxin interacts with full 
length RNF126 in cell pull-downs (75). However, it is not clear whether it was a full length 
frataxin precursor or which domain of RNF126 is necessary for the interaction. Since, there were 
no substrates identified for RNF126 before, we aimed to test whether the two proteins interact 
directly in solution. Frataxin constructs were kindly provided by our collaborators (Dr Robert Yan 
from Prof Annalisa Pastore lab, King’s College London). The full-length RNF126 could not be 
produced in sufficient amounts, therefore RNF126_NZF was tested for interaction. The 1H- 15N 
HSQC spectrum shows some signal broadening upon RNF126_NZF titration into 15N-labelled 
Frataxin (Figure 78) and the reciprocal titration shows similar results (not shown). However, 
more experiments are needed to verify whether there is an interaction between the two proteins 
and if it is the N-terminal of RNF126 which interacts. 
 















4.12   RNF126 alignment with RNF115 
Since, full length RNF126 is not very stable and producing high enough yields for binding studies 
proved to be challenging, we planned to construct its homologue RNF115 (Figure 79). RNF115 
is another soluble E3 ligase which shares near identical NZF and RING domains with RNF126 
(with 42.3% overall sequence identity and 52.6% similarity). We planned to investigate whether 
RNF115 can bind to the BAG6_UBL which would support its role in the selective ubiquitination 
of MLPs. 
 
Figure 79: Sequence alignment of human E3 ligase proteins RNF126 and RNF115. The proteins 
present high conservation in the N-terminal zinc finger (10-40 of RNF126) and in a region comprising the 
RING domain (229-270 of RNF126). Boxes show conserved residues while red highlights sequence 
identity; figure generated using ESPript 3.0 server. 
 
4.13   Summary 
The backbone and side chain assignment of N-terminal RNF126 zinc-finger, together with NOE 
assignments were used in structural calculations. Moreover, residues 1-40 of RNF126 have been 
identified to be sufficient to interact with UBL domain of BAG6 and UBL4A. The analysis of the 
interaction between RNF126_NZF and the UBL domains of BAG6 and UBL4A showed that they 
do not bind simultaneously but compete for the same binding site, just like SGTA. This has been 
shown in a reciprocal titration experiment, in which CSP peaks, shifted back to the unbound state 




Binding affinities of these complexes were determined using MST and ITC. MST showed that 
the binding affinity of RNF126_NZF)/UBL4A_UBL complex was an order of magnitude weaker 
than the one of RNF126_NZF/BAG6_UBL. However, the binding affinity of 
RNF126_NZF/BAG6_UBL derived from MST was an order of magnitude stronger compared to 
the one obtained from ITC (0.4 µM). Furthermore, ITC was not sensitive enough to detect the 
binding of RNF126_NZF with UBL4A_UBL in any of the tested conditions. 
 
In addition, the structural models generated of complexes of RNF126_NZF with UBLs using 
NMR (for RNF126_NZF/BAG6_UBL) and HADDOCK (for RNF126_NZF/UBL4A_UBL) 
showed that the binding interfaces of the two models are essentially similar with some differences 














Chapter 5.   Structure and interactions of the TPR domain of Sgt2 with 
yeast chaperones and Ybr137wp.  
The TPR domain of Sgt2 and SGTA is a highly conserved motif known to form transient 
complexes with molecular chaperones such as Hsp70/Hsp90 (Ssa1 and Hsc82 in yeast) and 
Ybr137wp (conserved only in yeast). This chapter, describes the first high resolution crystal 
structure of the free Sgt2_TPR and the same protein in complex with a C-terminal peptide 
PTVEEVD from Ssa1. Furthermore, it reports the complete assignment of the Sgt2_TPR 
backbone and, by using NMR and ITC, we demonstrate that Sgt2_TPR interacts with C-terminal 
fragments of Ssa1, Hsc82 and Ybr137wp with a similar binding mode and comparable binding 
affinities. 
 
5.1   Protein production  
Two Sgt2_TPR constructs (residues 93–229 and 96-225 for the shorter construct) were produced 
by cloning and overexpression in E. coli described in the Methods Section 2.2. Overexpressed 
protein was recovered in the soluble fraction. Enrichment of expressed protein was achieved by 
Nickel affinity chromatography, fusion protein and histidine tag removal, and size exclusion 
chromatography (Figure 80). This resulted in pure protein with typical final yields of 1.5g/L for 
expression in LB and 1g/L for expression in M9 minimal media. Proteins were purified in a buffer 




Figure 80: Purification of Sgt2_TPR. A) SDS-­‐page analysis of purification and the removal of the 
fusion/histidine tag by affinity chromatography of unlabelled Sgt2_TPR (lanes 1-6) and 15N Sgt2_TPR 
(lanes 7-12). 1) flow through after column loaded with the cell lysate, 2) wash with 5 CV of wash buffer 
(20 mM potassium phosphate pH 8.0, 300 mM NaCl and 250 µ M TCEP), 3) elution with 2 CV of elution 
buffer (20 mM potassium phosphate pH 8.0, 300 mM NaCl and 250 µ M TCEP, 300mM Imidazole), 4) 
total cleavage reaction, 5) flow through after column loaded with total cleavage reaction, 6) elution with 2 
CV of elution buffer. B) SDS-­‐page analysis and C) Chromatogram of size exclusion chromatography using 
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5.2   Crystallisation of Sgt2_TPR 
We aimed to crystallize Sgt2 alone and in complex with C-terminal fragments of Ssa1 
(PTVEEVD peptide), Hsc82 (MEEVD peptide) and Ybr137wp (SLEENDNLD) in order to gain 
insight into how the TPR domain of Sgt2 recognises its targets. The longer construct of Sgt2_TPR 
(residues 93–229) produced a thick plate crystal (dimensions 200 x 400 µM) in  0.1M SPG, pH 
6.0, 25% w/v PEG 1500 within four days (Figure 81). It was used to collect a diffraction dataset 
and solve the X-ray structure of the free Sgt2_TPR. The peptides used for co-crystallisation were 
prepared as described in Methods (Section 2.1.10). Attempts to crystallise the longer TPR 
construct in complex with peptides failed, possibly due to the flexible N-terminal and C-terminal 
ends of the symmetry-related molecules in the crystal occluding the binding interface and 
preventing complex formation during crystal growth. To demonstrate this, we used an initial 
model of our x-ray Sgt2_TPR structure and modelled the MEEVD peptide into the binding 
interface based on the SRMEEVD peptide in TPR_Tah1 complex (PDB accession number: 
4CGQ) (Figure 81). This supported our theory so we used the model to design a shorter 
Sgt2_TPR (96-225) construct by removing EDD residues from the N-terminus and EKTV from 
the C-terminus. This resulted in successful crystallization of the Sgt2_TPR/PTVEEVD complex 
after seven days. Initially, we observed two different crystal morphologies in the screens including 
plates and thin needles. The needles crystallized in 0.2M Zinc Acetate, pH 6.3, 20% w/v PEG 
3350 and were optimised by varying the PEG concentration from 8-30% and pH from 5.9-7.3. 
This yielded rod-shaped crystals in 0.2M Zinc Acetate, pH 7.2, 30% w/v PEG 3350 and enabled 
a dataset collection for the complex (Figure 81). We found that zinc was essential for the 
crystallization of the complex and the crystals produced in conditions without it did not result in 
the complex formation, suggesting that the metal ion is needed to stabilize complex formation 
within the crystal. The PTVEEVD peptide was the only one to effectively crystallize in a complex 
with Sgt2_TPR. All attempts at crystal soaking with increasing concentrations of MEEVD and 




Figure 81: Crystallisation of Sgt2_TPR. A) Crystal morphology of the free Sgt2_TPR, B) A model of 
Sgt2_TPR with MEEVD peptide modelled in the binding interface based on the SRMEEVD peptide in 
TPR_Tah1 complex (PDB accession number: 4CGQ) to show the N-terminal (NT) and C-terminal (CT) 
ends of neighbouring symmetry molecules occluding the binding interface. Model made using Pymol. C) 
Crystal optimisation from thin needles to rods of the Sgt2_TPR/PTVEEVD complex. 
 
5.3   Overall Sgt2_TPR x-ray structure 
The structure of Sgt2_TPR was determined by molecular replacement and refined to 1.55 Å 
resolution (Figure 82 A). The coordinates file and the mtz reflection file were deposited to PDBe 
after the model was validated by MolProbity (335) (PDB Accession Number: 5LYP; statistical 
parameters from MolProbity and Aimless in Table 15). The coordinates of SGTA_TPR (PDB 
accession number: 2VYI) were used as a search model due to high structural homology (57% 
sequence identity) (Figure 82 C). The structure was solved with the space group P 21 21 21 and 
the cell parameters are 36.86Å (a) 50.76Å (b) 67.12Å (c) 90.00° (α) 90.00 ° (β) 90.00 ° (γ). All 
residues could be built into electron density maps except for the C-terminal Val229 and the 














molecules and a single BO4 ion from the crystallization condition, which were added manually in 
Coot. The refined structure shows very good stereochemical properties with no Ramachandran 
outliers, 1% of sidechain outliers and 0.7% of the RSR Z-score (RSRZ) outliers (statistics from 
the Molprobity report and Aimless shown in Table 15). The TPR domain of Sgt2 consists of three 
TPR repeats, comprising six almost identical α-helices and a C-terminal ‘capping’ helix 
(α1 =A96- N115; α2 =  Y118-V131; α3 =  A136-L149; α4 =  Y152-I165; α5=F170-183Q; α6=P186-
E200; α7=E206-L225) connected by short loops and arranged in an antiparallel fold homologous 
to that of SGTA_TPR. A structural overlay with the equivalent human domain is shown in Figure 
82 A (RMSD of 1.13Å over 135Ca).  
 
Figure 82: Crystal structure of Sgt2_TPR. A) Superimposition of TPR domains from Sgt2 (magenta, 
PDB accession code: 5LYN) with human SGTA (gray, PDB accession code: 2VYI) Structures were 
superposed using secondary-structure matching in ccp4mg (328). The structures align with RMSD 1.13 Å. 
B). Superimposition of TPR domains from free Sgt2 and Sgt2 bound to the Ssa1 derived peptide 
PTVEEVD. (teal). The peptides align with RMSD 0.77 Å.  C) Structure-based sequence alignment of SGT 
TPR domains from S.Cerevisiae (Sc), A.fumigatus (Af), C.elegans (Ce), Homo sapiens (Hs) and human 
HOP TPR1, (T1). The residues involved in protein-protein interactions and forming a two-carboxylate 
clamp are indicated with asterisks; boxes show conserved residues while red highlights sequence identity; 
structural motifs are labelled on the top. The residue numbering is from S.Cerevisiae. Figure generated 




Table 15: Data collection and refinement statistics of Sgt2_TPR. 
 
Statistics for the highest-resolution shell are shown in parentheses. 
 
5.4   X-ray Structure of Sgt2_TPR in complex with Ssa1 C-terminus 
The Sgt2_TPR (96-225)/PTVEEVD complex structure was determined by molecular replacement 
using our recently solved Sgt2_TPR (93–229) structure as a search model (Figure 83,  PDB 
Resolution range 
32.31  - 1.55 
(1.605  - 1.55) CC(work) 
0.939 
(0.928) 





67.1162 90 90 90 
Number of non-hydrogen 
atoms 1157 
Total reflections 232024 (23272)   macromolecules 1062 
Unique reflections 18908 (1864)   ligands 5 
Multiplicity 12.3 (12.5) Protein residues 137 
Completeness (%) 1.00 (1.00) RMS(bonds) 0.005 
Mean I/sigma(I) 12.89 (8.72) RMS(angles) 0.62 
Wilson B-factor 8.98 Ramachandran favored (%) 1e+02 
R-merge 0.2183 (1.061) Ramachandran allowed (%) 0 
R-meas 0.2277 (1.104) Ramachandran outliers (%) 0 
CC1/2 0.995 (0.975) Rotamer outliers (%) 0.95 
CC* 0.999 (0.994) Clashscore 0.95 
Reflections used in 
refinement 
18908 (1864) Average B-factor 10.96 
Reflections used for 
R-free 
937 (89)   macromolecules 10.50 
R-work 0.1936 (0.1711)   ligands 19.64 
R-free 0.2186 (0.2231)   solvent 15.95 
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Accession Number: 5LYN, Table 16 for statistics). The structure was solved with space group P 
1 21 1 and cell dimensions, 45.49Å (a) 61.09Å (b) 55.25Å (c) 90.00° (α)108.81° (β) 90.00 ° (γ). 
Two copies of the TPR domain were present in the asymmetric unit (Figure 86 A). All residues 
of Sgt2_TPR could be built into electron density maps in chain A and chain B. The two peptides 
(chain C and D) showed partial occupancy at the binding groove and were thoroughly verified 
after building. They were modelled into a fair electron density (Figure 83 A) and then verified 
by producing a simulated annealing omit map (Figure 84). The overall structures of the two 
chains, A and B, are essentially identical in the case of backbone (RMSD of 0.77Å over 135Ca), 
with some deviations observed for the R171 sidechains due to their flexibility and significant 
differences in the modelled C and D peptide (Figure 86 A and B). The electron density was less 
unambiguous for peptide C at chain B, especially for Pro1 with some electron density appearing 
in the Fo-Fc map which could be suggesting the presence of another atom. However, neither the 
zinc ion or water molecule could be fitted. Nevertheless, all PTVEEVD (1-7) residues were 
successfully modelled. The occupancy for both peptides (chain C and D) were refined to an 
Rfactor of 0.158 and an Rfree 0.202, and both converged to occupancy 0.93.  The complex was 
refined with Phenix script (322) using NCS   and TLS (321). TLS groups for both protein chains 
and peptides were automatically identified by Phenix. The NCS option was run using chain 
Aresidues as a reference and compared with chain B. We choose to automatically check for 
rotamer consistencies without restraining B_factors.  The final model also contains 148 water 
molecules, nine Zinc ions and a single BO4 ion added manually in Coot. Zinc ions were added at 
peaks of the phased anomalous difference map (DANO) (Appendix). The DANO map was 
analysed in Coot after opening in an expert mode and showed densities for all nine zinc atoms. 
The refined structure shows good stereochemical properties with no Ramachandran or sidechain 
outliers and 1.1% of the RSR Z-score (RSRZ) outliers (statistics from the Molprobity report are 




Figure 83: Crystal structure of the Sgt2_TPR/ PTVEEVD complex. A) Surface representation of the Sgt2 
hydrophobic groove with bound Ssa1 derived PTVEEVD peptide (PDB accession number 5LYP). The 
2Fo-Fc map for the peptide was contoured at 1.0 σ. B) Superimposition of Sgt2_TPR/ PTVEEVD complex 
(peptide in yellow) onto Hsc70 peptide-bound HOP TPR1A (peptide in grey, PDB accession number 
1ELW) highlighting similarities in peptide conformation at the binding interface. The peptides align with 
RMSD 0.52 Å. C) Network of interactions formed at the complex interface. Residues shown as sticks are 
involved in the formation of hydrogen bonds or electrostatic interactions (shown as yellow dashed lines). 
Residues K106, N110, N141, R171, R175 and Y169 are involved in the formation of two-carboxylate 





Figure 84: Sgt2_TPR groove with 1σ 2Fo-Fc map calculated for the peptide. Fo-Fc map of Sgt2_TPR 
groove with 1σ 2Fo-Fc map calculated for the peptide region (green) using the final model from which the 
peptide was omitted following simulated annealing to remove the model bias. 
 
The interaction between the Sgt2_TPR and a PTVEEVD peptide is mostly driven by the 
formation of a two-carboxylate clamp. Most of the electrostatic interactions between the TPR 
domain and the peptide occur in the C-terminal EEVD region and anchor the peptide in place. 
Direct backbone contacts involve hydrogen bond formation between the carboxamide sidechain 
of Asn141 and Asn110 in Sgt2_TPR, and the sidechain of the terminal Asp7 of the Ssa1 peptide. 
Also, the sidechain amine of Lys 106 binds to the same carbonyl sidechain of Asp7. The 
guanidinium group of Arg171 forms a salt bridge with the carbonyl main chain of Asp7 and forms 
an additional internal contact with Tyr169. The Arg175 sidechain interacts with the carbonyl main 
chain of Glu4 and Glu5 of the peptide (Figure 83 C). Moreover, the N-terminal of the peptide is 
involved in hydrophobic and van der Waals interactions. Phe178 and Tyr181 contribute to 




Met113 makes a hydrophobic contact with Val6 of the peptide (Figure 85). The ‘two-carboxylate 
clamp’ binding mode is characteristic for TPR domains interacting with the conserved C-terminal 
IEEVD and MEEVD motifs of Hsp70 and Hsp90 chaperones, respectively (261, 336). The 
comparison of Sgt2_TPR/PTVEEVD binding interface with a previously published complex of 
HOP TPR1/GPTIEEVD (Hsp70-derivative) (261, 336) shows that the PTVEEVD peptide 
occupies the same position at the Sgt2 TPR groove as GPTIEEVD. Both peptides essentially 
overlap except for the difference in the conformation of the main chain and the sidechain of the 
terminal Asp7 (Figure 83 B). This however corresponds to the Asp7 conformation in our chain 
B peptide bound Sgt2_TPR/PTVEEVD complex structure. Other differences between chain A 
and chain B are the sidechain conformation of chain B Arg171 is slightly different due to its 
flexibility and small variations in the orientation of Pro1, Thr2 and Val3 sidechains. The 
differences between the peptides modelled within the two Sgt2_TPR groove chains cause a 
change at the interface. In Chain B the sidechains of Asn141 and Asn110 of Sgt2_TPR bind to 
the main chain of the terminal Asp7 of the Ssa1 (Hsp70) peptide. Also, the hydroxyl group of 





Figure 85: Vacuum electrostatics view of Sgt2_TPR hydrophobic pockets. Vacuum electrostatics view 
of Sgt2_TPR hydrophobic pockets highlighting hydrophobic interactions between M113, F178 and Y181 
and Valine, Threonine and Proline of the PTVEEVD peptide (shown as sticks). The C-terminal end of the 
peptide is involved in electrostatic interactions. Red corresponds to the negatively charged electrostatic 
potential on the surface; blue for the positively charged and grey for the neutral. The bound peptides are 





Figure 86: The asymmetric unit of Sgt2_TPR/PTVEEVD complex x-ray structure. A) The asymmetric 
unit shown as a cartoon representation of Sgt2_TPR chain A (teal) and chain B (grey) and bound peptides 
(yellow and grey respectively). Zinc ions shown as balls. B) Superimposition of Sgt2_TPR Chain A (teal) 
and Chain B (green) bound peptides (yellow and wheat respectively) highlighting main differences. 
Peptides were superposed using secondary-structure CA matching in ccp4mg. The peptides align with 






Table 16: Statistics for the highest-resolution shell are shown in parentheses. 
 
Statistics for the highest-resolution shell are shown in parentheses. 
 
5.5   Backbone 1H, 13C, and 15N Chemical Shift Assignments for Sgt2_TPR 
The complete battery of NMR triple resonance experiments using the longer construct of 
Sgt2_TPR (93–229) were performed to facilitate the full backbone assignment. 15N HSQC and 
the following 3D experiments (HNCO, HNCA, HN(CA)CO, CBCA(CO)NH, and CBCANH) 
were recorded on a 500 MHz spectrometer. Peaks were picked manually using CCPN Analysis  
Resolution range 33.59  - 2.0 (2.071  - 2.0) CC(work) 0.845 (0.345) 
Space group P 1 21 1 CC(free) 0.725 (0.476) 
Unit cell 45.49 61.09 55.25 90 108.81 90 
Number of non-hydrogen 
atoms 2340 
Total reflections 117547 (10486)   macromolecules 2183 
Unique 
reflections 19189 (1904)   ligands 9 
Multiplicity 6.1 (5.6) Protein residues 280 
Completeness 
(%) 0.99 (0.97) RMS(bonds) 0.006 
Mean I/sigma(I) 6.49 (2.84) RMS(angles) 0.68 
Wilson B-factor 25.49 Ramachandran favored (%) 1e+02 
R-merge 0.354 (0.8515) Ramachandran allowed (%) 0.37 
R-meas 0.3851 (0.9392) Ramachandran outliers (%) 0 
CC1/2 0.92 (0.531) Rotamer outliers (%) 0 
CC* 0.979 (0.833) Clashscore 2.77 
Reflections used 
in refinement 19279 (1903) Average B-factor 30.91 
Reflections used 
for R-free 928 (83)   macromolecules 30.60 
R-work 0.1576 (0.1903)   ligands 50.77 
R-free 0.2025 (0.2587)   solvent 34.38 
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and the sequential assignments for the shifts of Cai, Cb i, Ca i-1, Cb i-1, C¢ i, C¢ i-1 were manually 
performed using the same software. A number of overlapped amide resonances were observed in 
the middle of the spectrum and were initially difficult to resolve, therefore an additional 15N 
HSQC, HNCO and CBCANH experiments were recorded at 700 MHz to improve the quality of 
the data. All the protein residues were assigned except for Prolines and Arg171 for which NH 
peaks were missing (Figure 87).  
 
Figure 87: 15N HSQC assigned spectrum of Sgt2_TPR. 
 
 
Prior to the BMRB submission, the chemical shifts from the following experiments: HNCO, 
HN(CA)CO, CBCA(CO)NH, and CBCANH were converted into the required STAR format 




































































































































for referencing and assignment errors by the software PANAV (run by BMRB team). The 
validation report indicated no deviant assignments and an unusually high chemical shift for one 
residue, Glu4 of Cb = 41.206, where the average chemical shift values for this residue is 30.01. 
Closer inspection indicated a good connectivity of Ca , Cb ,and C for the preceding and following 
residues and therefore the assignment remained unchanged. All chemical shifts were calibrated 
by the reference offsets: C¢: -0.58ppm, Ca: -0.67ppm, Cb: 0.45ppm, N: -0.75ppm.  
 
5.5.1   TALOS 
TALOS+ was run to predict the backbone torsion angles from the chemical shifts assignments 
and to generate the random coil index (RCI) with a predicted order parameters for each residue 
and a chemical shift index (CSI) (Figure 88). Secondary structure prediction/RCI perfectly agrees 
with the structure solved by crystallography indicating the presence of seven a helices and the 
flexible N-terminal and C-terminal ends. . 
 
Figure 88: Secondary Structure and Random Coil Index (RCI)-S2 Prediction Window of Sgt2_TPR. 
The RCI shows the predicted order parameter S2 (upper panel) and CSI-predicted secondary structure 
(lower panel; red, helix) for all residues. The height of the bars reflects the probability of the neural network 
secondary structure prediction. The residue number is labelled at the bottom of the panel. 
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5.6   Interactions of the TPR domain of Sgt2 with yeast chaperones and 
Ybr137wp 
To understand the molecular details of the interactions between Sgt2_TPR with chaperones and 
Ybr137wp, we focused on probing protein-peptide interactions using the C-terminal fragments of 
Ssa1 (PTVEEVD), Hsp82 (MEEVD) and Ybr137wp (SLEENDNLD) in binding experiments 
combining NMR and ITC. NMR allowed us to identify the residues involved in the interaction 
for all three peptides and ITC delivered binding affinities.  
 
5.6.1    Chemical shift perturbation assays 
Chemical shift perturbation (CSP) experiments were carried out by titrating unlabelled peptides 
PTVEEVD, MEEVD and SLEENDNLD into 15N-labelled Sgt2_TPR (93–229) with up to a 6-
fold molar excess of PTVEEVD and MEEVD and a 5-fold excess in the case of SLEENDNLD. 
The 15N HSQC experiment was used to monitor for chemical shift changes. We could not produce 
SLEENDNLD at the 6-fold molar excess due to the lower solubility of this peptide in water or 
buffer. The NMR backbone assignment of Sgt2_TPR (described in the Section 5.5) allowed us to 
identify the residues involved in the interactions in all three titrations. The full 15N HSQC 
spectrum and the selected enlarged peaks for the titration experiments are shown in Figure 89, 
Figure 90 and Figure 91. The CSP graphs displaying chemical shifts plotted against the residues 
of Sgt2_TPR are presented in Figure 93. CSP analysis exhibited a similar pattern for all three 
peptide titrations and showed binding in a fast exchange regimen, with a number of peaks shifting 
in a non-linear manner suggesting the formation of an intermediate during the titration. We 
analysed the Sgt2_TPR CSPs by applying a titration cut-off at 3 molar equivalents of the peptide 
for all the peaks and then dividing them into two groups. The first group consisted of peaks which 
shift between 0 and 3 molar equivalents and was named the ‘first event’ and the second group, 
called ‘second event’ comprised the peaks shifting between 3 and 6 (or 5 in the case of 
SLEELDNLD) molar equivalents (marked as red and black arrows respectively in Figure 90 B, 
Figure 91 B Figure 92 B. The CSP of Sgt2_TPR/PTVEEVD binding for the ‘first event’, plotted 
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onto our x-ray structure is shown in Figure 92 A on the left and the ‘second event’ on the right.  
The most perturbed resides for the ‘first event’ correspond to the residues at the binding interface 
in the x-ray complex structure and/or the neighbouring residues. The behaviour of the two subsets 





Figure 89: The 15N HSQC spectrum of 15N-labelled Sgt2_TPR titrated with PTVEEVD. The CSP of 
15N-labelled Sgt2_TPR peaks upon binding to unlabelled PTVEEVD at ratios: 1:0 (teal, assigned), 1:0.5 
(purple), 1:1 (red), 1:2 (light pink), 1:3 (moroon), 1:4 (blue), 1:5 (cyan), and 1:6 (green). Bottom: Enlarged 






Figure 90: The 15N HSQC spectrum of 15N-labelled Sgt2_TPR titrated with MEEVD. A) The CSP of 
15N-labelled Sgt2_TPR peaks upon binding to unlabelled MEEVD at ratios: 1:0 (teal, assigned), 1:0.5 
(purple), 1:1 (red), 1:2 (light pink), 1:3 (maroon), 1:4 (blue), 1:5 (cyan), and 1:6 (green). B) Detailed view 
of 15N HSQC spectrum showing chemical shift perturbations (CSP) for the selected residues. Black and red 





Figure 91: The 15N HSQC spectrum of 15N-labelled Sgt2_TPR titrated with SLEEDNLD. A) The 15N 
HSQC spectrum of 15N-labelled Sgt2_TPR titrated with unlabelled SLEEDNLD at ratios: 1:0 (teal, 
assigned), 1:0.5 (purple), 1:1 (red), 1:2 (light pink), 1:3 (maroon), 1:4 (blue), 1:5 (cyan). B) Detailed view 
of 15N HSQC spectrum the showing chemical shift perturbation (CSP) for the selected residues. Black and 





Figure 92: Sgt2_TPR binds yeast chaperones and Ybr137wp. A) Sgt2_TPR domain colored according 
to chemical shift perturbation (CSP) upon additions of unlabelled PTVEEVD peptide. The model on the 
left shows the titration points between 0 and 1:3 protein/peptide molar ratio and on the right between 1:3 
and 1:6 molar ratio. The most perturbed residues were selected at > 0.4 ppm (red) and >0.3 ppm (light red) 
for the model on the left and >0.2 (red) and >0.15 (light red) for the model on the right. B) Small regions 
of the 15N HSQC spectrum of 15N-labelled Sgt2_TPR titrated with unlabelled PTVEEVD at ratios: 1:0 
(teal), 1:0.5 (purple), 1:1 (red), 1:2 (light pink), 1:3 (maroon), 1:4 (blue), 1:5 (cyan), and 1:6 (green). Black 










































































Figure 93: CSP graphs of Sgt2_TPR upon titration with peptides. A) PTVEEVD, B) MEEVD, C) 
Ybr137wp. The chemical shifts were normalized and calculated by using the equation described in Methods 
(Section 2) for the last titration point plotted for each residue. 
 
5.6.2   ITC 
In addition, we characterised the binding between Sgt2_TPR (93–229) and PTVEEVD, MEEVD 
and SLEENDNLD peptides by ITC (Figure 94 C). The ITC results indicate similar binding 
affinity for all three complexes with dissociation constants (Kd) of 9.00  ±  0.05  µM for 
Sgt2_TPR/PTVEEVD, 2.95  ±  0.30  µM for Sgt2_TPR/MEEVD and 1.53  ±  0.05 µM for 
Sgt2_TPR/SLEEDLNLD. Interestingly the Sgt2_TPR/PTVEEVD complex with the lowest 

















































obtained from ITC suggest that all complex formations were driven by the establishment of both 
hydrogen bonds and hydrophobic interactions in agreement with the x-ray structure of the 
Sgt2_TPR/PTVEEVD complex (Figure 94 C). 
 
 
Figure 94: ITC binding curves for Sgt2_TPR and peptides. ITC data showing binding of Sgt2_TPR to 
SLEENDNLD, PTVEEVD and MEEVD. Binding parameters, determined by ITC were Kd=  1.53  ±  0.05, 
ΔH  =  −  7.073±  0.99  kcal/mol; ΔS  =  3.19cal/mol/deg for SLEENDNLD; Kd=  9.01  ±  0.05  µM, 
ΔH  =  −  6.719±  0.07  kcal/mol,ΔS  =  140cal/mol/deg for PTVEEVD and Kd=  2.95  ±  0.30  µM, 
ΔH  =  −  4.513±  0.03  kcal/mol; ΔS  =  10.9 cal/mol/deg, for MEEVD. 
 
5.7   Summary 
Chapter 5 reports the structural and biophysical study of Sgt2_TPR and its complexes with C-
terminal peptides of Ssa1, Hsc82 and Ybr137wp. The structures of the free Sgt2_TPR and in a 
complex with PTVEEVD were crystallised and solved. Interestingly, the zinc was essential for 
the crystallisation of the complex possibly acting as an additive stabilizing the crystal lattice 
(suggesting that metal ion is needed to stabilize the complex formation within the crystal) and 
crystals formed in conditions without zinc did not produced the complexes. While the presence 
of zinc is not biologically relevant, other metal atoms such as nickel are also present in the 
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homologous complex structures of Hop TPR1/GASSGPTIEEVD, Hop TPR2A/MEEVD and 
CHIP TPR/DDTSRMEEVD (261, 336). Attempts to co-crystallise MEEVD and SLEELDNLD 
bound to Sgt2_TPR failed and only the PTVEEVD formed a complex. 
Furthermore, the backbone of Sgt2_TPR was assigned using NMR spectroscopy and this allowed 
us to study the binding with C-terminal fragments of Ssa1 (PTVEEVD), Hsc82 (Hsp90) and 
Ybr137wp. The structural data confirm that the binding mode of the Ssa1 to the TPR domain of 
Sgt2 protein is via the carboxylate clamp mechanism and we can speculate that Hsc82 and 
Ybr137wp interact in a similar mode due to the homology we have found in the binding 















Chapter 6.   Discussion 
6.1   SGTA, the BAG6 complex and RNF126 in a biological context 
Newly synthesized hydrophobic proteins are either targeted to membranes or degraded to 
maintain cellular homeostasis, but the decision making processes are still not well understood. 
Over the years, several research studies on the mammalian and the yeast TA targeting 
pathway(71-73, 76, 88-90, 99, 160, 171, 255, 256) and mammalian ubiquitination (74, 75) have 
identified core proteins involved in a sorting mechanism for hydrophobic proteins in danger of 
exposure to the aqueous cytoplasm. They have also provided new mechanistic insights into the 
co-chaperone SGTA and its relationship with the BAG6 complex (which contains BAG6, UBL4A 
and TRC35) and the equivalent fungal model (which is Sgt2 and Get4/Get5). SGTA can interact 
with the UBL domains of both, UBL4A and BAG6, which are displayed at the C-terminal and N-
terminal of the BAG6 complex. The ability of SGTA to bind to two UBL domains of the BAG6 
complex and the same range of hydrophobic substrates enables the transfer of protein clients onto 
the BAG6 complex for sorting while determining their fate. Furthermore, a complex between 
SGTA and the C-terminal domain of BAG6 was shown to recognize and stabilise the 
transmembrane domains (TMD) of TA proteins for handover to the targeting factor TRC40, 
which can deliver TA proteins to the ER for insertion. The opposite end of BAG6 on the other 
hand (the N-terminal domain) can recruit the RNF126 E3 ligase for the ubiquitination of 
hydrophobic protein clients. Recent depletion-replenishment experiments by Shao et al. ((73)), in 
which endogenous proteins were replaced with recombinant variants, supported the proposed 
functional roles of the components of the sorting mechanism (Figure 95) and showed that SGTA, 
itself, can facilitate both targeting and ubiquitination, suggesting that TA proteins bound to SGTA 
are initially uncommitted to either fate. However, it is still unclear how different targets are 
precisely recognised and triaged between appropriate pathways. In this thesis I consolidate our 
latest molecular-level contributions to the field by solving the structures of the dimerisation 
domain of SGTA and the zinc finger motif of RNF126 within the BAG6 quality control module 
and structural/biophysical characterisation of RNF126 and SGTA complexes with the UBL 
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domains of BAG6 and UBL4A. I also studied the yeast counterpart of SGTA, Sgt2, and its 
interactions with molecular chaperones Ssa1, Hsc82 and Ybr137wp through the TPR domain.  
 
 
Figure 95: Schematic illustration of the roles of SGTA and the BAG6 complex in quality control 
pathways for hydrophobic proteins. A) SGTA with bound hydrophobic substrate reaches the BAG6 
complex and binds the UBL4A_UBL domain, or the BAG6_UBL. The substrate (TA proteins and/or 
MLPs) remains bound to SGTA (and handover directly to heat-shock chaperones that bind the TPR) or is 
passed onto BAG6. B) TA substrates are transferred to TRC40 for ER membrane insertion through SGTA 
bound to UBL4A which binds TRC35 and recruits TRC40. C) BAG6 also participates in protein quality 
control of hydrophobic substrates. RNF126_NZF binds BAG6_UBL, likely replacing SGTA and, in 
collaboration with E2 enzymes could ubiquitinate the hydrophobic proteins from BAG6 or SGTA, targeting 
them for proteasomal degradation (174) 
 
6.2   SGTA (1-69) dimer in structural context 
Mammalian SGTA and its yeast equivalent, Sgt2, share 26.81% sequence identity and a three-
domain structure comprised of an N-terminal dimerization domain, a central TPR domain and C-
terminal glutamine-rich domain (Figure 96). The tendency of full length SGTA to aggregate in 
solution and the reported flexibility between the three domains, and at the C-terminal end of 
SGTA, present significant challenges for structural studies. Thus excised domains of SGTA and 
Sgt2 have been studied independently by us and others. The TPR domain from SGTA has been 
solved previously by X-ray crystallography (240). The solution structure of Sgt2 N-terminal 
dimerisation domain was determined in our laboratory (90). Various other SGTA/Sgt2 structures 
have also been added to the literature, namely NMR solution (263) and X-ray structures (255) of 
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partial constructs of the N-terminal domain of Sgt2 in the context of its complex with Get5, and 
the N-terminal domain of SGTA (89) comprising only the first two or three out of the four helices 
in each monomer as compared to the full structure presented in this thesis. These structures mostly 
agree with each other, and confirm the structurally unusual dimer interface, with some differences 
at the C-terminal end far from the UBL binding interface. Our SGTA (1-69) structure presented 
in this thesis (82) overlaps well with the yeast homologue with an RMSD of 2.4 Å. There are 
slight differences between the structures at helix α3 and the loop between helices α2 and α3 
(Figure 21 D) which are part of the UBL interaction site. These differences may explain the 
variation in SGTA binding to the UBLs from BAG6 and UBL4A and are discussed later.  
 
 
Figure 96: Sequence alignment of SGTA and Sgt2 using Clustal-Omega. Asterisks indicate sequence 
identity and dots indicate sequence similarity. TPR domains are shown in purple. 
 
6.3   SGTA (1-69) binding to BAG6 and UBL4A  
The SGT dimers bind UBLs. In the mammalian system, SGTA binds to the UBLs of BAG6 and 
UBL4A from the heterotrimeric BAG6 complex with comparable affinity. The yeast system 
differs in that there is no known homologue for BAG6. Sgt2 binds to the homologue of UBL4A, 
Get5, which is part of the heterotetrameric Get4-Get5 complex, with considerably higher affinity 
than the mammalian system. These apparent difference may hint at a more complex role for 
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SGTA. As noted above, there are small structural differences between SGTA and Sgt2. Could 
these differences have evolved due to the different demands upon these two proteins in the 
mammalian and yeast systems. The discussion that follows attempts to evaluate the structures of 
SGTA, Sgt2 and their complexes with the UBLs of BAG6, UBL4A and Get5 to try to give a 
structural explanation to the difference in affinities.  
The structure of the N-terminal dimerization domain of SGTA contributes structural details into 
its role in TA membrane protein insertion and its interaction with the BAG6 complex in MLP 
quality control pathways. The analysis of our mammalian complex structures of SGTA with 
UBLs indicates that the orientation of the SGTA binding helices relative to the UBL partner in 
the SGTA complexes is slightly different and rotated by approximately 45 degrees in comparison 
to the yeast complex, as shown in Figure 32 D, E, F. As described in the Results, the binding is 
driven mostly by electrostatic interactions and therefore these differences in orientation contribute 
to some differences in the negative charge distribution of the α2 central binding helices of SGTA 
(1-69) and Sgt2 N-terminal and also to the differences in positive charge distribution on the 
surface of the UBLs. Namely, the structural equivalent of Lys85 in the Get5_UBL is Glu12 in 
UBL4A_UBL which cannot form the same salt bridge. Instead UBL4A_UBL Lys66 and Lys46 
pull the SGTA_NT domain around slightly to satisfy the charge interactions. On SGT, the four 
negatively-charged amino acids are located along the helix slightly differect in Sgt2 and SGTA, 
with Sgt2 displaying two at each end (Asp28/Asp31 and Asp38/Asp42) and SGTA showing three 
at one end (Asp27/Glu30/Glu33, where the Lys85 interaction was lost, and one at the other end 
(Glu40). The comparison of binding interfaces between SGTA (1-69)/UBL4A_UBL and SGTA 
(1-69)/BAG6_UBL HADDOCK models shows similarities however, the BAG6_UBL binding 
site displays a slightly narrower site. The conserved lysine residues on UBL4A_UBL (6, 46, 42, 
48, and 66) and their equivalents on BAG6_UBL (22, 58, 64, 80) make electrostatic contacts with 
the charged residues on SGTA (1-69), Asp27, Glu30, Glu33, and Glu40. The equivalent of Lys46 
is missing in the BAG6_UBL and is replaced by Gln62 which cannot make the same salt bridge. 
Analysis of the biophysical properties of the complexes show that one SGTA (1-69) dimer binds 
to one UBL domain. Our NMR titration experiments indicate that the binding affinities of SGTA 
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(1-69)/UBL4A_UBL and SGTA (1-69)/BAG6_UBL are comparable however it could not be 
precisely verified by ITC, where we obtained a molar ratio value,n, of 0.4-0.6 in most titrations 
for SGTA (1-69)/BAG6_UBL and approaching 1 in the SGTA (1-69)/UBL4A_UBL complex, 
and the binding affinity could not be derived unambiguously. An additional difference was 
observed in CSP analysis in which there were several peaks splitting for SGTA (1-69) during the 
titration with BAG6_UBL but no apparent peak splitting in SGTA (1-69)/UBL4A_UBL 
titrations. The peaks splitting can be explained by the presence of two chemically different local 
environments of the same residue on each SGTA monomer in contact with different residues in 
the BAG6_UBL. For example, residue Q37 on each SGTA protomer interacts with different 
residues of BAG6 (Figure 97). A similar situation occurs at the SGTA (1-69) dimer and 
UBL4A_UBL binding interface and additionally one Q37 on SGTA contacts the flexible C-
terminal of UBL4A_UBL which could potentially explain no peak splitting of that particular 
residue. The lack of obvious peak splitting in the SGTA (1-69)/UBL4A_UBL interaction might 
suggest differences in the binding dynamics of the two UBLs where the exchange between the 
two symmetry-related binding sites on the SGTA (1-69) dimer is significantly slower than the 
NMR chemical shift timescale in the case of the BAG6_UBL but it is faster for UBL4A. In the 
case of SGTA (1-69)/UBL4A_UBL we do not observe peaks splits because of the potential 
averaging of frequencies at the elevated temperatures required for analysis (310 K). If on the other 
hand we were to expect two peaks at similar chemical shifts to the SGTA(1-69)/BAG6_UBL 
complex, but only observe one, we could speculate that the absence of the second peak could be 
attributed to exchange broadening caused by motions on the intermediate timescale of the flexible 
UBL4A_UBL C-terminus, which is near to Q37 of the second protomer.. We also consider that 
the binding might be in intermediate exchange for other residues and that signal broadening 
causes one of the peaks to disappear. Furthermore, HADDOCK models show that first two 
clusters are similar in both SGTA (1-69)/UBLs and the other two clusters slightly differ in the 
conformation of UBLs. Since BAG6 could bind in two, considerably different, conformations, of 
which one might not give as strong a signal in ITC due to fewer electrostatic interactions, 
decreasing the enthalpy which could explain the impossible molar ratio value of 0.4. In addition, 
analysis of the binding interface shows that there are fewer Lysine residues on BAG6_UBL in 
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contact with SGTA (1-69) as compared to UBL4A which may allow for more conformational 
flexibility in binding. Figure 98 shows SGTA (1-69)/BAG6_UBL HADDOCK models from 
cluster 1 and cluster 2 highlighting the positions of splitting residues on SGTA, which might be 
in different environments in the two different conformations. However, more experiments 
including mutagenesis would be needed to investigate the differences in SGTA (1-69)/UBL 
complexes fully. 
 
In the yeast system there is only one type of UBL on the Get4/Get5 complex (located at the centre 
of each Get5 subunit), and it interacts with Sgt2 with higher affinity. The two UBLs of the larger 
mammalian BAG6 complex are capable of binding to SGTA, each with comparable affinity that 
is lower than the Kd reported in yeast. We have also shown that the mammalian UBLs interact 
with SGTA in a slightly different orientation as compared to fungal equivalent. These differences 
may reflect the seemingly more complex role of SGTA as compared to Sgt2. Current models 
shows that both SGTA and Sgt2 capture free TA-proteins before handing them on to BAG6 and 
heterotetrameric Get4/Get5 complexes (88, 101). In the yeast system, the main function of the 
Get4/Get5 complex appears to be to deliver TA proteins directly onto Get3 for membrane 
targeting. The intermediate form of the Get4/Get5 complex was shown to rapidly rearrange to the 
final Get3·Get4/5 structure for the hand off of TA-proteins to Get3 for ER delivery (78, 98). The 
mammalian BAG6 complex, however, has the dual role of being able to triage substrates towards 
distinct targeting or degradation. Hence, we speculated that one of the factors that impacts the 
fate of SGTA-associated hydrophobic substrates is which one of the two BAG6 complex UBLs 
first interacts with SGTA prior to substrate release. Thus, one of the UBLs might favor substrate 
handover on to TRC40 for ER targeting, as seen for TA-proteins (71, 72), whilst the other UBL 
may promote the ubiquitination of aberrant substrates including MLPs (74) and ERAD substrates 
in the retrotranslocation process out of the ER membrane (171). A recent study supports our 
hypothesis. Using depletion-replenishment experiments by replacing endogenous proteins with 
recombinant variants and photo-cross linking assays, it shows that TA-proteins are captured 
favorably by SGTA (as compared to direct substrate to Trc40 or BAG6 complex formation). The 
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TA proteins are then rapidly and preferentially transferred on to TRC40 through the interaction 
with the C-terminal end of the BAG6 complex (a module comprised of BAG6-C 
terminal/Ubl4A/Trc35) for ER targeting. The substrate transfer is twice as fast as the rate of 
spontaneous TA protein dissociation from SGTA. In contrast, client ubiquitination is dictated 
predominantly by relatively slower substrate dissociation from SGTA followed by a free TA 
protein intermediate which is captured by the N-terminal of the BAG6 subunit (containing the 
UBL domain) (73). In cells, the affinity of SGTA towards BAG6 is lower than to UBL4A (73) 
and the process is likely to be even more complex, since the heterotrimeric BAG6 complex, whose 
architecture and stoichiometry have been debated, has been shown to form homo-oligomers (176) 
that would present multiple UBL domains to which SGTA and/or other interacting partners could 
bind. Meanwhile, the polyubiquitination of UBL4A regulates BAG6 activity via targeted 
proteolysis (182). It is possible that TRC35 and UBL4A exist as dimers, like their yeast 
homologues, although UBL4A lacks the N-terminal domain of Get5 which forms the main contact 
with Get4. Possibly, a part of BAG6 can bring together the UBL4A and TRC35 subunits in the 
mammalian system. Moreover, it appears that only a small C-terminal fragment of the BAG6 
protein that connects the UBL4A and TRC35 is necessary to allow the transfer of TAs from SGTA 
to the TRC40 delivery complex (73, 76). 
 
Results from our lab and others highlight the structural complexity of the relationship between 
SGTA and the BAG6 complex and indicate that further structural and functional work is required 
to completely understand the sorting mechanism. The structure of the full-length heterotrimeric 
BAG6 complex has yet to be solved and its large size, dynamic behavior and transient interactions 
are challenging to the structural biologist. Structures of several isolated domains from various 
species provided some detail on its function at a molecular level. However, the complete structure 





Figure 97: Detail view of the differences in a chemical environment of Q37 residue on SGTA, at the 
SGTA (1-69)/UBLs binding interfaces, which splits in CSP experiments. Q37 on each SGTA protomer 
interacts with different residues of UBLs. Additionally, one Q37 on SGTA contacts the flexible C-terminal 
of UBL4A_UBL which could potentially explain no peak splitting of that particular residue. 
 
 
Figure 98: SGTA (1-69)/BAG6_UBL HADDOCK models from cluster 1 and cluster 2 showing 
splitting residues on SGTA. 
227 
 
6.4   Structure and interactions of RNF126_NZF and the BAG6 complex 
The RNF126 E3 ubiquitin ligase belongs to the large RING family of ligases, whose significant 
feature is a zinc-binding RING finger domain which plays an important role in the ubiquitination 
pathway by interaction with an E2 (ubiquitin-conjugating) enzyme. There are hundreds of E3 
ubiquitin ligases in mammalian cells able to recognize the wide variety of protein degrons (337) 
but the specific substrate selection mechanisms are unclear. Many of the RING E3 ligases contain 
an additional zinc-finger motif which can act as a recognition site for ubiquitination clients. 
RNF126 can bind to the BAG6, and ubiquitinate hydrophobic substrates to mark them for 
degradation at the proteasome (75). In this work we characterise the interactions between RNF126 
and BAG6 at a molecular level and report an additional, lower-affinity RNF126 interaction with 
UBL4A, another subunit of the BAG6 complex. 
 
We solved the first high-resolution structure of N-terminal RNF126 zinc finger which comprises 
a three-stranded short antiparallel β-sheet with four cysteine residues coordinating zinc and one 
solvent exposed side of the β-sheet, which creates a platform for protein-protein interaction. The 
structure of the RNF126_NZF displays a similar fold to at least two other zinc finger motifs 
namely, the zinc finger domain of human Pirh2, an E3 ubiquitin ligase (with 27% sequence 
similarity and RMSD of 2.75 Å) and the Npl4 Zinc-Finger, an Ubiquitin recognition domain (with 
26% sequence similarity and RMSD of 2.35 Å). To date, full-length RNF126 has not been 
structurally characterised, although a solution structure of the mouse RING domain has been 
solved (PDB Accession Number: 2ECT with no associated publication). The structure solution of 
the full length RNF126 presents some challenges because of the predicted, long flexible region 
linking the N-terminal zinc finger with the C-terminal part of the protein and a hydrophobic region 
towards the C-terminal. Our attempts to express and purify the full length RNF126 and the 
hydrophobic constructs were not fully successful due to protein instability and more work is 
necessary to optimise protein production. 
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In this study we have also identified the minimal domain of N-terminal RNF126 which is 
sufficient for the interaction with BAG6_UBL. We show that RNF126, although capable of 
binding to two different UBL domains on the BAG6 complex, has a clear preference i.e. a stronger 
affinity for the BAG6_UBL. We have compared the structure of RNF126_NZF/BAG6_UBL 
complex solved by NMR with a HADDOCK model of RNF126_NZF/UBL4A_UBL which we 
produced to gain some insight into the differences in binding affinities (Figure 30 C, D). 
Although the binding interfaces between RNF126_NZF and the two UBLs is conserved (Figure 
31 A), the binding affinity between RNF126_NZF and UBL4A_UBL is significantly lower. We 
observed some differences in the residues on the surface of the UBLs which could account for 
this difference in affinity (Figure 31 C, D). The conformation of the loop between the β1 and β2 
strands in UBL4A_UBL is different from that of the BAG6_UBL and the Leu8 sidechain points 
away from the RNF126_NZF hydrophobic pocket which is formed mainly by Phe36. 
Furthermore, the backbone NH group of the UBL4A Leu8 is solvent-exposed and lines this 
cavity. On the other hand, the equivalent backbone NH group of Leu24 in the BAG6_UBL is 
instead buried within the hydrophobic core. Additionally, the sidechain NH group of Asn68 in 
the UBL4A_UBL also lines this binding cavity whereas it is the aliphatic part of the His83 
sidechain that occupies the binding pocket in the BAG6_UBL (Figure 31 C, D). These 
differences point to a reduced hydrophobicity of the RNF126 Phe36 hydrophobic pocket in the 
UBL4A_UBL relative to the BAG6_UBL, which likely affects the binding affinity. An additional 
decrease in affinity may be caused by the lower capacity of Lys48 in UBL4A_UBL to form 
hydrogen bonds with Glu38 in RNF_NZF as compared to Arg64 in BAG6_UBL. Moreover, the 
contact between Gln62 in BAG6_UBL and Tyr27 in RNF126_NZF and equivalent Lys53 in 
UBL4A is reduced. (Figure 30 C, D). Taken together, this study illustrates structural differences 
at the binding interfaces of the two complex structures which may explain a discrepancy in 
binding affinities, although data are limited to comparison between a higher resolution NMR 
structure of RNF126_NZF/BAG6_UBL and a HADDOCK model of 
RNF126_NZF/UBL4A_UBL derived from solved component structures and chemical shift 
perturbation data.  
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In chapter 3 we showed that, just like RNF126, cochaperone SGTA can also bind to the UBLs of 
both BAG6 and UBL4A, in the same binding site but with slightly higher affinity to UBL4A than 
to BAG6. The SGTA binding interface for UBLs differs from that of RNF126 and exhibits more 
electrostatic interactions, which are stronger for UBL4A_UBL. We have also shown that 
RNF126_NZF does not directly bind to SGTA (1-69), which supports the model in which 
RNF126 binds to BAG6 to get access to its protein clients. Furthermore, we analysed whether 
SGTA and RNF126 bind to BAG6 _UBL in a competitive manner or if they can bind at the same 
time. The results show that RNF126_NZF competes with SGTA (1-86) for the same binding site 
on BAG6_UBL (and on UBL4A_UBL) and cannot bind simultaneously. In addition, the 
BAG6_UBL binds more tightly to RNF126_NZF than it does to SGTA (1-86). The subtle 
variations in binding affinities amongst the components of the sorting mechanism might be key 
in understanding the details pertaining the decision-making processes at the BAG6 complex 
(Figure 95).  
 
Since SGTA can initially capture tail-anchored proteins emerging into the cytosol and it seems to 
preferentially bind to the UBL4A_UBL subunit of the BAG6 complex (BAG6-UBL4A-TRC35), 
both in vitro and inside cells (73, 87), the question is how the hydrophobic substrates that are 
destined for RNF126 mediated ubiquitination are transferred on to the BAG6 subunit? It seems 
that the fate of hydrophobic clients depends on the relative abilities of SGTA and the BAG6 
complex components to capture them and also their ability to retain the bound substrate (73, 86, 
99). Given that the transfer of TA proteins from SGTA to TRC40  for ER delivery (via UBL4A) 
is faster, and TA protein transfer from SGTA to the BAG6 subunit is slower (73), the proteins 
which fail the initial capture by TRC40 can be then collected by the BAG6 subunit and targeted 
for quality control (Figure 95). However, TA proteins seem to be able to spontaneously associate 
and dissociate from SGTA more quickly than they are caught by BAG6, allowing for multiple 
cycles of triage. In contrast, TA proteins once bound to BAG6 subunit, dissociate from BAG6 
relatively slowly to allow for quality control (73, 106). The decision making process, and why 
TRC40 fails to capture hydrophobic substrates independently, can also depend on the type of the 
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substrate and the biophysical features of the TRC40 binding site, which could have evolved to 
favor ER-destined TA proteins (78, 256). In the case of TA proteins, their well-defined helical 
TMDs ensure that they are quickly transferred from SGTA through a UBL4A mediated 
interaction with the BAG6 complex to TRC40 for ER delivery. In contrast to this, the failure of 
substrates such as mislocalised proteins with large hydrophobic patches to be efficiently passed 
from SGTA on to TRC40 would instead target them towards the BAG6 subunit for an alternative 
quality control pathway. Alternatively, MLPs may not be released to TRC40 if SGTA, with 
substrate bound, first associates with UBL4A subunit if SGTA can somehow detect unfolded or 
non-native hydrophobic regions. The BAG6 subunit is capable of distinguishing between 
different substrates as moderately hydrophobic polypeptides are reported to bind close to its N-
terminal UBL domain (133) whereas membrane proteins and heat denatured luciferase bind its 
central proline rich region (19, 176). As for MLPs, we suggest that competition between SGTA 
and RNF126 for binding to the BAG6 subunit effects the fate of these substrates since increased 
residence time of SGTA on BAG6 would reduce the access of RNF126 to its BAG6 associated 
substrates, thus reducing their ubiquitination and degradation.  
 
Our structural and biophysical study of RNF126 and BAG6 expands our understanding of the 
way in which hydrophobic proteins are triaged between diverse quality control pathways. 
Furthermore, there is a growing interests in using E3 ubiquitin ligases as drug targets and 
prognostic biomarkers since, the client specificity of E3 ligases is proposed to limit the potential 
side-effects of drugs that target them, thus the new RNF126 structure presented here provides a 





6.5   Structure and interactions of the Sgt2_TPR with yeast chaperones and 
Ybr137wp 
The roles of SGTA and Sgt2 have long been linked to Hsp70 and Hsp90 chaperones {Liou, 2005 
#10888}. SGTs can, via their central TPR domain, directly bind to several heat-shock proteins 
which help them to facilitate correct folding of client proteins (88, 275). It is possible that these 
chaperones might funnel substrates towards SGTA and enable their access to additional quality 
control pathways. It has also been proposed that SGTA can regulate the ATPase activity and 
folding rates of Hsp70 (242). However, the full significance of the relationship between the 
SGTA/Sgt2 and chaperones, remains to be discovered. Sgt2 was also reported to interact with 
Ybr137wp, a poorly-characterised protein with its function linked to the Get pathway and TA 
targeting. However, the exact role of Ybr137wp in the Get pathway is unclear. 
 
In this study we solved the first high-resolution structure of the free Sgt2_TPR domain and the 
same domain in complex with the last seven amino acids of Ssa1 (Hsp70) using crystallography. 
We have also assigned the backbone of the Sgt2_TPR using NMR spectroscopy, and 
characterized the interaction between Sgt2_TPR and the extreme C-terminal fragments of Hsc82 
(Hsp90) and Ybr137wp. Analysis of the complex structure shows that Sgt2_TPR binds Ssa1 in 
well-established carboxylate clamp mode that is common in interactions between heat shock 
proteins and chaperones (338-340). Therefore, we speculate that Sgt2_TPR may be interacting 
with Hsc82 and Ybr1372p in a similar binding mechanisms due to their similar behavior as 
analysed by NMR and ITC. 
The structure of Sgt2_TPR complex with Ssa1 indicates at a subtle conformational change spread 
over the entire structure, which appears to be more compacted upon binding a peptide (Figure 82 
B). The Sgt2_TPR residues affected by the addition of the MEEVD and SLEENDNLD peptides 
(Figure 88 and 90 respectively) were the same as those perturbed by PTVEEVD (Figure 88), 
with the intriguing double event binding mode in all titrations. Several peaks in the HSQC spectra 
of the binding experiments shift in a non-linear manner suggesting the presence of an additional 
232 
 
form to completely free and bound states like the ones previously reported in other protein 
interaction studies (341). This could explain the discrepancies which were observed for the 
SGTA_TPR binding to the C-terminal peptide from the ubiquitin receptor of the 26S proteasome, 
Rpn13 (168). The Kd measured by ITC indicated tight binding but the fast exchange regimen in 
the NMR titrations suggests a medium to low affinity interaction (168). Since the most perturbed 
residues in the case of the first Sgt2_TPR and peptides binding “event” (using 1:3 protein to 
peptide molar ratio) correspond to the residues at the binding interface in the x-ray complex 
structure, and/or the neighboring residues, and we speculate that the residues perturbed the most 
in the second event may be due to the global TPR conformational change. Similar results were 
obtained in the interaction of Rpn13 and SGTA_TPR, in which many NMR signals corresponding 
to amino acid residues widespread along the TPR were affected upon titration and were not 
localised in a well-defined interface (168). The binding affinity values we obtained from the ITC 
reactions are comparable to examples in the literature of TPR domains binding HSP-derived 
peptides such as TPR domains interacting with carboxylate clamps from Hsp70 and Hsp90 
chaperones at micromolar scale (261, 271, 342). The orientation of the Hsp peptides at the 
Sgt2_TPR groove slightly varies between homologues. Although, the conserved carboxylate 
clamp mode of interaction is consistent, there are some differences observed at the N-terminal 
end of the peptides, which is unsurprising given that the carboxylate clamp can act as an anchor 
at the interface. The elongated conformation of the PTVEEVD peptide within the Sgt2_TPR 
groove in the structure of the complex presented here is similar to that of the HOP 
TPR1/GPTIEEVD complex (PDB ID 1elw) (261). In contrast, in the two structures of 
GPTIEEVD/Chip TPR (PDB ID 3q49; (171)and PDB ID 4kbq; (336)) the peptide lines the groove 
in a curved conformation and also the orientations of the N-terminal proline varies slightly within 
the binding site Figure 99. In addition, in our Sgt2_TPR/PTVEEVD complex structure, we can 
observe some differences between the Pro1, Thr2 and Val3 sidechains in the two chains (A and 
B) indicating possible flexibility in the association between TPR and Hsp peptides at the same 
interface. Sgt2_TPR serves as a binding interface for transient interactions with many proteins 
including chaperones. Furthermore, the preceding residues to EEVD are also important for the 
binding affinity and it has been reported that trimming the peptide sequence to EEVD only, 
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significantly reduced the affinity (261). Since Sgt2 exists as a homodimer it is possible that it can 
target a broad range of substrates by binding more than one protein simultaneously, either one on 
each of its two TPR domains or other combinations of domains and bring them into closer 
proximity promoting interactions. 
 
The role of Ybr137wp in the Get pathway is yet to be established. Our and others’ results show 
that it binds to Sgt2 with the same binding interface as heat shock chaperones (300). Previous ITC 
experiments showed that one full-length Ybr137w decamer is capable of binding to five 
Sgt2_TPR dimers with a dissociation constant (Kd) of 1.38 ± 0.09 µM (300). This is almost 
identical to the ITC results we obtained for the association of Sgt2_TPR with the extreme C-
terminal nine- residue Ybr137wp-derived peptide (Kd of 1.53  ±  0.05), suggesting that the 
SLEEDLNLD fragment is sufficient for the interaction. Moreover, it has been shown that 
removing ESLEEDLNLD from the C-terminal of Ybr137wp abolished the interaction, 
confirming that this flexible C-terminal region is also necessary for the interaction (300). 
 
Further work is required to define the exact role of ybr137wp in ER delivery of tail-anchored 
membrane proteins. To date it is known that the function of Ybr137 is associated with altering 
the failure of TA protein delivery and cell viability derived by the impaired GET system in cell 
starvation conditions but not under normal conditions (300).  However, it is yet not known 
whether Ybr137 is linked to any other alternative TA targeting pathways the signal recognition 
particle (SRP), SRP-independent targeting (SND) proteins or Hsc70 family of chaperones. Thus 
it has been shown that a deletion of ybr137w from the yeast strain promotes the association of 
heat-shock chaperones Hsp104 or Hsp70 with Sgt2 (88) suggesting that Ybr137wp and the 
chaperones compete for the same binding site on the Sgt2 TPR domain. Interestingly, Ybr137wp 
can also form a complex with Kap142p in the cytosol (301). Kap142p is a karyopherin that 
mediates nuclear export and import (301). However, the role of Ybr137wp in this interaction with 




Figure 99: Different conformations of peptide bound to several TPR domains. A) our 
Sgt2_TPR/PTVEEVD, B) HOP TPR1 /GPTIEEVD (PDB ID: 1elw), C) CHIP TPR/GPTIEEVD (PDB ID: 
3q49), D) CHIP TPR/GPTIEEVD (PDB ID: 4kbq) and E) HOP TPR2A/MEEVD (PDB ID: 1elr). 
Elongated peptide conformations are present in A) and B) and curled conformation are shown in C), D) and 






6.6   Overall conclusions and future goals 
The key players of protein quality control are chaperone networks and degradation machineries. 
The failure of sorting mechanisms which maintain homeostasis between protein biosynthesis and 
disposal of damaged proteins is associated with a broad spectrum of human diseases like cancer 
or neurodegenerative disorders, hence making them important targets to study. The past years 
showed that the triage system comprising co-chaperone SGTA, the BAG6 complex and E3 
ubiquitin ligase RNF126 is vital in cellular quality control of MLPs, TA protein targeting and also 
regulation of hormone receptor signaling and viral lifecycles. However, mechanistic details 
concerning most of these roles are still not well understood and are often limited to 
characterization of excised subunits from the triage machinery. Moreover, it is still unclear how 
the particular components of the sorting system recognize distinct types of hydrophobic substrates 
in order to direct them along appropriate routes like the TRC targeting pathway or proteasomal 
degradation. 
In this work, we combine biophysical and structural approaches to provide insights into the 
functions of SGTA and RNF126, as part of the BAG6 quality control module. We achieved this 
by solving the structures of the dimerisation domain of SGTA (Chapter 3) and the zinc finger 
motif of RNF126 (Chapter 4). We also characterise the interaction of both RNF126 and SGTA 
with the UBL domains of BAG6 and UBL4A. In addition, we generate structural models of 
complexes of RNF126 and SGTA with UBLs using NMR spectroscopy and HADDOCK 
(Chapters 3 and 4). We also focus on an additional role of Sgt2, which is the interaction with 
molecular chaperones (Hsp70 and Hsp90) and also with Ybr137wp, through its TPR domain. 
Chapter 5 describes the x-ray structures of Sgt2_TPR and its complex with the extreme C-
terminus of Ssa1. In addition, we demonstrate that Sgt2_TPR interacts with C-terminal fragments 
of Ssa1, Hsc82 and Ybr137wp with a similar binding mode and with comparable binding 
affinities. Together, this work aims to shed more light on quality control mechanism in yeast and 
mammals, by describing the relationships between, and providing useful molecular details of, the 




Future work will focus on studying the full-length components of SGTA/BAG6 triage system and 
even larger complex structures which will add a great value to understanding the sorting 
mechanism. To date, the full length structures of the BAG6 protein itself and of SGTA have not 
been solved because of large size and possible oligomerisation in the case of BAG6, and 
hydrophobicity and lack of structure for the C-terminal domain of SGTA. Nevertheless, it is the 
structural and functional characterisation of its C-terminus which will increase progress in 
understanding the function of SGTA, and in particular, of how it binds hydrophobic substrates. 
This will help to clarify how specific hydrophobic substrates are recognized and triaged by SGTA 
between the subunits of the sorting system. Furthermore, it will be interesting to determine the 
structure of full-length SGTA to understand its interactions with all the other binding partners at 
the macromolecular level especially since SGTA is reported to play an important role in 
oncogenesis (e.g.of breast cancer, esophageal squamous cell carcinoma and human hepatocellular 
carcinoma) and is hence suggested to be a potential prognostic marker and therapeutic target 
(173).  
 
We will also continue with studying full-length RNF126, which so far has been a challenge due 
to protein instability. The two different constructs we designed and tested in our lab for their 
expression and purification, showed signs of major degradation, especially after tag removal (as 
described in Chapter 4). Although, production of a stable construct suitable for further structural 
studies has not yet been achieved, a number of techniques will be employed with an aim to aid 
the construction of a more suitable sample for NMR and biophysical studies. Future experiments 
will involve using RNF126 with Thioredoxin tag to prevent protein degradation. We will also 
employ Differential Scanning Fluorimetry (DSF) which will give information on the temperature 
at which a protein unfolds in a particular buffer, salt concentration, detergents and additives. This 
will enable the screening of many different buffers, which in turn may help to find a better 
condition that promotes protein stability, and also to overcome the aggregation problem. Other 
homologous proteins will be also considered. A different E3 ligase RNF115 shares near identical 
NZF and RING domains with RNF126 (with 42.3% overall sequence identity and 52.6% 
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similarity) and may also be capable of binding to BAG6 thereby, perhaps, conferring some 
redundancy on the system. In fact, inhibiting the interaction between RNF126 and BAG6 had 
only a partial effect on ubiquitination levels in cells (75) which could be a result of RNF115 
activity. Therefore, RNF115 will be tested to establish whether this protein is more stable. 
Moreover, we may consider using eukaryotic organisms as an alternative expression system such 
as yeast or baculovirus infected insect cells which would allow for post-translational 
modifications to occur if necessary. It would be also interesting to investigate which (if any) part 
of RNF126 can bind hydrophobic substrates. Since, there were no direct RNF126 substrates 
identified before except for the recently reported interaction with Frataxin, we aimed to test 
whether the two proteins interact directly in solution. However, it is not clear in the literature if it 
was a full length frataxin precursor and also which domain of RNF126 is necessary for the 
interaction. The full-length RNF126 could not be produced in sufficient amounts, therefore 
RNF126_NZF was tested in interaction experiments. 1H- 15N HSQC spectrum displayed some 
signal broadening upon RNF126_NZF titration into 15N-labelled Frataxin and the vice-versa 
titration shows similar results. However, more experiments are needed to verify whether there is 
an interaction between the two proteins and if it is the N-terminal of RNF126 which interacts. 
 
The TPR domains of SGTA and Sgt2 act as a platform allowing for interactions with many 
different proteins and they physically link the GET pathway to further chaperone pathways. 
Characterisation of complex structure and interaction of the TPR domain of SGTA with the C-
terminus of Ssa1 and comparison to binding with peptides of Hsc82 and Ybr137wp was just a 
small step towards understanding how these transiently formed interactions maintain the substrate 
specificity and target recognition. Moreover, further work defining the exact function of 
Ybr137wp in ER delivery of tail-anchored membrane proteins will clarify whether there is any 




Overall, it is crucial to further our understanding of the various quality control networks in which 
the multichaperone triage system composed of the BAG6 complex, SGTA and RNF126 plays a 
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Appendix A.   Primers 
Primer Name Primer Sequence 
SGTA (1-69) 5’- GACGACAAGATGGACAACAAGAAGCGCCTGGCC 
GAGGAGAAGCCCGGTTACTTGCCCGTGGCAGCCGC - 3’ 
UBL4A_UBL 5’- GACGACGACAAGATGCAGCTGACGGTGAAGGCG 
GAGGAGAAGCCCGGTTACAGGGGTTTGACCACTAGGTT -3’       
BAG6_UBL 5’- GACGACGACAAGATGGAACCGAATGATAGTACC 
GAGGAGAAGCCCGGTTAACCAGAGCTTGCACCGCT -3’ 
Sgt2_TPR (96-225) 5’-GCCGCGGATCCATGGCGGAAACTAAAGCCAAAGCTGAGG 
GGCCGGCTCGAGTTACAGATTCAAAGATTGCTCAACCTTCTT
C-3’ 
RNF126_ H14A 5’-CGGGTCGTTATTTTTGTGCTTGTTGTAGCGTTG 
CAACGCTACAACAAGCACAAAAATAACGACCCG -3’ 


















w   
5’- GCCGCGGATCCATGGGTGTTCCGACCCTGGAAG GTAT 
RNF126_FL 5’-­‐	  GCCGCGGATCCATGGCAGAAGCAAGTCCGCATCCGG	  
GTCCGCTGAGCAATCTGACCCTGTAACTCGAGCCGGCC	  -­‐3’	  













MAEAS P H P G R Y F C H C C S V E I V P R L P D Y I C P R C E S G F I E E L 
RNF126_NZF (1-100) 
MAEAS P H P G R Y F C H C C S V E I V P R L P D Y I C P R C E S G F I E E L P E E T R S T E N G S A P S T A P T D Q S R P PL E H V D Q H L F 
T L P Q G Y G Q F A F G I F D D S F E I P TFPPGA  
RNF126 (full-length) 
MAEAS P H P G R Y F C H C C S V E I V P R L P D Y I C P R C E S G F I E E L P E E T R S T E N G S A P S T A P T D Q S R P P L E H V D Q H L 
F T L P Q G Y G Q F A F G I F D D S F E I P T F P P G A Q A D D G R D P E S R R E R D H P S R H R Y G A R Q P R A R L T T R R A T G R H E G 
V P T L E G I I Q Q L V N G I I T P A T I P S L G P W G V L H S N P MD Y A W G A N G L D A I I T Q L L N Q F E N T G P P P A D K E K I Q A L 
P T V P V T E E H V G S G L E C P V C K D D Y A L G E R V R Q L P C N H L F H D G C I V P W L E Q H D S C P V C R K S L T G Q N T A T N 















Appendix C.   Chemical shifts of RNF126_NZF 
 
 
-1 Gly 3.90 43.50
0 Ser 4.52 3.87
3.91
58.40 64.08




2.10 55.77 32.94 32.09 16.97
2 Ala 8.34 125.80 4.30 1.38 52.79 19.28
3 Glu 8.28 120.73 4.26 2.05
1.95
2.27 56.35 30.51 36.31
4 Ala 8.27 125.68 4.34 1.39 52.43 19.49
5 Ser 8.26 117.16 4.74 3.84
3.80
56.34 63.49




63.28 32.20 27.17 50.73
7 His 8.49 120.18 4.99 3.22
3.15
53.51 29.18




63.51 32.39 27.34 50.61
9 Gly 8.63 110.41 3.95
4.05
45.13






55.44 32.99 27.16 43.70
10 Arg 7.55
11 Tyr 8.69 121.35 5.33 2.57
2.94
6.95 6.84 56.96 43.10 133.50 118.02
12 Phe 9.41 122.43 4.89 2.77 6.52 7.04 56.98 44.05 131.64 129.74
13 Cys 7.94 128.43 4.65 2.80
2.73
58.36 31.22
14 His 8.97 126.46 4.32 2.76
3.06
58.71 29.22
15 Cys 9.20 123.86 4.44 3.28
3.22
61.70 28.37
16 Cys 9.79 124.87 4.00 2.88
2.63
30.96
17 Ser 7.95 114.11 3.76 3.89
4.21
58.87 61.70




19 Glu 8.35 123.39 5.02 2.05 2.67
2.30
56.70 30.33 36.92
20 Ile 8.54 117.72 4.74 1.68 1.25
1.07
0.74 58.97 44.64 26.54
21.24
15.33










62.58 32.05 26.63 51.07
23 Arg 7.31




55.98 30.90 27.07 43.97




52.96 41.44 27.30 24.75
22.51




63.67 34.62 24.24 50.29
26 Asp 8.75 122.04 4.39 2.35
2.60
56.34 41.01
27 Tyr 8.67 117.59 3.44 3.04 6.78 6.70 60.40 35.03 132.89 118.32
28 Ile 6.76 111.77 4.78 1.41 1.04
0.80
0.63
0.70 57.58 42.06 25.56
17.24
12.58
29 Cys 8.79 126.92 4.42 3.24
2.81
56.38 32.21




64.06 32.32 26.81 51.41
31 Arg 7.32




58.20 31.65 27.50 43.77
32 Cys 8.55 119.73 4.84 2.45
3.22
58.56 33.24





34 Ser 8.78 117.20 4.43 4.30
3.86
59.28 65.47
35 Gly 8.51 111.10 3.77
4.11
45.22
36 Phe 8.85 126.40 5.15 3.46
3.08
7.28 7.30 7.20 55.24 36.08
37 Ile 7.97 117.33 5.35 1.68 1.37
1.00
0.82
0.33 58.62 41.13 26.06
18.05
14.29
38 Glu 9.13 124.83 4.88 2.14 2.31
2.37
54.68 34.56 35.93





40 Leu 8.19 133.53 4.14 1.41 1.40 0.66
0.71
56.33 43.39 27.36 23.01
25.77
H N εN αH βH γH δH εH ζH αC βC γC δC εC
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Appendix E.   Dano of Sgt2_TPR_PTVEEVD 
Fragment of the DANO Anomalous difference for anomalous Fourier (DANO) is a difference 
Patterson electron density map used to identify the positions of Zinc ions in the structure of 
Sgt2_TPR/PTVEEVD complex. 
 
 
 
 
 
 
 
 
 
 
 
